
<html lang="en"     class="pb-page"  data-request-id="1d38051d-942c-4a1d-b681-5d22c7402a50"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2016.59.issue-13;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.6b00373"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and Structure–Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)" /></meta><meta name="dc.Creator" content="John L.  Gilmore" /></meta><meta name="dc.Creator" content="James E.  Sheppeck, II" /></meta><meta name="dc.Creator" content="Scott H.  Watterson" /></meta><meta name="dc.Creator" content="Lauren  Haque" /></meta><meta name="dc.Creator" content="Parag  Mukhopadhyay" /></meta><meta name="dc.Creator" content="Andrew J.  Tebben" /></meta><meta name="dc.Creator" content="Michael A.  Galella" /></meta><meta name="dc.Creator" content="Ding Ren  Shen" /></meta><meta name="dc.Creator" content="Melissa  Yarde" /></meta><meta name="dc.Creator" content="Mary Ellen  Cvijic" /></meta><meta name="dc.Creator" content="Virna  Borowski" /></meta><meta name="dc.Creator" content="Kathleen  Gillooly" /></meta><meta name="dc.Creator" content="Tracy  Taylor" /></meta><meta name="dc.Creator" content="Kim W.  McIntyre" /></meta><meta name="dc.Creator" content="Bethanne  Warrack" /></meta><meta name="dc.Creator" content="Paul C.  Levesque" /></meta><meta name="dc.Creator" content="Julia P.  Li" /></meta><meta name="dc.Creator" content="Georgia  Cornelius" /></meta><meta name="dc.Creator" content="Celia  D’Arienzo" /></meta><meta name="dc.Creator" content="Anthony  Marino" /></meta><meta name="dc.Creator" content="Praveen  Balimane" /></meta><meta name="dc.Creator" content="Luisa  Salter-Cid" /></meta><meta name="dc.Creator" content="Joel C.  Barrish" /></meta><meta name="dc.Creator" content="William J.  Pitts" /></meta><meta name="dc.Creator" content="Percy H.  Carter" /></meta><meta name="dc.Creator" content="Jenny  Xie" /></meta><meta name="dc.Creator" content="Alaric J.  Dyckman" /></meta><meta name="dc.Description" content="Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite that regulates a multitude of physiological processes such as lymphocyte trafficking, cardiac function, vascular development, an..." /></meta><meta name="Description" content="Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite that regulates a multitude of physiological processes such as lymphocyte trafficking, cardiac function, vascular development, an..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 1, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00373" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00373" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00373" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00373" /></link>
        
    
    

<title>Discovery and Structure–Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00373" /></meta><meta property="og:title" content="Discovery and Structure–Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0017.jpeg" /></meta><meta property="og:description" content="Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite that regulates a multitude of physiological processes such as lymphocyte trafficking, cardiac function, vascular development, and inflammation. Because of the ability of S1P1 receptor agonists to suppress lymphocyte egress, they have great potential as therapeutic agents in a variety of autoimmune diseases. In this article, the discovery of selective, direct acting S1P1 agonists utilizing an ethanolamine scaffold containing a terminal carboxylic acid is described. Potent S1P1 agonists such as compounds 18a and 19a which have greater than 1000-fold selectivity over S1P3 are described. These compounds efficiently reduce blood lymphocyte counts in rats through 24 h after single doses of 1 and 0.3 mpk, respectively. Pharmacodynamic properties of both compounds are discussed. Compound 19a was further studied in two preclinical models of disease, exhibiting good efficacy in both the rat adjuvant arthritis model (AA) and the mouse experimental autoimmune encephalomyelitis model (EAE)." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00373"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00373">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00373&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00373&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00373&amp;href=/doi/10.1021/acs.jmedchem.6b00373" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 6248-6264</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00415" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00478" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Structure–Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P<sub>1</sub>)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+L.++Gilmore">John L. Gilmore</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+E.++Sheppeck%2C++II">James E. Sheppeck, II</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott+H.++Watterson">Scott H. Watterson</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lauren++Haque">Lauren Haque</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Parag++Mukhopadhyay">Parag Mukhopadhyay</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+J.++Tebben">Andrew J. Tebben</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+A.++Galella">Michael A. Galella</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ding+Ren++Shen">Ding Ren Shen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Melissa++Yarde">Melissa Yarde</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mary+Ellen++Cvijic">Mary Ellen Cvijic</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Virna++Borowski">Virna Borowski</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kathleen++Gillooly">Kathleen Gillooly</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tracy++Taylor">Tracy Taylor</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kim+W.++McIntyre">Kim W. McIntyre</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bethanne++Warrack">Bethanne Warrack</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+C.++Levesque">Paul C. Levesque</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julia+P.++Li">Julia P. Li</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Georgia++Cornelius">Georgia Cornelius</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Celia++D%E2%80%99Arienzo">Celia D’Arienzo</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony++Marino">Anthony Marino</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Praveen++Balimane">Praveen Balimane</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luisa++Salter-Cid">Luisa Salter-Cid</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joel+C.++Barrish">Joel C. Barrish</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+J.++Pitts">William J. Pitts</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Percy+H.++Carter">Percy H. Carter</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jenny++Xie">Jenny Xie</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alaric+J.++Dyckman">Alaric J. Dyckman</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Research and Development, Bristol-Myers Squibb, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 609-252-3153. E-mail: <a href="/cdn-cgi/l/email-protection#7d17121513531a141110120f183d1f100e531e1210"><span class="__cf_email__" data-cfemail="2c46434442024b454041435e496c4e415f024f4341">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00373&amp;href=/doi/10.1021%2Facs.jmedchem.6b00373" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 6248–6264</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 16, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 March 2016</li><li><span class="item_label"><b>Published</b> online</span>1 July 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 July 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00373" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00373</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6248%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJohn%2BL.%2BGilmore%252C%2BJames%2BE.%2BSheppeck%252C%2BScott%2BH.%2BWatterson%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D13%26contentID%3Dacs.jmedchem.6b00373%26title%3DDiscovery%2Band%2BStructure%25E2%2580%2593Activity%2BRelationship%2B%2528SAR%2529%2Bof%2Ba%2BSeries%2Bof%2BEthanolamine-Based%2BDirect-Acting%2BAgonists%2Bof%2BSphingosine-1-phosphate%2B%2528S1P1%2529%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6264%26publicationDate%3DJuly%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00373"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1699</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">17</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00373" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Structure–Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;L. Gilmore&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;E. Sheppeck&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;H. Watterson&quot;},{&quot;first_name&quot;:&quot;Lauren&quot;,&quot;last_name&quot;:&quot;Haque&quot;},{&quot;first_name&quot;:&quot;Parag&quot;,&quot;last_name&quot;:&quot;Mukhopadhyay&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;J. Tebben&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;A. Galella&quot;},{&quot;first_name&quot;:&quot;Ding&quot;,&quot;last_name&quot;:&quot;Ren Shen&quot;},{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;Yarde&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;Ellen Cvijic&quot;},{&quot;first_name&quot;:&quot;Virna&quot;,&quot;last_name&quot;:&quot;Borowski&quot;},{&quot;first_name&quot;:&quot;Kathleen&quot;,&quot;last_name&quot;:&quot;Gillooly&quot;},{&quot;first_name&quot;:&quot;Tracy&quot;,&quot;last_name&quot;:&quot;Taylor&quot;},{&quot;first_name&quot;:&quot;Kim&quot;,&quot;last_name&quot;:&quot;W. McIntyre&quot;},{&quot;first_name&quot;:&quot;Bethanne&quot;,&quot;last_name&quot;:&quot;Warrack&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;C. Levesque&quot;},{&quot;first_name&quot;:&quot;Julia&quot;,&quot;last_name&quot;:&quot;P. Li&quot;},{&quot;first_name&quot;:&quot;Georgia&quot;,&quot;last_name&quot;:&quot;Cornelius&quot;},{&quot;first_name&quot;:&quot;Celia&quot;,&quot;last_name&quot;:&quot;D’Arienzo&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;Marino&quot;},{&quot;first_name&quot;:&quot;Praveen&quot;,&quot;last_name&quot;:&quot;Balimane&quot;},{&quot;first_name&quot;:&quot;Luisa&quot;,&quot;last_name&quot;:&quot;Salter-Cid&quot;},{&quot;first_name&quot;:&quot;Joel&quot;,&quot;last_name&quot;:&quot;C. Barrish&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;J. Pitts&quot;},{&quot;first_name&quot;:&quot;Percy&quot;,&quot;last_name&quot;:&quot;H. Carter&quot;},{&quot;first_name&quot;:&quot;Jenny&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Alaric&quot;,&quot;last_name&quot;:&quot;J. Dyckman&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;6248-6264&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00373&quot;},&quot;abstract&quot;:&quot;Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite that regulates a multitude of physiological processes such as lymphocyte trafficking, cardiac function, vascular development, and inflammation. Because of the ability of S1P1 receptor agonists to suppress lymphocyte egress, they have great potential as therapeutic agents in a variety of autoimmune diseases. In this article, the discovery of selective, direct acting S1P1 agonists utilizing an ethanolamine scaffold containing a terminal carboxylic acid is described. Potent S1P1 agonists such as compounds 18a and 19a which have greater than 1000-fold selectivity over S1P3 are described. These compounds efficiently reduce blood lymphocyte counts in rats through 24 h after single doses of 1 and 0.3 mpk, respectively. Pharmacodynamic properties of both compounds are discussed. Compound 19a was further studied in two preclinical models of disease, exhibiting good efficacy in both the rat adjuvant arthritis model (AA) and the mouse experimental auto&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00373&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00373" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00373&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00373" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00373&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00373" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00373&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00373&amp;href=/doi/10.1021/acs.jmedchem.6b00373" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00373" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00373" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00373%26sid%3Dliteratum%253Aachs%26pmid%3D27309907%26genre%3Darticle%26aulast%3DGilmore%26date%3D2016%26atitle%3DDiscovery%2Band%2BStructure%25E2%2580%2593Activity%2BRelationship%2B%2528SAR%2529%2Bof%2Ba%2BSeries%2Bof%2BEthanolamine-Based%2BDirect-Acting%2BAgonists%2Bof%2BSphingosine-1-phosphate%2B%2528S1P1%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D13%26spage%3D6248%26epage%3D6264%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=292200" title="Layers">Layers</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/jmcmar.2016.59.issue-13/20160714/jmcmar.2016.59.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite that regulates a multitude of physiological processes such as lymphocyte trafficking, cardiac function, vascular development, and inflammation. Because of the ability of S1P<sub>1</sub> receptor agonists to suppress lymphocyte egress, they have great potential as therapeutic agents in a variety of autoimmune diseases. In this article, the discovery of selective, direct acting S1P<sub>1</sub> agonists utilizing an ethanolamine scaffold containing a terminal carboxylic acid is described. Potent S1P<sub>1</sub> agonists such as compounds <b>18a</b> and <b>19a</b> which have greater than 1000-fold selectivity over S1P<sub>3</sub> are described. These compounds efficiently reduce blood lymphocyte counts in rats through 24 h after single doses of 1 and 0.3 mpk, respectively. Pharmacodynamic properties of both compounds are discussed. Compound <b>19a</b> was further studied in two preclinical models of disease, exhibiting good efficacy in both the rat adjuvant arthritis model (AA) and the mouse experimental autoimmune encephalomyelitis model (EAE).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67762" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67762" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite formed from the conversion of ceramide by ceramidase followed by subsequent phosphorylation by sphingosine kinases.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> S1P regulates a multitude of physiological processes including lymphocyte trafficking, cardiac function, vascular development, and inflammation. These biological functions are mediated through the interaction of S1P with five G-protein coupled receptors known as S1P<sub>1–5</sub>.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Agonism of the S1P<sub>1</sub> receptor has been shown to block lymphocyte trafficking from the thymus and secondary lymph nodes, resulting in immunosuppression.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> One theory explains this effect of S1P<sub>1</sub> agonism by postulating that it causes a tightening of the lymphatic endothelial cell junctions which prevents lymphocytes from leaving the lymphoid tissue.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> Another theory postulates that the activation of the S1P receptor by synthetic agonists leads to prolonged receptor internalization, causing a desensitization of the cell toward the S1P concentration gradient.<a onclick="showRef(event, 'ref6 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref8">(6, 8)</a> This S1P concentration gradient between blood plasma and lymph is proposed to be the driving force for the lymphocytes to exit the lymph nodes. These S1P receptor agonists are thus behaving as functional antagonists, preventing the egress of lymphocytes from the thymus and lymph nodes. Because of the ability of S1P<sub>1</sub> receptor agonists to suppress lymphocyte egress, they have great potential as therapeutic agents in a variety of autoimmune diseases such as rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease.</div><div class="NLM_p">Fingolimod (<b>1</b>) was approved for the treatment of relapsing/remitting multiple sclerosis.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Compound <b>1</b> (fingolimod) is a nonselective S1P receptor agonist which is dosed as a prodrug and subsequently phosphorylated (<b>1</b>-<b>P</b>) in vivo, much like S1P.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Compound <b>1</b> is an effective immunosuppressant; however, it has been to shown to cause a transient, dose-dependent decrease of heart rate in clinical studies.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> This undesired effect as well as several others were thought to be caused by agonism of the S1P<sub>3</sub> receptor.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Studies in rodents have shown that S1P<sub>3</sub> activation leads to many undesired effects such as heart rate reduction, vasoconstriction, bronchoconstriction, and blood pressure increase.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> Because S1P<sub>3</sub> receptor agonism is not required to prevent lymphocyte egress, many research groups have been working toward the discovery of potent S1P<sub>1</sub> agonists which are S1P<sub>3</sub> sparing in hopes of finding compounds that will not have these undesired effects.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> However, recent clinical studies with S1P agonists with selectivity for S1P<sub>1</sub> over S1P<sub>3</sub> have suggested that in humans, heart rate effects are controlled, at least in part, by the S1P<sub>1</sub> receptor.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> Nonetheless, because S1P<sub>3</sub> receptor agonism does not contribute to the efficacy, finding selective compounds remained an emphasis for our research efforts.</div><div class="NLM_p">Our initial research efforts in the identification of improved S1P<sub>1</sub> compounds were aimed at direct acting agonists rather than the pro-drug class exemplified by <b>1</b>. A direct-acting agonist avoids the complication of two overlapping structure–activity relationships because it does not require an in vivo phosphorylation step to produce the active species. Another advantage of the direct-acting compounds is the potential to reduce the in vivo half-life of the compounds. The human half-life of <b>1</b> is 6–9 days, which resulted in an extended pharmacodynamic effect upon drug discontinuation.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p last">The general motif of these direct-acting S1P<sub>1</sub> agonists is to have a lipophilic tail and a polar headgroup joined by a rigid aryl or heteroaryl linker. Others have replaced the phosphate polar headgroup with a carboxylic acid to achieve very potent and selective S1P<sub>1</sub> agonists.<a onclick="showRef(event, 'ref15 ref19'); return false;" href="javascript:void(0);" class="ref ref15 ref19">(15, 19)</a> More specifically, an azetidine carboxylic acid group has been effectively utilized as a replacement for the phosphate (<b>2</b>),<a onclick="showRef(event, 'ref14 ref20'); return false;" href="javascript:void(0);" class="ref ref14 ref20">(14, 20)</a> and we have previously explored its use with a variety of lipophilic tails and linkers.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Use of the azetidine carboxylic acid group led to the discovery of <b>4</b> (BMS-520), which was our first development candidate.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In our continued research efforts, we sought to discover new polar headgroups that would produce compounds with the requisite activity, selectivity, and pharmacokinetic profile. Herein, we describe our medicinal chemistry efforts which resulted in the discovery of novel polar headgroups based on an ethanolamine scaffold containing a terminal carboxylic acid group.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60678" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60678" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our search began by utilizing a readily accessible lipophilic tail (3-phenyl-4-propylisoxazole) previously discovered in our laboratories as contained in compound <b>3</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). The routes employed to synthesize our ethanolamine scaffolds are shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The first step was to build the isoxazole carboxylic acid by heating pent-1-ynylbenzene and diethyl 2-nitromalonate in a stainless steel pressure bomb at 160 °C for 18 h to form ethyl 5-phenyl-4-propylisoxazole-3-carboxylate. Next, the ethyl ester was hydrolyzed with aqueous base and the resulting acid (<b>5</b>) was converted to an acid fluoride with cyanuric fluoride. This acid fluoride was coupled with <i>N</i>′-hydroxy-4-vinylbenzimidamide (<b>6</b>), which was prepared by heating 4-vinylbenzonitrile with hydroxylamine in 2-propanol. This coupled intermediate was subsequently cyclized to form the central oxadiazole ring by heating at 70 °C in acetonitrile to afford <b>7</b>. Compound <b>7</b> was converted to epoxide <b>8</b> using <i>m</i>-CPBA. From the epoxide, two methods were employed to obtain the final products. The first method was to open the epoxide with phthalimide, followed by treatment with hydrazine to form ethanolamine <b>9</b>. The terminal amine of <b>9</b> was then coupled with an appropriately substituted alkyl halide containing a terminal ester. Deprotection of the terminal ester by treatment with TFA afforded the final product (<b>11a</b>). The second method employed was to open epoxide <b>8</b> by treatment with bromotriethylsilane at −78 °C in THF to yield <b>10</b>. Reaction of the resulting bromo group with an appropriately substituted amine using DBU or tetrabutylammonium hydroxide as a base afforded the desired compounds after purification (<b>11b</b>–<b>m</b>). All of the propylisoxazole analogues (<b>9</b>, <b>11a</b>–<b>m</b>) described above were synthesized as a mixture of isomers with regard to the hydroxyl moiety of the ethanolamine framework. Many of these compounds exhibited promising activity and selectivity, and <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> shows the key results of these ethanolamine-based compounds.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Propylisoxazole Ethanolamines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 160 °C, 18 h, 87%; (b) 1 M NaOH, EtOH, 75 °C, 12 h, 95%; (c) cyanuric fluoride, pyridine, DCM, rt, 1 h, 90%; (d) DIEA, CH<sub>3</sub>CN, rt then heat at 70 °C, 18 h, 45%; (e) <i>m</i>-CPBA, DCM, rt, 12 h, 62%; (f) phthalimide, cat. potassium phthalimide, 100 °C, 12 h, 85%; (g) NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, EtOH, 75 °C, 35%; (h) bromotriethylsilane, THF, −78 °C, 2 h, 50%; (i) R-Br, NaI, pyridine, 80 °C; (j) 6 N HCl, EtOH or MeOH, 70 °C, 12 h, 95% or TFA/DCM (1:1); (k) <i>RR</i>′-NH, DBU, or tetrabutylammonium hydroxide, DMSO, 80 °C, 10–50%.</p></p></figure><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of Propylisoxazole Ethanolamines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0008.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0009.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub>/EC<sub>50</sub> values are shown as single determinations.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">IC<sub>50</sub>/EC<sub>50</sub> values are shown as a mean of two determinations.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">IC<sub>50</sub>/EC<sub>50</sub> values are shown as a mean of at least three determinations; nt = not tested.</p></div></div><div></div></div><div class="NLM_p">Interestingly, <b>9</b>, which has no terminal carboxylic acid group to mimic the phosphate moiety, had excellent activity in the S1P<sub>1</sub> binding assay with an IC<sub>50</sub> of 1.5 nM and had modest activity in the functional S1P<sub>1</sub> GTPγS assay with an EC<sub>50</sub> of 64 nM. This compound also exhibited some selectivity against S1P<sub>3</sub> (∼34-fold). To increase the activity in the functional assay, a linear alkyl chain with a terminal acid was appended off of this amino group (<b>11a</b>). This compound was a subnanomolar binder in the S1P<sub>1</sub> binding assay and the addition of the terminal carboxylic acid did indeed increase the S1P<sub>1</sub> GTPγS activity, giving an EC<sub>50</sub> of 38 nM. Next, a variety of pyrrolidine, piperidine, cyclopentyl, and piperazine compounds containing a carboxylic acid were synthesized (<b>11b</b>–<b>j</b>). These compounds all have the carboxylic acid positioned two carbons from the ethanolamine nitrogen, as compounds with the carboxylic acid one carbon away had reduced activity (data not shown). The pyrrolidine-3-carboxylic acid compound (<b>11b</b>) was potent in the S1P<sub>1</sub> binding assay with an IC<sub>50</sub> of 0.69 nM; however, its functional activity was only modest (S1P<sub>1</sub> GTPγS EC<sub>50</sub> of 61 nM). Compound <b>11c</b>, which contains a 2-pyrrolidine acetic acid, and <b>11d</b>, which contains a 2-piperidine acetic acid, both demonstrated poor activity in both the binding and functional assays. We next examined piperidine compounds with the carboxylic acid moiety directly attached to the 3-position of the piperidine (<b>11e</b>–<b>f</b>). Compound <b>11e</b>, which has the <i>S</i> stereochemistry at this position, proved to be optimal with an EC<sub>50</sub> of 6.9 nM in the S1P<sub>1</sub> GTPγS assay. The corresponding diastereomeric mixture (<b>11f</b>) was greater than 20 times less potent. Compounds <b>11g</b>–<b>h</b> are cyclopentyl derivatives in which the amine and carboxylic acid are exocyclic and have a cis configuration. Both isomers had excellent S1P<sub>1</sub> binding with <b>11g</b>, being roughly three times more potent than <b>11h</b>. This more potent compound was analyzed in the S1P<sub>1</sub> GTPγS functional assay, providing an EC<sub>50</sub> of 27 nM. Replacing the 3-carboxylic acid of the piperidine with a hydroxyl group (<b>11i</b>) proved to be detrimental for both binding and functional activity, and converting the piperidine to a piperazine while maintaining the carboxylic acid in the 3 position (<b>11j</b>) also reduced both the S1P<sub>1</sub> binding and GTPγS activity. Placing a methylene spacer in between the piperidine and carboxylic acid in the 3 position, however, provided compounds with potent functional activity (<b>11k</b>–<b>m</b>). After preparing the compounds with <i>R</i> (<b>11l</b>) and <i>S</i> (<b>11m</b>) stereochemistry at the acid center, <b>11l</b>, was the most potent compound in this series with a GTPγS activity of 3.9 nM and a 300-fold selectivity over S1P<sub>3</sub>.</div><div class="NLM_p">Select compounds were chosen from <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> to be evaluated in an in vivo rat blood lymphocyte reduction (BLR) pharmacodynamic/pharmacokinetic (PD/PK) assay to assess their ability to reduce peripheral blood lymphocyte counts in Lewis rats. The linear alkyl analogue (<b>11a</b>) and the two most potent compounds from the piperidine series (<b>11e</b> and <b>11l</b>) were all evaluated in this assay, and the results are shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. At an oral dose of 30 mpk, compound <b>11a</b> reduced the peripheral lymphocyte counts by 74% when checked 4 h post administration. By the 24 h time point, the lymphocyte counts had returned to normal levels. Compound <b>11e</b> was dosed at 10 mpk and exhibited a 77% reduction in the peripheral lymphocyte counts. Again, by the 24 h time point, the lymphocyte counts had returned to normal levels. Compound <b>11l</b>, which was the most potent of the compounds evaluated in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, was dosed at 3 mpk. At 4 h postdose, this compound exhibited an 81% reduction in the peripheral lymphocyte count and at 24 h showed a 25% reduction. The return of lymphocyte counts to baseline for these analogues was consistent with the reduction in compound plasma concentrations from 4 to 24 h. These results prompted us to evaluate these new polar headgroups with our optimal lipophilic tails.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Effects of Select Propylisoxazole Ethanolamines on Blood Lymphocyte Counts in Lewis Rats (<i>n</i> = 3)</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">lymphoyte red, 4 h (exposure, nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">lymphoyte red, 24 h (exposure, nM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="center">30</td><td class="colsep0 rowsep0" align="center">–74% (142)</td><td class="colsep0 rowsep0" align="center">–11% (LLQ)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11e</b></td><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">–77% (1595)</td><td class="colsep0 rowsep0" align="center">–5.3% (38)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11l</b></td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">–81% (685)</td><td class="colsep0 rowsep0" align="center">–25% (40)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">LLQ = below detectable limits.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Exposure: plasma concentration at the time indicated.</p></div></div></div><div class="NLM_p">We combined the lipophilic tail (3-phenyl-4-(trifluoromethyl)isoxazole) from <b>4</b> with the preferred fragments found here (<b>11e</b> and <b>11l</b>). The same relative stereochemistry for both these piperidine headgroups was found to be optimal, and this stereochemistry was kept constant for these new analogues. Again, the initial SAR studies of these analogues was performed on a mixture of isomers with regard to the hydroxyl moiety of the ethanolamine framework. The azetidine-3-carboxylic acid moiety, which has been utilized by a number of groups with great success, albeit on different scaffolds, was also incorporated here as part of the ethanolamine framework. Our synthesis (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) began by coupling the commercially available (2-bromoacetyl)benzonitrile with <i>tert</i>-butyl azetidine-3-carboxylate, (<i>S</i>)-ethylpiperidine-3-carboxylate, and (<i>R</i>)-ethyl 2-(piperidin-3-yl)acetate. These compounds were then reduced using sodium borohydride in ethanol to give the corresponding alcohols (<b>12</b>, <b>14</b>, <b>15</b>). To install the lipophilic tail piece of <b>4</b>, the nitrile group was first heated with hydroxylamine and sodium bicarbonate in 2-propanol and then coupled with 3-phenyl-4-(trifluoromethyl)isoxazole-5-carbonyl fluoride. Treatment of this intermediate with 1 M TBAF in THF cyclized the coupled product to form the central oxadiazole ring. Finally, deprotection of the terminal ester either by aqueous acid hydrolysis or treatment with TFA afforded the final products (<b>13</b>, <b>16</b>, <b>17</b>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Trifluoromethyloxazole Ethanolamines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) toluene, rt, 18 h; (b) NaBH<sub>4</sub>, EtOH or MeOH, 80–95% (c) NH<sub>2</sub>OH, NaHCO<sub>3</sub>, <sup><i>i</i></sup>PrOH 85–90%; (d) 3-phenyl-4-(trifluoromethyl)isoxazole-5-carbonyl fluoride, DIEA, CH<sub>3</sub>CN, rt, 2 h then TBAF/THF, 12 h, 20–50%; (e) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1) (f) 6 N HCl, CH<sub>3</sub>CN or dioxane, 80 °C, 12 h, 80%; (g) chiral HPLC separation of isomers.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> contains the binding and functional activities of <b>13</b>, <b>16</b>, and <b>17</b> as well as their ability to reduce lymphocyte counts in an in vivo BLR PK/PD assay. Compound <b>13</b>, which incorporates the azetidine-3-carboxylic acid and the lipophilic tail from <b>4</b>, provided a compound with an S1P<sub>1</sub> binding IC<sub>50</sub> of 5.8 nM and demonstated impressive S1P<sub>1</sub> functional activity and selectivity against S1P<sub>3</sub> (EC<sub>50</sub> = 7.8 nM, ∼1500-fold selectivity). In the BLR PK/PD assay, <b>13</b> reduced the lymphocyte count by 70% at a dose of 3 mpk when measured at the 24 h time point. The (<i>S</i>)-piperidine-3-carboxylic acid headgroup with the lipophilic tail of <b>4</b> (<b>16</b>) also gave a compound with impressive binding and functional activity (S1P<sub>1</sub> binding IC<sub>50</sub> = 0.47 nM; S1P<sub>1</sub> GTPγS EC<sub>50</sub> = 7.8 ± 3.5 nM), and this compound also gave greater than 1500-fold selectivity over S1P<sub>3</sub>. In the BLR PK/PD assay, <b>16</b> exhibited an 81% reduction in lymphocytes at a dose of 3 mpk at the 24 h time point. As in the propylisoxazole series, the (<i>R</i>)-piperidin-3-yl)acetic acid ethanolamine headgroup was the most potent compound (<b>17</b>). Compound <b>17</b> had an S1P<sub>1</sub> GTPγS EC<sub>50</sub> of 4.2 ± 1.0 and displayed ∼1000-fold selectivity over S1P<sub>3</sub>. When dosed at 1 mpk in the BLR PK/PD assay, <b>17</b> reduced the lymphocyte count by 75% when checked after 24 h. These compounds all showed a marked improvement over the initial propylisoxazole series as that series showed little to no significant reduction of lymphocytes after 24 h at a dose of 3–10 mpk.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR of Trifluoromethyloxazole Ethanolamines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0010.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0011.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub>/EC<sub>50</sub> values are shown as single determinations.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">IC<sub>50</sub>/EC<sub>50</sub> values are shown as a mean of two determinations.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">IC<sub>50</sub>/EC<sub>50</sub> values are shown as a mean of at least three determinations.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Compounds tested in Lewis rat (<i>n</i> = 3).</p></div></div><div></div></div><div class="NLM_p">Next, the stereochemistry at the hydroxyl position for the piperidine analogues (<b>16</b>, <b>17</b>) was analyzed to determine if there was a preference at this chiral center as well. Compounds <b>14</b> and <b>15</b> were again reduced using sodium borohydride in ethanol to give the corresponding alcohols (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). These alcohols were then separated under chiral SFC conditions to provide each isomer (<b>14a</b>, <b>14b</b>, <b>15a</b>, <b>15b</b>). The stereochemistry of both centers of <b>14a</b> was unambiguously determined by small molecule X-ray analysis.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The stereochemistry of <b>15a</b> was later determined through a synthesis using a chiral reducing agent of known induction.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Each compound was then carried through the next steps as previously described to afford the two piperidine carboxylic acid isomers <b>18a</b> and <b>18b</b> and the two piperidine acetic acid isomers <b>19a</b> and <b>19b</b>.</div><div class="NLM_p">The functional activities of the homochiral optimal polar headgroups combined with the lipophilic tailpiece of <b>4</b> are shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. In the piperidine carboxylic acid series, the stereochemistry at the acid center was set as <i>S</i> because this proved to be more active in the previous series, and the stereochemistry at the alcohol center was studied with both the <i>R</i> and <i>S</i> configuration. The compound with the 1<i>S</i>,2<i>S</i> stereochemistry (<b>18a</b>) was more active in the S1P<sub>1</sub> GTPγS assay with an EC<sub>50</sub> of 3.5 ± 1.5 nM as compared to 30 ± 9 nM for the 1<i>S</i>,2<i>R</i> isomer (<b>18b</b>). In the piperidine acetic acid series, the same relative stereochemistry at the alcohol center proved to be the more active isomer and <b>19a</b> was the most active in the series with an EC<sub>50</sub> of 1.2 ± 0.52 nM in the GTPγS assay. These compounds all show excellent selectivity against S1P<sub>3</sub> (>1000 fold). The two more active isomers were also tested against S1P<sub>4</sub> and S1P<sub>5</sub>. Compound <b>18a</b> had EC<sub>50</sub>s of around 1 nM for both these receptors, while <b>19a</b> was slightly more active with EC<sub>50</sub>s of roughly 0.5 nM against both.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR of Homochiral Trifluoromethyloxazole Ethanolamines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0012.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0013.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values are shown as a mean of at least three determinations.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">EC<sub>50</sub> values are shown as a mean of two determinations.</p></div></div><div></div></div><div class="NLM_p">After determining the most favorable stereochemistry at both the hydroxyl centers (<i>S</i> for both series) and carboxylic acid centers (<i>S</i> for the piperidine carboxylic acid and <i>R</i> for the piperidine acetic acid), other lipophilic tails were synthesized with these two novel polar headgroups using the methods shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a> shows the results of selected compounds in both the S1P<sub>1</sub> and S1P<sub>3</sub> functional assays as well as results from in vivo BLR PK/PD to determine lymphocyte reductions at the 24 h time point. The first two compounds are with the lipophilic tail from <b>4</b>, and their in vitro activities were previously discussed. At an oral dose of 0.3 mpk, both of these analogues were very effective at reducing the peripheral lymphocyte count, with <b>18a</b> showing 54% reduction and <b>19a</b> showing 80% reduction after 24 h. Changing the phenyl group on the oxazole to a pyridyl group (<b>20a</b>–<b>b</b>) gave a compound with similar potency in the S1P<sub>1</sub> GTPgS assay and was even more selective against S1P<sub>3</sub>. There was, however, a slight reduction in efficacy in the BLR PK/PD assay. Reversing the N and O to form the alternate isoxazole isomer resulted in roughly equal potency in the functional assays (<b>21a</b>–<b>b</b>). In the BLR PK/PD assay, the alternate isoxazole isomer with the piperidine carboxylic acid (<b>21a</b>) was somewhat less effective, exhibiting a 13% reduction of lymphocytes at 1 mpk. However, the alternate isoxazole isomer with the piperidine acetic acid (<b>21b</b>) was equally as effective as its counterpart (<b>19a</b>), with a 76% reduction at a dose of 0.3 mpk. Next, we examined replacing the phenyl group with alkyl and cycloalkyl derivatives and limited these to the piperidine acetic acid polar headgroup (<b>22</b>–<b>23</b>). In general, the compounds with an alkyl substituent were sufficiently active in the S1P<sub>1</sub> GTPγS functional assay but were much less effective in the BLR PK/PD assay. The best compound from these analogues is <b>23</b> which had a 49% reduction in lymphocytes. While we had several lipophilic tails which showed promise with these ethanolamine-based polar headgroups, we decided to further analyze <b>18a</b> and <b>19a</b> both in vitro and in vivo to assess whether they would be candidates for further progression.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SAR of 5-Substituted Trifluoromethyloxazole Ethanolamines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0014.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0015.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values are shown as single determinations.</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">EC<sub>50</sub> values are shown as a mean of two determinations.</p></div><div class="footnote" id="t5fn3"><sup>Table c</sup><p class="last">EC<sub>50</sub> values are shown as a mean of at least three determinations.</p></div><div class="footnote" id="t5fn4"><sup>Table d</sup><p class="last">Compounds tested in Lewis rat (<i>n</i> = 3).</p></div></div><div></div></div><div class="NLM_p">To understand the specific interactions with S1P<sub>1</sub>, compound <b>19a</b> was docked into the crystal structure of S1P<sub>1</sub> in complex with <b>24</b> (ML056)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). The model suggests that the aromatic tail is buried deeply within the transmembrane bundle in a cavity formed between TM2, TM3, TM5, and TM6. The polar headpiece is predicted to be oriented toward the extracellular side of the receptor, forming hydrogen bonding interactions with residues at the top of TM1 and TM7 as well as the N-terminus. Two salt bridges are predicted to be present with residues on TM7: the terminal acetic acid moiety and R292 and the piperidine nitrogen and E294. Additional hydrogen bonds are predicted between the acetic acid-T48 and the hydroxyl group-E294/K34. The strong interactions with the hydroxyl group are consistent with the SAR, showing it to be a critical group.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Although <b>24</b> and <b>19a</b> putatively fill the same hydrophobic pocket, the polar interactions predicted by the model are different than those observed to the amino phosphonate moiety in <b>24</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>b). The amino group is more deeply buried within the transmembrane region, forming a hydrogen bond with N101. The phosphonate is in a salt bridge with K34, and hydrogen bonded with Y29. Compound <b>19a</b> is predicted to share an interaction with K34, but the remaining polar interactions are on the protein surface.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Predicted binding mode of compound <b>19a</b> in S1P<sub>1</sub>. (A) Docked conformation of compound <b>19a</b> in the S1P<sub>1</sub> crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V2W">3V2W</a>). The hydrophobic pocket is shown as a surface and the polar interactions as sticks. (B) Overlay of the crystallographic ligand <b>24</b> (blue) and <b>19a</b> (orange).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> shows the results of a BLR PK/PD study to investigate the dose response for compounds <b>18a</b> and <b>19a</b>. The compounds were assessed at three doses, and the blood lymphocyte count was determined at 4 and 24 h. Compound <b>18a</b> was dosed orally at 1, 0.3, and 0.1 mpk. At 1 mpk, <b>18a</b> showed maximal lymphocyte reduction at both the 4 and 24 h time points and a clear dose dependency was observed. Using the exposure data from this experiment, the EC<sub>50</sub> and ED<sub>50</sub> for <b>18a</b> were estimated to be 19 nM and 0.6 mpk, respectively, at the 24 h time points. Being more potent, <b>19a</b> was dosed at 0.03, 0.1, and 0.3 mpk. Again, a clear dose response was observed, with the highest dose giving maximal lymphocyte reduction for this assay at both the 4 and 24 h time points. For <b>19a</b>, the exposure data at the 24 h time point gave an EC<sub>50</sub> of 19 nM with an ED<sub>50</sub> of 0.1 mpk.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Dose response of <b>18a</b> (0.1, 0.3, and 1.0 mg/kg) and <b>19a</b> (0.03, 0.1, and 0.3 mg/kg) vs vehicle in the blood lymphocyte reduction assay in Lewis Rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The pharmacodynamic properties of <b>18a</b> and <b>19a</b> are shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. These compounds are both highly bound to plasma proteins in mouse, rat, monkey, dog, and human (>98.7%) and in vitro liver microsomes studies indicated the metabolic clearance of <b>18a</b> and <b>19a</b> was very low in all species (>98% remaining). Consistent with the low in vitro clearance, both compounds had low systemic clearance in vivo ranging from 0.1 to 1.7 mL/mg/kg. Compound <b>18a</b> had consistently good absolute bioavailability in all species, with <i>F</i>% ranging from 62 to 90%. The <i>T</i><sub>1/2</sub> from species to species was somewhat inconsistent, with a low of 9 h in rat to high of 33 h in cynomolgus monkey. Additionally, the peak to trough ratio was inconsistent with mouse and monkey, having ratio of 1.7 while rat and dog had ratios of 6.7 and 11.3, respectively. In contrast, compound <b>19a</b> exhibited very consistent PK across all species. The <i>T</i><sub>1/2</sub> ranged from 23 to 28 h and the peak to trough was equally consistent, ranging from 1.3 to 2.8. The absolute bioavailabilities were very good, with <b>19a</b> exhibiting slightly better results than <b>18a</b> in rat, monkey, and dog.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Parameters for Compound <b>18a</b> and <b>19a</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub>, μM (<i>T</i><sub>max</sub>, h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (0–24h) (μM·h)</th><th class="colsep0 rowsep0" align="center" char=".">IV CL (L/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">IV <i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i>% (PO)</th><th class="colsep0 rowsep0" align="center" char=".">peak/trough</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="center">Pharmacodynamic Properties of <b>18a</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">IV: 1 PO: 1</td><td class="colsep0 rowsep0" align="center">45 (1)</td><td class="colsep0 rowsep0" align="char" char=".">362</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">66</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">IV: 2 PO: 5</td><td class="colsep0 rowsep0" align="center">5.3 (3.3)</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="char" char=".">6.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="left">IV: 1 PO: 1</td><td class="colsep0 rowsep0" align="center">1.1 (4)</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">IV: 1 PO: 1</td><td class="colsep0 rowsep0" align="center">0.84 (0.8)</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">74</td><td class="colsep0 rowsep0" align="char" char=".">11.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="center">Pharmacodynamic Properties of <b>19a</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">IV: 1 PO: 1</td><td class="colsep0 rowsep0" align="center">44 (0.5)</td><td class="colsep0 rowsep0" align="char" char=".">315</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">IV: 2 PO: 5</td><td class="colsep0 rowsep0" align="center">4.7 (3.7)</td><td class="colsep0 rowsep0" align="char" char=".">66</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">87</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="left">IV: 1 PO: 1</td><td class="colsep0 rowsep0" align="center">1.5 (10)</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">27</td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">IV: 0.5 PO: 0.5</td><td class="colsep0 rowsep0" align="center">489 (4)</td><td class="colsep0 rowsep0" align="char" char=".">7.8</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">90</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last"><i>F</i> = bioavailability; <i>C</i><sub>max</sub> = maximal concentration reached in plasma; <i>T</i><sub>max</sub> = time at which <i>C</i><sub>max</sub> was reached; Cl = clearance, <i>V</i><sub>ss</sub> = volume of distribution at steady state.</p></div></div></div><div class="NLM_p">The ability of <b>19a</b> to drive receptor internalization was investigated using CHO cells transfected with human S1P<sub>1</sub> fused with GFP. In this assay, <b>19a</b> acted as a full agonist inducing S1P<sub>1</sub> internalization with an EC<sub>50</sub> of 5.0 ± 4.6 nM (<i>n</i> = 35). Compound <b>19a</b> was further characterized for off-target as well as genotoxic potential (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). It was screened for its selectivity against a large panel of receptors, transporters, and kinases, and no appreciable activities were detected (data not shown) and <b>19a</b> was negative in the Ames assay. Some activity was detected in the ion channel assays. In cardiac repolarization assays (hERG patch clamp), <b>19a</b> exhibited an IC<sub>50</sub> of 4.1 μM. Given the high level of protein binding observed with this compound, we surmised it would still have a low cardiac liability. As <b>19a</b> exhibited consistent pharmacodynamic behavior across multiple species and possessed an acceptable liability profile, we chose to study it in animal models.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. In Vitro Profiling Data for Compound <b>19a</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0016.gif" alt="" id="fx9" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">result</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein binding (% bound)</td><td class="colsep0 rowsep0" align="left"><99.0 human</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">99.8 mouse</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">99.5 rat</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">99.3 dog</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">99.1 monkey</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mutagenicity</td><td class="colsep0 rowsep0" align="left">Ames negative</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG (patch clamp)</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 4.1 μM<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Na<sup>+</sup> (patch clamp)</td><td class="colsep0 rowsep0" align="left">14% @ 10 μM (1 and 4 Hz)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ca<sup>+</sup> (patch clamp)</td><td class="colsep0 rowsep0" align="left">14% @ 10 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> inhibition (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">>40 μM 1A2, 2B6, 2C9, 2C19, 2D6, 3A4; 2C8 = 22 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aqueous solubility</td><td class="colsep0 rowsep0" align="left">>850 μg/mL (pH 1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">229 μg/mL (pH 6.5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PAMPA<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a> permeability</td><td class="colsep0 rowsep0" align="left">295 nm/s @ pH 7.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p<i>K</i><sub>a</sub></td><td class="colsep0 rowsep0" align="left">8.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i> (pH 6.5)</td><td class="colsep0 rowsep0" align="left">3.94</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Average of three replicates.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Cyp = cytochrome P450. PAMPA = parallel artificial membrane permeability assay.</p></div></div></div><div class="NLM_p"><a class="ref internalNav" href="#fig4" aria-label="Figures 4">Figures 4</a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> show compound <b>19a</b> in two preclinical models of disease. <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a> shows the results of a rat adjuvant induced arthritis model (rat AA), a model for human rheumatoid arthritis,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and the data shown demonstrates the suppressive effects of orally administered <b>19a</b> over the 21-day study. In rats dosed with vehicle only, there was an increase in paw volume beginning at day 11, and this swelling reached a maximum level at day 15 (1.5 mL increase). Rats given <b>19a</b> at doses of 0.06, 0.2, and 1.0 mpk exhibited a dose dependent reduction in the amount of paw edema. In fact, in the groups treated with 0.2 and 1 mpk of <b>19a</b>, there was no paw volume increase observed throughout the duration of the study. The rats dosed at 0.06 mpk had paw edema beginning at day 13 and at day 20 had roughly half the amount of swelling as the vehicle group. From this study, the compound was determined to have an ED<sub>50</sub> of 0.05 mpk in the rat AA model.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Efficacy of <b>19a</b> (0.06, 0.2, and 1.0 mg/kg) vs vehicle in a rat adjuvant arthritis model. Rats (<i>n</i> = 8/group) were administered <b>19a</b> PO/QD starting on day 0 at the time of immunization. Vehicle: PEG300. <i>p</i> value <0.05 compared to vehicle treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Efficacy of <b>19a</b> (0.01, 0.1, and 1.0 mg/kg) and vs vehicle in a mouse experimental autoimmune encephalomyelitis model (EAE). Mice (<i>n</i> = 10/group) were administered <b>19a</b> PO/QD starting on day 0 at the time of immunization with MOG-peptide (myelin oligodendrocyte glycoprotein). Vehicle: PEG300. <i>p</i> value <0.05 compared to vehicle treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We also evaluated the suppressive effect of <b>19a</b> on experimental autoimmune encephalomyelitis (EAE). EAE has been used as a preclinical animal model for proof of concept studies for multiple sclerosis therapy. The graph in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a> demonstrates the effects of orally administered <b>19a</b> in this EAE study. Vehicle-administered mice began to show clinical signs from day 10, and thereafter an acute increase of the EAE score was observed reaching maximal level on day 18. Compound <b>19a</b> was given at once-daily doses of 0.01, 0.1, and 1 mpk with po dosing initiated at the time of immunization. All doses were efficacious in lowering the EAE clinical scores taken from day 12 until the completion of the study when compared to the vehicle treated group.</div></div><div id="sec99" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54312" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54312" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have discovered selective, direct acting S1P<sub>1</sub> agonists utilizing a novel polar headgroup consisting of an ethanolamine scaffold with a terminal carboxylic acid. This campaign resulted in the discovery of <b>19a</b>. This very potent and selective compound efficiently reduced blood lymphocyte counts in rats, had an acceptable liability profile, and had desirable pharmacokinetic and pharmacodynamic properties. Furthermore, studies in two preclinical models of arthritis and multiple sclerosis demonstrated <b>19a</b> to have robust efficacy. In comparison to our first development candidate (<b>4</b>), compound <b>19a</b> exhibited similar in vitro activity and comparable efficacy in two preclinical disease models (rat AA and mouse EAE); however, the PK/PD profile of <b>19a</b> was more consistent across multiple species (mouse, rat, monkey, and dog). On the basis of these encouraging results, <b>19a</b> was progressed to advanced studies for consideration as a clinical development candidate.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33831" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33831" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Biological Assays</h3><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> S1P<sub>1</sub> Binding Assay</h4><div class="NLM_p last">Membranes were prepared from CHO cells expressing human S1P<sub>1</sub>. Cells were dissociated in buffer containing 20 mM HEPES, pH 7.5, 50 mM NaCl, 2 mM EDTA, and protease inhibitor cocktail (Roche) and disrupted on ice using the Polytron homogenizer. The homogenate was centrifuged at 20000 rpm (48000<i>g</i>), and the supernatant was discarded. The membrane pellets were resuspended in buffer containing 50 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM MgCl<sub>2</sub>, and 2 mM EDTA and stored in aliquots at −80 °C after protein concentration determination. Membranes (2 μg/well) and 0.03 nM final concentration of <sup>33</sup>P–S1P ligand (1 mCi/ml, American Radiolabeled Chemicals) were added to the compound plates. Binding was performed for 45 min at room temperature and terminated by collecting the membranes onto GF/B filter plates, and radioactivity was measured by TopCount. The competition data of the test compounds over a range of concentrations was plotted as percentage inhibition of radioligand specific binding. The IC<sub>50</sub> is defined as the concentration of competing ligand needed to reduce specific binding by 50%.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Receptor [<sup>35</sup>S] GTPγS Binding Assays</h4><div class="NLM_p last">Compounds were loaded in a 384 Falcon V-bottom plate (0.5 μL/well in a 3-fold dilution). Membranes prepared from S1P<sub>1</sub>/CHO cells or EDG3-Ga15-bla HEK293T cells were added to the compound plate (40 μL/well, final protein 3 μg/well) with multidrop. [<sup>35</sup>S]GTP (1250 Ci/mmol, PerkinElmer) was diluted in assay buffer: 20 mM HEPES, pH 7.5, 10 mM MgCl<sub>2</sub>, 150 mM NaCl, 1 mM EGTA, 1 mM DTT, 10 μM GDP, 0.1% fatty acid free BSA, and 10 μg/mL saponin to 0.4 nM. Then 40 μL of the [<sup>35</sup>S] GTP solution was added to the compound plate with a final concentration of 0.2 nM. The reaction was kept at room temperature for 45 min. At the end of incubation, all the mixtures in the compound plate were transferred to a 384-well FB filter plates via GPCR robot system. The filter plate was washed with water four times by using the modified manifold Embla plate washer and dried at 60 °C for 45 min. Then 30 μL of MicroScint 20 scintillation fluid was added to each well for counting at Packard TopCount. EC<sub>50</sub> is defined as the agonist concentration that corresponds to 50% of the <i>Y</i><sub>max</sub> (maximal response) obtained for each individual compound tested.</div></div><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Blood Lymphocyte Reduction Assay (BLR) in Rodents</h4><div class="NLM_p last">Lewis rats were dosed orally with test article (as a solution or suspension in the vehicle) or vehicle alone (polyethylene glycol 300, PEG300). Blood was drawn at 4 h and at 24 h by retro-orbital bleeding. Blood lymphocyte counts were determined on an ADVIA 120 hematology analyzer (Siemens Healthcare Diagnostics). The results were measured as a reduction in the percentage of circulating lymphocytes as compared to the vehicle treated group at the 4 and 24 h measurements. The results represent the average results of all animals within each treatment group (<i>n</i> = 3–4).</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Rat Adjuvant Induced Arthritis Assay (AA)</h4><div class="NLM_p last">Male Lewis rats (150–175 g; Harlan, <i>n</i> = 8 treatment group) were immunized at the base of the tail with 100 μL of 10 mg/mL freshly ground <i>Mycobacterium butyricum</i> (Difco Laboratories) in incomplete Freund’s adjuvant (sigma). Animals were dosed once daily with the test article (as a solution or suspension in the vehicle) or vehicle alone (polyethylene glycol 300, PEG300) starting from the day of immunization. The volumes of their hind paws were measured in a water displacement plethysmometer (Ugo Basile, Italy). The baseline paw measurements were taken before onset of the disease (between day 7 to day 10). The paw measurements were then taken three times a week until the end of the study on day 20. All procedures involving animals were reviewed and approved by the Institutional Animal Care Use Committee.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Mouse Experimental Autoimmune Encephalomyelitis Assay (EAE)</h4><div class="NLM_p last">Mice (C57BL/6 female, 6–8 weeks of age, Charles River, <i>n</i> = 10–12 treatment group) were immunized subcutaneously with 150 μg MOG35-55 emulsified 1:1 with incomplete Freund’s adjuvant (sigma) supplemented with 150 μg <i>Mycobacterium tuberculosis</i> H37RA (Difco Laboratories). Then 400 ng of pertussis toxin (CalBiochem) was injected intraperitoneally on the day of immunization, and 2 days later, animals were dosed once daily with the test article (as a solution or suspension in the vehicle) or vehicle alone (polyethylene glycol 300, PEG300) starting from 1 day after immunization. Clinical scoring and body weight were taken 3 times per week until the end of the study on day 24. Clinical scoring system: 0.5, partial tail weakness; 1, limp tail or waddling gait with tail tonicity; 1.5, waddling gait with partial tail weakness; 2, waddling gait with limp tail (ataxia); 2.5, ataxia with partial limb paralysis; 3, full paralysis of one limb; 3.5, full paralysis of one limb with partial paralysis of a second limb; 4, full paralysis of two limbs; 4.5, moribund; 5, death.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> S1P<sub>1</sub> Internalization Assay</h4><div class="NLM_p last">hS1P<sub>1</sub> internalization assay: For quantification of S1P-1 expression using a high content system, GFP was fused to hS1P<sub>1</sub> at its C-terminus and a stable CHO cell line expressing hS1P<sub>1</sub>/GFP was established. Cells were suspended in assay medium (F12 medium with 5% charcoal-dextran treated FBS, 20 mM HEPES, and 1× Pen/Strep) at 7.5 × 104 cells/mL and plated into 384-well plates (in 20 μL, 1500 cells/well final) with a Multidrop liquid handler (Thermo Scientific, Waltham, MA). Cell plates were incubated at 37 °C for 48 h. Titrated S1P and BMS compounds were dispensed into the cell plates (concentration range from 100 to 0.005 μM), and the plates were further incubated at 37 °C for 50 min. Cells were fixed by adding 10 μL of fixation buffer (7.4% v/v formaldehyde containing 15 μM Draq5 in DPBS) directly onto the assay medium and incubated for 15 min at rt followed by two washes with DPBS. This was followed by the addition of 50 μL of DPBS to the cell layer, and the plates were sealed with a transparent plate seal (PerkinElmer no. 6005185). Imaging was carried out using the Evotec Opera high content confocal system (PerkinElmer, Boston, MA) equipped with three diode lasers, Peltier cooled CCD camera detector, and a Nipkow spinning disk. Cell images were quantified using a membrane fluorescent scoring algorithm. Data was analyzed using a customized HTS data analysis software package. EC<sub>50</sub> values were determined using XL-Fit software program.</div></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Molecular Modeling Methods</h3><div class="NLM_p last">All modeling calculations were carried out using Maestro v2015-1 (Schrodinger LLC). The S1P1 crystal structure in complex with <b>24</b> (RCSB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V2W">3V2W</a>) was the receptor template used for docking studies. The protein was prepared using the Protein Prep module following the default protocols. Candidate compounds were docked with Glide into a binding site centered on the crystallographic ligand and including residues within 5 Å of the ligand. Compounds were docked without constraints and 20 poses returned. Favorable poses were selected by visual inspection and minimized using the Protein Refinement Minimize module. The ligand and residues within 5 Å were freely mobile, with the remainder frozen. The final pose was selected from the minimized complexes via visual inspection.</div></div><div id="sec3_6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Chemistry</h3><div class="NLM_p">All commercially available chemicals and solvents were used without further purification. Reactions were performed under an atmosphere of nitrogen. All flash column chromatography was performed on EM Science silica gel 60 (particle size of 40–60 μm). All new compounds gave satisfactory <sup>1</sup>H NMR, LC/MS, and/or HRMS and mass spectrometry results. <sup>1</sup>H NMR spectra were obtained on a Bruker 400 MHz or a JEOL 500 MHz NMR spectrometer using the residual signal of deuterated NMR solvent as internal reference. Electrospray ionization (ESI) mass spectra were obtained on a Waters ZQ single quadrupole mass spectrometer. High-resolution mass spectral analysis was performed on an LTQ-FT mass spectrometer interfaced to a Waters Acquity ultraperformance liquid chromatography.</div><div class="NLM_p">HPLC analyses were performed using the following conditions. All final compounds had an HPLC purity of ≥95%.</div><div id="sec3_6_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Method A</h4><div class="NLM_p last">A linear gradient using 10% methanol, 90% water, and 0.1% TFA (solvent A) and 90% methanol, 10% water, and 0.1% TFA (solvent B); <i>t</i> = 0 min, 0% B, <i>t</i> = 2 min, 100% B (1 min) was employed on a Waters Sunfire C18 5 μm 4.6 mm × 30 mm column. Flow rate was 5.0 mL/min, and UV detection was set to 220/254 nm. The LC column was maintained at ambient temperature.</div></div><div id="sec3_6_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Method B</h4><div class="NLM_p last">A linear gradient using 10% methanol, 90% water, and 0.1% TFA (solvent A) and 90% methanol, 10% water, and 0.1% TFA (solvent B); <i>t</i> = 0 min, 0% B, <i>t</i> = 4 min, 100% B (1 min hold) was employed on a Waters Sunfire C18 4.6 mm × 50 mm column. Flow rate was 4.0 mL/min, and UV detection was set to 220/254 nm. The LC column was maintained at ambient temperature.</div></div><div id="sec3_6_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Method C</h4><div class="NLM_p last">A linear gradient using 5% CH<sub>3</sub>CN, 95% water with 10 μM ammonium acetate (solvent A) and 95% CH<sub>3</sub>CN, 5% water with 10 mM ammonium acetate (solvent B); <i>t</i> = 0 min, 0% B, <i>t</i> = 4 min, 100% B (1 min hold) was employed on a Supelco Ascentis Express C18, 4.6 mm × 50 mm, 2.7 μm particles column. Flow: 4 mL/min. The LC column was maintained at ambient temperature.</div></div><div id="sec3_6_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Method E</h4><div class="NLM_p last">A linear gradient using 10% methanol, 90% water, and 0.1% TFA (solvent A) and 90% methanol, 10% water, and 0.1% TFA (solvent B); <i>t</i> = 0 min, 0% B, <i>t</i> = 4 min, 100% B (1 min hold) was employed on a Chromolith SpeedROD 4.6 mm × 50 mm column. Flow rate was 4.0 mL/min. The LC column was maintained at ambient temperature.</div></div><div id="sec3_6_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Method F</h4><div class="NLM_p last">A linear gradient using 5% acetonitrile, 95% water, and 0.05% TFA (solvent A) and 95% acetonitrile, 5% water, and 0.05% TFA (solvent B); <i>t</i> = 0 min, 10% B, <i>t</i> = 15 min, 100% B (20 min) was employed on a SunFire C18 3.5 μm 4.6 mm × 150 mm column. Flow rate was 1.0 mL/min, and UV detection was set to 220/254 nm. The LC column was maintained at ambient temperature.</div></div><div id="sec3_6_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Method G</h4><div class="NLM_p last">A linear gradient using 5% acetonitrile, 95% water, and 0.05% TFA (solvent A) and 95% acetonitrile, 5% water, and 0.05% TFA (solvent B); <i>t</i> = 0 min, 10% B, <i>t</i> = 15 min, 100% B (20 min) was employed on a XBridge Ph 3.5 μm 4.6 mm × 150 mm column. Flow rate was 1.0 mL/min, and UV detection was set to 220/254 nm. The LC column was maintained at ambient temperature.</div></div><div id="sec3_6_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Method H</h4><div class="NLM_p last">A linear gradient using 5:95 acetonitrile:water with 10 mM ammonium acetate and 95:5 acetonitrile:water with 10 mM ammonium acetate; <i>t</i> = 0 min, 0% B, <i>t</i> = 4 min, 100% B, then a 1 min hold at 100% B was employed on a Supelco Ascentis Express C18 column (4.6 mm × 50 mm, 2.7 μm particles). Flow rate was 4 mL/min. Temperature 45 °C.</div></div><div id="sec3_6_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Method I</h4><div class="NLM_p last">A linear gradient using 5:95 acetonitrile:water with 0.05% TFA and 95:5 acetonitrile:water with 0.05% TFA; <i>t</i> = 0 min, 0% B, <i>t</i> = 4 min, 100% B, then a 1 min hold at 100% B was employed on a Supelco Ascentis Express C18 column (4.6 mm × 50 mm, 2.7 μm particles). Flow rate was 4 mL/min. Temperature 45 °C.</div></div><div id="sec3_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 5-Phenyl-4-propylisoxazole-3-carboxylic Acid (<b>5</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Pent-1-ynylbenzene (17 mL, 106 mmol) and diethyl 2-nitromalonate (30 mL, 172 mmol) were placed in a stainless steel pressure bomb and heated to 160 °C for 18 h. The reaction mixture was cooled in an ice bath, and then the remaining pressure was slowly released. The reaction mixture was diluted with EtOAc and washed with 1 N NaOH. The aqueous layer was back-extracted once. The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated. The crude material was treated with 1 N NaOH/EtOH at 75 °C for 2 h, diluted with water, and washed with EtOAc. The aqueous layer was separated, acidified with concentrated HCl, and extracted with EtOAc. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated to afford 20 g of 5-phenyl-4-propylisoxazole-3-carboxylic acid as a white solid (<b>5</b>, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 7.61–7.67 (2 H, m), 7.43–7.57 (3 H, m), 2.65–2.73 (2 H, m), 1.47–1.58 (2 H, m), 0.85 (3 H, t, <i>J</i> = 7.36 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 232. HPLC <i>t</i><sub>r</sub> = 3.37 min (<a class="ref internalNav" href="#sec3_6_1_1" aria-label="method A">method A</a>).</div></div><div id="sec3_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>N</i>′-Hydroxy-4-vinylbenzimidamide (<b>6</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a solution of 4-vinylbenzonitrile (4.4 g, 34 mmol) and hydroxylamine hydrochloride (4.7 g, 67.5 mmol) in 2-propanol (50 mL) was added sodium bicarbonate (11.3 g, 135 mmol). The reaction was heated at 80 °C for 2 h. The reaction mixture was diluted with EtOAc and washed with water. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated to afford 5.3 g of <i>N</i>′-hydroxy-4-vinylbenzimidamide (<b>6,</b> 96%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 9.65 (1 H, s), 7.64 (2 H, d, <i>J</i> = 8.52 Hz), 7.46 (2 H, d, <i>J</i> = 8.25 Hz), 6.73 (1 H, dd, <i>J</i> = 17.73, 10.86 Hz), 5.86 (1 H, d, <i>J</i> = 17.87 Hz), 5.80 (2 H, s), 5.27 (1 H, d, <i>J</i> = 11.82 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 163. HPLC <i>t</i><sub>r</sub> = 0.57 min (<a class="ref internalNav" href="#sec3_6_1_1" aria-label="method A">method A</a>).</div></div><div id="sec3_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 5-(5-Phenyl-4-propylisoxazol-3-yl)-3-(4-vinylphenyl)-1,2,4-oxadiazole (<b>7</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of 5-phenyl-4-propylisoxazole-3-carboxylic acid (<b>5</b>), (3 g, 13 mmol), and pyridine (1 mL, 13 mmol) in DCM (50 mL) was added cyanuric fluoride (1.1 mL, 13 mmol). The reaction mixture was stirred 1 h at room temperature. The reaction mixture was diluted with DCM (50 mL) and washed with 1 M HCl. The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was dissolved in CH<sub>3</sub>CN (50 mL) and then <b>6</b> (2.1 g, 13 mmol) and DIEA (3.40 mL, 19.5 mmol) were added. The mixture was heated at 70 °C overnight. The reaction mixture was diluted with EtOAc and washed with saturated KH<sub>2</sub>PO<sub>4</sub>. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated to afford 4.6 g of 5-(5-phenyl-4-propylisoxazol-3-yl)-3-(4-vinylphenyl)-1,2,4-oxadiazole as a solid (<b>7</b>, 45%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) d 8.19 (d, <i>J</i> = 8.4 Hz, 2H), 7.80 (dd, <i>J</i> = 8.0, 1.7 Hz, 2H), 7.64–7.52 (m, 5H), 6.82 (dd, <i>J</i> = 17.6, 10.8 Hz, 1H), 5.91 (dd, <i>J</i> = 17.6, 0.4 Hz, 1H), 5.42 (d, <i>J</i> = 11.4 Hz, 1H), 3.15–2.97 (m, 2H), 1.96–1.70 (m, 2H), 1.09 (t, <i>J</i> = 7.4 Hz, 3H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 358. HPLC <i>t</i><sub>r</sub> = 2.34 min (<a class="ref internalNav" href="#sec3_6_1_1" aria-label="method A">method A</a>).</div></div><div id="sec3_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3-(4-(Oxiran-2-yl)phenyl)-5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazole (<b>8</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of 5-(5-phenyl-4-propylisoxazol-3-yl)-3-(4-vinylphenyl)-1,2,4-oxadiazole (4.6 g, 13 mmol) in DCM (500 mL) was added <i>m</i>-CPBA (9 g, 52 mmol). The reaction mixture was stirred overnight at room temperature. Next, the reaction mixture was washed with 1 N NaOH. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated to afford 3 g of 3-(4-(oxiran-2-yl)phenyl)-5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazole as a solid (<b>8</b>, 62%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.16–8.22 (2 H, m), 7.78 (2 H, dd, <i>J</i> = 8.02, 1.65 Hz), 7.50–7.59 (3 H, m), 7.46 (2 H, d, <i>J</i> = 8.13 Hz), 3.95 (1 H, dd, <i>J</i> = 4.06, 2.53 Hz), 3.22 (1 H, dd, <i>J</i> = 5.49, 4.17 Hz), 2.98–3.06 (2 H, m), 2.85 (1 H, dd, <i>J</i> = 5.49, 2.64 Hz), 1.72–1.83 (2 H, m), 1.06 (3 H, t, <i>J</i> = 7.25 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 374. HPLC <i>t</i><sub>r</sub> = 4.31 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>).</div></div><div id="sec3_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-(2-Hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)isoindoline-1,3-dione<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of 3-(4-(oxiran-2-yl)phenyl)-5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazole (100 mg, 0.27 mmol) and phthalimide (43 mg, 0.30 mmol) in DMF (2 mL) was added potassium phthalimide, (6 mg, 0.032 mmol) and heated to 100 °C overnight. The reaction mixture was diluted with EtOAc and washed with satd NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. Purified by HPLC. HPLC conditions: Phenomenex Luna C18 5 μm column (250 mm × 30 mm); 50–100% CH<sub>3</sub>CN/water (0.1% TFA); 25 min gradient; 30 mL/min. Recovered 85 mg of 2-(2-hydroxy2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)isoindoline-1,3-dione (61%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.15–8.24 (2 H, m), 7.86 (2 H, dd, <i>J</i> = 5.49, 3.08 Hz), 7.75–7.79 (2 H, m), 7.74 (2 H, dd, <i>J</i> = 5.27, 3.08 Hz), 7.61–7.66 (2 H, m), 7.50–7.59 (4 H, m), 5.18 (1 H, dd, <i>J</i> = 8.02, 3.63 Hz), 3.96–4.12 (2 H, m), 2.98–3.05 (2 H, m), 1.71–1.82 (2 H, m), 1.06 (3 H, t, <i>J</i> = 7.36 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 521. HPLC <i>t</i><sub>r</sub> = 4.22 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>).</div></div><div id="sec3_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2-Amino-1-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethanol (<b>9</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of 2-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)isoindoline-1,3-dione (75 mg, 0.14 mmol) in ethanol (5 mL) was added hydrazine monohydrate (1 mL, 20.6 mmol) and heated at 80 °C for 2 h. The reaction mixture was diluted with EtOAc and washed with satd NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The material was dissolved in CH<sub>3</sub>CN and purified by HPLC. HPLC conditions: Phenomenex Luna C18 5 μm column (250 mm × 30 mm); 25–100% CH<sub>3</sub>CN/water (0.1% TFA); 25 min gradient; 30 mL/min. Recovered 30 mg of 2-amino-1-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethanol as a white solid (<b>9</b>, 55%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.08 (2 H, d, <i>J</i> = 8.35 Hz), 7.88 (2 H, br s), 7.74–7.80 (2 H, m), 7.53–7.64 (5 H, m), 6.22 (1 H, d, <i>J</i> = 3.95 Hz), 4.82–4.88 (1 H, m), 3.07 (1 H, dd, <i>J</i> = 12.74, 2.86 Hz), 2.91–2.98 (2 H, m), 2.84 (1 H, dd, <i>J</i> = 12.74, 9.67 Hz), 1.60–1.68 (2 H, m), 0.92 (3 H, t, <i>J</i> = 7.36 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 391. HPLC purity: 95.1%, <i>t</i><sub>r</sub> = 7.51 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 96.1%, <i>t</i><sub>r</sub> = 8.06 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>).</div></div><div id="sec3_6_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-Bromo-1-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethanol (<b>10</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of 3-(4-(oxiran-2-yl)phenyl)-5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazole (205 mg, 0.55 mmol) in THF (5 mL) at −78 °C was slowly added bromotriethylsilane (100 μL, 0.58 mmol). The reaction mixture was stirred for 1 h at −78 °C. The reaction was quenched with water and extracted with EtOAc. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The solids were purified on a silica cartridge using an EtOAc/hexanes gradient to afford 130 mg of 2-bromo-1-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethanol (10, 52%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 8.16–8.24 (2 H, m), 7.72–7.81 (2 H, m), 7.61 (2 H, m, <i>J</i> = 8.13 Hz), 7.49–7.58 (3 H, m), 5.12 (1 H, dd, <i>J</i> = 7.47, 5.93 Hz), 4.09–4.17 (1 H, m), 4.01–4.08 (1 H, m), 2.97–3.05 (2 H, m), 1.70–1.83 (2 H, m), 1.06 (3 H, t, <i>J</i> = 7.36 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 455. HPLC <i>t</i><sub>r</sub> = 2.12 min (<a class="ref internalNav" href="#sec3_6_1_1" aria-label="method A">method A</a>).</div></div><div id="sec3_6_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 3-((2-Hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)amino)propanoic Acid (<b>11a</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of <b>9</b> (27 mg, 0.069 mmol) in pyridine (1 mL) was added <i>tert</i>-butyl 3-bromopropanoate (0.012 mL, 0.069 mmol) and heated at 80 °C for 1 h. The reaction mixture was cooled, filtered, and purified by HPLC. HPLC conditions: Phenomenex Luna C18 5 μm column (250 mm × 30 mm); 25–100% CH<sub>3</sub>CN/water (0.1% TFA); 25 min gradient; 30 mL/min. Isolated fractions with correct mass and freeze-dried overnight. Residue was treated with TFA/DCM (1:1) for 1 h. Solvents were removed in vacuo and freeze-dried from CH<sub>3</sub>CN. Recovered 3 mg of 3-((2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)amino)propanoic acid, TFA salt as a white solid (<b>11a</b>, 9.4%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.64 (1 H, br s), 8.14 (2 H, d, <i>J</i> = 8.35 Hz), 7.82 (2 H, dd, <i>J</i> = 7.91, 1.76 Hz), 7.58–7.70 (5 H, m), 6.41 (1 H, br s), 5.01 (1 H, dd, <i>J</i> = 10.00, 1.65 Hz), 3.18–3.30 (4 H, m), 2.94–3.03 (2 H, m), 2.71 (2 H, td, <i>J</i> = 7.25, 2.20 Hz), 1.64–1.74 (2 H, m, <i>J</i> = 7.56, 7.56, 7.56, 7.42, 7.25 Hz), 0.97 (3 H, t, <i>J</i> = 7.25 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 463. HPLC <i>t</i><sub>r</sub> = 3.4 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 99.4%, <i>t</i><sub>r</sub> = 8.73 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 99.8%, <i>t</i><sub>r</sub> = 7.51 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>).</div></div><div id="sec3_6_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 1-(2-Hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)pyrrolidine-3-carboxylic Acid (<b>11b</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p">To a mixture of <b>10</b> (30 mg, 0.066 mmol) and pyrrolidine-3-carboxylic acid (22.81 mg, 0.198 mmol) in DMSO (2 mL) was added DBU (0.030 mL, 0.198 mmol). The reaction mixture was heated at 80 °C for 2 h. The reaction mixture was filtered and purified by HPLC. HPLC conditions: Phenomenex Luna C18 5 μm column (250 mm × 30 mm); 30–100% CH<sub>3</sub>CN/water (0.1% TFA); 25 min gradient; 30 mL/min. Recovered 16 mg of 1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)pyrrolidine-3-carboxylic acid, TFA salt (<b>11b</b>, 39%) as a clear oil. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ ppm 8.21 (2 H, d, <i>J</i> = 8.35 Hz), 7.81 (2 H, dd, <i>J</i> = 8.02, 1.65 Hz), 7.69 (2 H, d, <i>J</i> = 8.35 Hz), 7.54–7.66 (3 H, m), 5.10–5.22 (1 H, m), 3.39–3.54 (4 H, m), 3.24–3.27 (3 H, m), 3.00–3.10 (2 H, m), 2.23–2.57 (2 H, m), 1.70–1.83 (2 H, m), 1.05 (3 H, t, <i>J</i> = 7.36 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 489. HPLC <i>t</i><sub>r</sub> = 2.08 min (<a class="ref internalNav" href="#sec3_6_1_7" aria-label="method H">method H</a>). HPLC purity: 96%, <i>t</i><sub>r</sub> = 2.19 min (<a class="ref internalNav" href="#sec3_6_1_8" aria-label="method I">method I</a>).</div><div class="NLM_p last">The following compounds were synthesized using the same method as <b>11b</b>.</div></div><div id="sec3_6_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-((2<i>S</i>)-1-(2-Hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)pyrrolidin-2-yl)acetic Acid (<b>11c</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 9 mg of 2-((2<i>S</i>)-1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)pyrrolidin-2-yl)acetic acid, TFA salt (<b>11e</b>, 20%) as a pale-yellow oil. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ ppm 8.18 (4 H, d, <i>J</i> = 8.35 Hz), 7.77–7.84 (2 H, m), 7.54–7.67 (5 H, m), 5.92–6.01 (1 H, m), 5.00–5.09 (2 H, m), 4.26–4.42 (1 H, m), 3.76–3.94 (1 H, m), 3.00–3.11 (2 H, m), 2.75–2.98 (2 H, m), 2.18–2.34 (1 H, m), 1.90–2.14 (2 H, m), 1.60–1.85 (3 H, m), 1.04 (3 H, t, <i>J</i> = 7.25 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 503. HPLC <i>t</i><sub>r</sub> = 3.50 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 98.6%, <i>t</i><sub>r</sub> = 9.08 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>).</div></div><div id="sec3_6_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2-(1-(2-Hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-2-yl)acetic Acid (<b>11d</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 9 mg of 2-(1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-2-yl)acetic acid, TFA salt (<b>11d</b>, 20%) as a clear oil. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ ppm 8.14–8.25 (2 H, m), 7.80 (3 H, dd, <i>J</i> = 8.02, 1.65 Hz), 7.66–7.74 (1 H, m), 7.53–7.66 (4 H, m), 5.04 (1 H, t, <i>J</i> = 5.82 Hz), 5.00–5.35 (1 H, m), 4.35 (2 H, d, <i>J</i> = 5.49 Hz), 3.80–4.02 (1 H, m), 3.70 (1 H, br s), 3.33–3.54 (4 H, m), 2.99–3.10 (2 H, m), 2.68–2.96 (1 H, m), 1.82–2.09 (2 H, m), 1.70–1.81 (2 H, m, <i>J</i> = 15.27, 7.58, 7.47, 7.47 Hz), 1.40–1.70 (1 H, m), 1.04 (2 H, t, <i>J</i> = 7.36 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 517. HPLC <i>t</i><sub>r</sub> = 3.35 and 3.53 min in a 6:4 ratio of diastereomers (with respect to above LC retention times) (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 95.1%, <i>t</i><sub>r</sub> = 9.25–9.30 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>).</div></div><div id="sec3_6_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (3<i>S</i>)-1-(2-Hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic Acid (<b>11e</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 60 mg of (3<i>S</i>)-1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid, TFA salt (<b>11e</b> 71%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.12 (2 H, dd, <i>J</i> = 8.24, 1.87 Hz), 7.79 (2 H, dd, <i>J</i> = 8.02, 1.65 Hz), 7.67 (2 H, d, <i>J</i> = 8.35 Hz), 7.56–7.64 (3 H, m), 5.13–5.28 (1 H, m), 3.81 (1 H, d, <i>J</i> = 11.86 Hz), 3.67 (2 H, t, <i>J</i> = 14.17 Hz), 3.21–3.33 (3 H, m), 2.92–3.01 (2 H, m), 1.77–2.14 (2 H, m), 1.61–1.73 (2 H, m), 1.33–1.51 (1 H, m), 0.94 (1 H, s), 0.94 (3 H, t, <i>J</i> = 7.36 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 503. HPLC <i>t</i><sub>r</sub> = 3.37 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 97.3%, <i>t</i><sub>r</sub> = 9.10 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 97.4%, <i>t</i><sub>r</sub> = 7.75 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>).</div></div><div id="sec3_6_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (3<i>R</i>)-1-(2-Hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic Acid (<b>11f</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 6 mg of (3<i>R</i>)-1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid, TFA salt (<b>11f</b>, 14%) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ ppm 8.21 (2 H, d, <i>J</i> = 7.91 Hz), 7.71 (2 H, dd, <i>J</i> = 8.02, 1.65 Hz), 7.47–7.56 (5 H, m), 4.46 (1 H, br s), 4.10 (2 H, d, <i>J</i> = 6.37 Hz), 3.25–3.61 (2 H, m), 2.92–3.03 (3 H, m), 2.91 (2 H, br s), 2.01–2.27 (1 H, m), 1.81–2.00 (3 H, m), 1.60–1.76 (2 H, m, <i>J</i> = 7.61, 7.61, 7.61, 7.61, 7.36 Hz), 1.20–1.59 (1 H, m), 0.95 (3 H, t, <i>J</i> = 7.36 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 503. HPLC <i>t</i><sub>r</sub> = 3.32 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 95.9%, <i>t</i><sub>r</sub> = 7.55 min. (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>).</div></div><div id="sec3_6_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (1<i>R</i>,2<i>S</i>)-2-(2-Hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethylamino)cyclopentanecarboxylic Acid (<b>11g</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 9 mg of (1<i>R</i>,2<i>S</i>)-2-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethylamino)cyclopentanecarboxylic acid, TFA salt (<b>11g</b>, 22%) as a clear oil. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ ppm 8.20 (2 H, m, <i>J</i> = 8.13 Hz), 7.76–7.83 (2 H, m), 7.67 (2 H, m, <i>J</i> = 8.35 Hz), 7.52–7.64 (3 H, m), 5.10 (1 H, ddd, <i>J</i> = 10.16, 3.68, 3.52 Hz), 3.70–3.81 (1 H, m), 3.15–3.27 (2 H, m), 2.99–3.08 (2 H, m), 2.17–2.29 (2 H, m), 2.05–2.16 (2 H, m), 1.86–1.99 (2 H, m), 1.70–1.82 (3 H, m), 1.04 (3 H, t, <i>J</i> = 7.25 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i>. HPLC <i>t</i><sub>r</sub> = 3.48 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 98.6%, <i>t</i><sub>r</sub> = 9.38 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>).</div></div><div id="sec3_6_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (1<i>S</i>,2<i>R</i>)-2-(2-Hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethylamino)cyclopentanecarboxylic Acid (<b>11h</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 7 mg of (1<i>S</i>,2<i>R</i>)-2-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethylamino)cyclopentanecarboxylic acid, TFA salt (<b>11h</b>, 17%) as a clear oil. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ 8.16–8.06 (m, 2H), 7.72 (dd, <i>J</i> = 7.9, 1.5 Hz, 2H), 7.63–7.43 (m, 5H), 5.06–4.93 (m, 1H), 4.39–4.17 (m, 1H), 3.76–3.55 (m, 1H), 3.45–3.01 (m, 5H), 3.00–2.90 (m, 2H), 2.33–1.96 (m, 2H), 1.91–1.75 (m, 2H), 1.74–1.59 (m, 3H), 0.95 (t, <i>J</i> = 7.4 Hz, 3H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 503. HPLC <i>t</i><sub>r</sub> = 3.48–3.56 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 98.4%, <i>t</i><sub>r</sub> = 9.35 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 96.1%, <i>t</i><sub>r</sub> = 8.1 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>).</div></div><div id="sec3_6_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 1-(2-Hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-ol (<b>11i</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p">To a mixture of piperidin-3-ol (20.04 mg, 0.198 mmol) in DMSO (2 mL) was added tetrabutylammonium hydroxide (0.198 mL, 0.198 mmol). After 5 min, <b>10</b> (30 mg, 0.066 mmol) was added. Heated at 80 °C for 2 h. The reaction mixture was filtered and purified by HPLC. HPLC conditions: Phenomenex Luna C18 5 μm column (250 mm × 30 mm); 25–100% CH<sub>3</sub>CN/water (0.1% TFA); 25 min gradient; 20 mL/min. Isolated fractions with correct mass and freeze-dried overnight. Recovered 22 mg of 1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-ol, TFA salt (<b>11i</b>, 56%) as a clear oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26–8.07 (m, 2H), 7.90–7.79 (m, 2H), 7.74–7.54 (m, 5H), 5.21 (d, <i>J</i> = 9.2 Hz, 1H), 4.20–3.70 (m, 3H), 3.50–3.09 (m, 6H), 3.06–2.95 (m, 2H), 2.22–1.77 (m, 1H), 1.76–1.66 (m, 3H), 0.98 (t, <i>J</i> = 7.4 Hz, 3H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 475. HPLC <i>t</i><sub>r</sub> = 3.32 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity = 98.8, <i>t</i><sub>r</sub> = 8.89 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>).</div><div class="NLM_p last">The following compounds were synthesized by the same method as <b>11i</b>.</div></div><div id="sec3_6_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 4-(2-Hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperazine-2-carboxylic Acid (<b>11j</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 5 mg of 4-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperazine-2-carboxylic acid, TFA salt (<b>11j</b>, 14%) as a clear oil. MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 504. HPLC purity = 99%, <i>t</i><sub>r</sub> = 2.06 min (<a class="ref internalNav" href="#sec3_6_1_8" aria-label="method I">method I</a>).</div></div><div id="sec3_6_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 2-(1-(2-Hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic Acid (<b>11k</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 6 mg of 2-(1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid, TFA salt (<b>11k</b>, 16%) as a clear oil. MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 517. HPLC <i>t</i><sub>r</sub> = 2.08 min (<a class="ref internalNav" href="#sec3_6_1_3" aria-label="method C">method C</a>). Purity = 100%.</div></div><div id="sec3_6_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 2-((3<i>R</i>)-1-(2-Hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic Acid (<b>11l</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 9 mg of 2-((3<i>R</i>)-1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid, TFA salt (<b>11l</b>, 15%) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ ppm 8.11 (2 H, m), 7.68–7.75 (2 H, m), 7.59 (2 H, m, <i>J</i> = 8.35 Hz), 7.43–7.55 (3 H, m), 5.16 (1 H, dd, <i>J</i> = 9.01, 4.61 Hz), 3.71–3.89 (1 H, m), 3.50–3.67 (2 H, m), 3.24 (1 H, d, <i>J</i> = 2.42 Hz), 2.96 (2 H, dd, <i>J</i> = 8.90, 6.92 Hz), 2.83–2.93 (1 H, m), 2.72 (1 H, td, <i>J</i> = 11.86, 5.27 Hz), 2.16–2.39 (3 H, m), 1.77–2.00 (3 H, m), 1.59–1.75 (2 H, m, <i>J</i> = 7.61, 7.61, 7.61, 7.61, 7.36 Hz), 1.13–1.32 (1 H, m), 0.95 (3 H, t, <i>J</i> = 7.25 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 517. HPLC <i>t</i><sub>r</sub> = 3.32 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 99.2%, <i>t</i><sub>r</sub> = 9.08 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 95.0%, <i>t</i><sub>r</sub> = 7.77 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>).</div></div><div id="sec3_6_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 2-((3<i>S</i>)-1-(2-Hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic Acid (<b>11m</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 5 mg of 2-((3<i>S</i>)-1-(2-hydroxy-2-(4-(5-(5-phenyl-4-propylisoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid, TFA salt (<b>11m</b>, 11%) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ ppm 8.12 (2 H, m, <i>J</i> = 8.35 Hz), 7.69–7.75 (2 H, m), 7.60 (2 H, m, <i>J</i> = 8.13 Hz), 7.43–7.55 (3 H, m), 5.16 (1 H, dd, <i>J</i> = 9.34, 4.50 Hz), 3.71–3.89 (1 H, m), 3.52–3.68 (3 H, m), 3.23–3.28 (1 H, m), 2.96 (2 H, dd, <i>J</i> = 8.90, 6.92 Hz), 2.84–2.92 (1 H, m), 2.17–2.38 (3 H, m), 1.76–1.93 (3 H, m), 1.62–1.73 (2 H, m), 1.21 (1 H, dd, <i>J</i> = 12.30, 4.17 Hz), 0.95 (3 H, t, <i>J</i> = 7.25 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 517. HPLC <i>t</i><sub>r</sub> = 3.37 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 97.6%, <i>t</i><sub>r</sub> = 9.1 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>).</div></div><div id="sec3_6_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>tert</i>-Butyl 1-(2-(4-Cyanophenyl)-2-oxoethyl)azetidine-3-carboxylate, Hydrobromide<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of 4-(2-bromoacetyl)benzonitrile (448 mg, 2 mmol) in toluene (10 mL) was added <i>tert</i>-butyl azetidine-3-carboxylate (346 mg, 2.2 mmol) and stirred overnight at rt. Solvent was removed in vacuo and residue triturated with EtOAC. Solid was collected and dried in vacuo. Recovered 170 mg of <i>tert</i>-butyl 1-(2-(4-cyanophenyl)-2-oxoethyl)azetidine-3-carboxylate (28%) as a solid. MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 301. HPLC <i>t</i><sub>r</sub> = 0.93 min (<a class="ref internalNav" href="#sec3_6_1_1" aria-label="method A">method A</a>).</div></div><div id="sec3_6_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>tert</i>-Butyl 1-(2-(4-Cyanophenyl)-2-hydroxyethyl)azetidine-3-carboxylate (<b>12</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of <i>tert</i>-butyl 1-(2-(4-cyanophenyl)-2-oxoethyl)azetidine-3-carboxylate (170 mg, 0.446 mmol) in ethanol (5 mL) was added sodium borohydride (25 mg, 0.661 mmol), and stirred for 1 h, then quenched with water and then diluted with ethyl acetate and washed with water. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. Recovered 100 mg of <i>tert</i>-butyl 1-(2-(4-cyanophenyl)-2-hydroxyethyl)azetidine-3-carboxylate (74%) as a solid. MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 303. HPLC <i>t</i><sub>r</sub> = 0.91 min (<a class="ref internalNav" href="#sec3_6_1_1" aria-label="method A">method A</a>).</div></div><div id="sec3_6_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>tert</i>-Butyl-1-(2-hydroxy-2-(4-(<i>N</i>′-hydroxycarbamimidoyl)phenyl)ethyl)azetidine-3-carboxylate<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of <b>12</b> (100 mg, 0.331 mmol) and sodium bicarbonate (111 mg, 1.323 mmol) in 2-propanol was added hydroxylamine hydrochloride (22.98 mg, 0.331 mmol) and heated at 80 °C for 12 h. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. Recovered 110 mg of <i>tert</i>-butyl-1-(2-hydroxy-2-(4-(<i>N</i>′-hydroxycarbamimidoyl)phenyl)ethyl)azetidine-3-carboxylate. MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 336. HPLC <i>t</i><sub>r</sub> = 1.2 min (<a class="ref internalNav" href="#sec3_6_1_1" aria-label="method A">method A</a>).</div></div><div id="sec3_6_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 3-Phenyl-4-(trifluoromethyl)isoxazole-5-carbonyl Fluoride<a onclick="showRef(event, 'ref21 ref27'); return false;" href="javascript:void(0);" class="ref ref21 ref27">(21, 27)</a></h4><div class="NLM_p last">To a mixture of 3-phenyl-4-(trifluoromethyl)isoxazole-5-carboxylic acid<a onclick="showRef(event, 'ref21 ref27'); return false;" href="javascript:void(0);" class="ref ref21 ref27">(21, 27)</a> (3 g, 11.7 mmol) and pyridine (1.1 mL, 14.0 mmol) in dichloromethane (100 mL) at room temperature was added 2,4,6-trifluoro-1,3,5-triazine (cyanuric fluoride) (1.2 mL, 14.0 mmol). The reaction mixture was stirred at room temperature overnight and then diluted with dichloromethane (300 mL), washed with an ice-cold solution of 0.5 N aqueous hydrochloric acid (2 × 100 mL), and the organic layer collected. The aqueous layer was back-extracted with dichloromethane (200 mL), and the combined organic layers were dried with anhydrous sodium sulfate and concentrated to afford 2.9 g of 3-phenyl-4-(trifluoromethyl)isoxazole-5-carbonyl fluoride (91%) as a solid. The product was found to react readily with methanol and on analysis was characterized as the methyl ester. HPLC <i>t</i><sub>r</sub> = 2.56 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 272 (methyl ester).</div></div><div id="sec3_6_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 1-(2-Hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)azetidine-3-carboxylic Acid (<b>13</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of 3-phenyl-4-(trifluoromethyl)isoxazole-5-carbonyl fluoride (86 mg, 0.33 mmol) and ((<i>E</i>)-<i>tert</i>-butyl 1-(2-hydroxy-2-(4-(<i>N</i>′-hydroxycarbamimidoyl)phenyl)ethyl)azetidine-3-carboxylate (111 mg, 0.33 mmol) in CH<sub>3</sub>CN (10 mL) was added DIEA (0.115 mL, 0.660 mmol). After 1 h, 1 M TBAF in THF (0.330 mL, 0.330 mmol) was added and the reaction was stirred overnight. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. Crude residue was treated with TFA/DCM (1:1, 1 mL) to remove <i>t</i>-butyl ester and then concentrated in vacuo and purified by HPLC. Recovered 36 mg of 1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)azetidine-3-carboxylic acid, TFA salt (<b>13</b>, 17%) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.22 (d, <i>J</i> = 8.3 Hz, 2H), 7.68 (d, <i>J</i> = 8.3 Hz, 5H), 7.63–7.52 (m, 3H), 5.04 (dd, <i>J</i> = 10.1, 3.1 Hz, 1H), 3.73 (br s, 1H), 3.61–3.38 (m, 2H), 3.26–3.16 (m, 4H)). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 501. HPLC <i>t</i><sub>r</sub> = 3.23 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 96.5%, <i>t</i><sub>r</sub> = 5.19 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>);</div></div><div id="sec3_6_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (<i>S</i>)-Ethyl 1-(2-(4-Cyanophenyl)-2-oxoethyl)piperidine-3-carboxylate Hydrobromide<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a solution of commercially available (<i>S</i>)-ethylpiperidine-3-carboxylate (10 g, 63.6 mmol) in 200 mL of toluene was added 4-(2-bromoacetyl)benzonitrile (17 g, 76 mmol). The reaction mixture was stirred overnight. The next day, the precipitated solid was collected by filtration and washed with EtOAc then dried under vacuum to afford 15.2 g of (<i>S</i>)-ethyl 1-(2-(4-cyanophenyl)-2-oxoethyl)piperidine-3-carboxylate hydrobromide (63%) as a solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.13 (d, <i>J</i> = 8.3 Hz, 2H), 7.81 (d, <i>J</i> = 8.3 Hz, 2H), 5.10 (q, <i>J</i> = 18.3 Hz, 2H), 4.13 (q, <i>J</i> = 7.0 Hz, 2H), 3.99–3.66 (m, 2H), 3.61–3.25 (m, 2H), 2.64–2.21 (m, 2H), 2.11–1.76 (m, 2H), 1.74–1.49 (m, 1H), 1.25 (t, <i>J</i> = 7.3 Hz, 3H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 301. HPLC <i>t</i><sub>r</sub> = 1.51 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>).</div></div><div id="sec3_6_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Ethyl 1-((<i>S</i>)-2-(4-Cyanophenyl)-2-hydroxyethyl)piperidine-3-carboxylate (<b>14</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of (<i>S</i>)-ethyl 1-(2-(4-cyanophenyl)-2-oxoethyl)piperidine-3-carboxylate hydrobromide (1.3 g, 8.3 mmol) in ethanol (20 mL) was added sodium borohydride (315 mg, 8.27 mmol) portionwise. After 1 h, the reaction mixture was quenched with water. The reaction mixture was diluted with EtOAc and washed with satd NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, concentrated, and purified on a silica gel cartridge using a EtOAc/hexanes gradient to afford 2.0 g of (<i>S</i>)-ethyl 1-(-2-(4-cyanophenyl)-2-hydroxyethyl)piperidine-3-carboxylate as a mixture of diastereomers (<b>14</b>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.64 (d, <i>J</i> = 8.4 Hz, 2H), 7.50 (d, <i>J</i> = 7.9 Hz, 2H), 4.77 (dd, <i>J</i> = 10.6, 3.5 Hz, 1H), 4.18 (q, <i>J</i> = 7.0 Hz, 2H), 3.13 (d, <i>J</i> = 9.0 Hz, 1H), 2.59 (dd, <i>J</i> = 12.5, 3.5 Hz, 3H), 2.51–2.28 (m, 3H), 2.02–1.85 (m, 1H), 1.83–1.69 (m, 1H), 1.68–1.50 (m, 2H), 1.29 (t, <i>J</i> = 7.2 Hz, 3H). HPLC <i>t</i><sub>r</sub> = 1.51 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>).</div></div><div id="sec3_6_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>S</i>)-Ethyl 1-((<i>S</i>)-2-(4-Cyanophenyl)-2-hydroxyethyl)piperidine-3-carboxylate (<b>14a</b>) and (<i>S</i>)-Ethyl 1-((<i>R</i>)-2-(4-Cyanophenyl)-2-hydroxyethyl)piperidine-3-carboxylate (<b>14b</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Compound <b>14</b> was separated by chiral HPLC (Berger SFC MGIII instrument equipped with a ChiralCel OJ (25 cm × 3 cm, 5 μm); temp, 30 °C; flow rate, 130 mL/min; mobile phase, CO<sub>2</sub>/(MeOH + 0.1%DEA) in 9:1 isocratic ratio). <b>14a</b>: Peak 1 (<i>t</i><sub>r</sub> = 2.9 min) from the chiral separation was isolated. The absolute and relative stereochemistry of compound <b>14a</b> was unambiguously assigned (<i>S</i>,<i>S</i>) by X-ray crystal structure.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.63 (2 H, m, <i>J</i> = 8.35 Hz), 7.49 (2 H, m, <i>J</i> = 8.35 Hz), 4.77 (1 H, dd, <i>J</i> = 10.55, 3.52 Hz), 4.17 (2 H, q, <i>J</i> = 7.03 Hz), 3.13 (1 H, d, <i>J</i> = 9.23 Hz), 2.53–2.67 (3 H, m), 2.44 (2 H, dd, <i>J</i> = 18.68, 9.89 Hz), 2.35 (1 H, dd, <i>J</i> = 12.74, 10.55 Hz), 1.87–2.01 (1 H, m), 1.71–1.82 (1 H, m), 1.52–1.70 (2 H, m), 1.28 (3 H, t, <i>J</i> = 7.03 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 303. HPLC purity: 100% with >99% de; <i>t</i><sub>r</sub> = 2.56 min (ChiralCel OJ (25 cm × 0.46 cm, 5 μm); temp, 35 °C; flow rate, 2 mL/min; mobile phase, CO<sub>2</sub>/(MeOH + 0.1%DEA) in 8:2 isocratic ratio). <b>14b</b>: Peak 2 (<i>t</i><sub>r</sub> = 3.8 min) from the chiral separation was isolated (>99% de). The absolute and relative stereochemistry of <b>14b</b> was assigned (<i>S</i>,<i>R</i>) based on the crystal structure of <b>14a</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.63 (2 H, m, <i>J</i> = 8.35 Hz), 7.49 (2 H, m, <i>J</i> = 8.35 Hz), 4.79 (1 H, dd, <i>J</i> = 10.55, 3.52 Hz), 4.16 (2 H, q, <i>J</i> = 7.03 Hz), 2.69–2.91 (3 H, m), 2.60–2.68 (1 H, m), 2.56 (1 H, dd, <i>J</i> = 12.30, 3.52 Hz), 2.36 (1 H, dd, <i>J</i> = 12.52, 10.77 Hz), 2.25 (1 H, t, <i>J</i> = 8.79 Hz), 1.65–1.90 (3 H, m), 1.52–1.64 (1 H, m, <i>J</i> = 12.69, 8.49, 8.49, 4.17 Hz), 1.27 (3 H, t, <i>J</i> = 7.25 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 303. HPLC purity: 99.6% with >99% de; <i>t</i><sub>r</sub> = 2.95 min (method: ChiralCel OJ (25 cm × 0.46 cm, 5 μm); temp, 35 °C; flow rate, 2 mL/min; mobile phase, CO<sub>2</sub>/(MeOH + 0.1%DEA)) in 8:2 isocratic ratio).</div></div><div id="sec3_6_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (<i>R</i>)-Ethyl 2-(1-(2-(4-Cyanophenyl)-2-oxoethyl)piperidin-3-yl)acetate Hydrobromide<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of 4-(2-bromoacetyl)benzonitrile (5.5 g, 24.5 mmol) in toluene was added (<i>R</i>)-ethyl 2-(piperidin-3-yl)acetate (4 g, 23.4 mmol). The reaction mixture was stirred for 4 days at room temperature and then stirred for 1 day at 50 °C. Solvents were removed in vacuo. The resulting solids were triturated with EtOAc then collected and dried to afford 5 g of (<i>R</i>)-ethyl 2-(1-(2-(4-cyanophenyl)-2-oxoethyl)piperidin-3-yl)acetate hydrobromide (70%) as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (br s, 1H), 8.43 (br s, 1H), 8.13 (s, 2H), 4.08 (q, <i>J</i> = 7.1 Hz, 2H), 3.53 (br s, 1H), 3.36 (br s, 2H), 3.23 (d, <i>J</i> = 11.9 Hz, 2H), 2.95–2.56 (m, 2H), 2.48–2.19 (m, 3H), 2.10 (ddt, <i>J</i> = 14.9, 7.5, 3.7 Hz, 1H), 1.84–1.68 (m, 2H), 1.20 (t, <i>J</i> = 7.2 Hz, 3H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 314. HPLC <i>t</i><sub>r</sub> = 0.77 min (<a class="ref internalNav" href="#sec3_6_1_1" aria-label="method A">method A</a>).</div></div><div id="sec3_6_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Ethyl 2-((3<i>R</i>)-1-(2-(4-Cyanophenyl)-2-hydroxyethyl)piperidin-3-yl)acetate (<b>15</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of (<i>R</i>)-ethyl 2-(1-(2-(4-cyanophenyl)-2-oxoethyl)piperidin-3-yl)acetate bydrobromide (1 g, 3.2 mmol) in ethanol (20 mL) was added sodium borohydride (0.120 g, 3.2 mmol). The reaction mixture was stirred for 1 h. The reaction was quenched with water then diluted with EtOAc and washed with H<sub>2</sub>O. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The resulting solids were purified on a silica gel cartridge using an EtOAc/hexanes gradient to afford 575 mg of ethyl 2-((3<i>R</i>)-1-(2-(4-cyanophenyl)-2-hydroxyethyl)piperidin-3-yl)acetate as a mixture of diastereomers. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.65 (d, <i>J</i> = 8.4 Hz, 2H), 7.51 (d, <i>J</i> = 8.1 Hz, 2H), 4.78 (dd, <i>J</i> = 10.6, 3.5 Hz, 1H), 4.18 (q, <i>J</i> = 7.1 Hz, 2H), 3.07 (d, <i>J</i> = 9.7 Hz, 1H), 2.67 (br s, 1H), 2.55 (dd, <i>J</i> = 12.4, 3.6 Hz, 1H), 2.46–2.22 (m, 4H), 2.20–2.03 (m, 1H), 1.92 (t, <i>J</i> = 10.3 Hz, 1H), 1.87–1.77 (m, 1H), 1.77–1.60 (m, 2H), 1.30 (t, <i>J</i> = 7.2 Hz, 3H), 1.18–0.98 (m, 1H). HPLC <i>t</i><sub>r</sub> = 1.21 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>).</div></div><div id="sec3_6_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Ethyl 2-((<i>R</i>)-1-((<i>S</i>)-2-(4-Cyanophenyl)-2-hydroxyethyl)-piperidin-3-yl)acetate (<b>15a</b>) and Ethyl 2-((<i>R</i>)-1-((<i>R</i>)-2-(4-Cyanophenyl)-2-hydroxyethyl)-piperidin-3-yl)acetate (<b>15b</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Compound <b>15</b> was separated by chiral HPLC (Thar preparative SFC instrument) equipped with a Chiralpak AD-H ((25 cm × 5 cm, 5 μm); temp, 35 °C; flow rate, 270 mL/min; mobile phase, CO<sub>2</sub>/(MeOH + 0.1%DEA) in 3:1 isocratic ratio). <b>15a</b>: Peak 1 (<i>t</i><sub>r</sub> = 5.5 min) was isolated (>99% de). The hydroxyl stereochemistry of compound <b>15a</b> was assigned (<i>R</i>,<i>S</i>) because it matched <sup>1</sup>H NMR and chiral HPLC retention of material that was prepared using a chiral reducing agent precedented to generate this stereoisomer.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.63 (2 H, m), 7.48 (2 H, m, <i>J</i> = 8.14 Hz), 4.75 (1 H, dd, <i>J</i> = 10.67, 3.41 Hz), 4.15 (2 H, q, <i>J</i> = 7.19 Hz), 3.04 (1 H, d, <i>J</i> = 9.90 Hz), 2.65 (1 H, d, <i>J</i> = 11.22 Hz), 2.52 (1 H, dd, <i>J</i> = 12.54, 3.52 Hz), 2.18–2.43 (4 H, m), 2.04–2.18 (1 H, m, <i>J</i> = 13.56, 6.81, 6.81, 3.63, 3.52 Hz), 1.88 (1 H, t, <i>J</i> = 10.34 Hz), 1.75–1.84 (1 H, m), 1.59–1.74 (2 H, m), 1.24–1.31 (3 H, m), 1.00–1.15 (1 H, m). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 317. HPLC purity: 95.4% with >99% de; <i>t</i><sub>r</sub> = 3.56 min (method: Chiralpak AD-H (0.46 cm × 25 cm, 5 μm); temp, 40 °C; flow rate, 3 mL/min; mobile phase, CO<sub>2</sub>/ MeOH w 0.1%DEA in 7:3 isocratic ratio). <b>15b</b>: Peak 2 (<i>t</i><sub>r</sub> = 7.0 min) was isolated (>99% de). The hydroxyl stereochemistry of compound <b>15b</b> was assigned (<i>R</i>,<i>R</i>) based on the assignment of the other isomer. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.63 (2 H, m), 7.48 (2 H, m, <i>J</i> = 7.92 Hz), 4.75 (1 H, dd, <i>J</i> = 10.56, 3.52 Hz), 4.14 (2 H, q, <i>J</i> = 7.04 Hz), 3.00 (1 H, d, <i>J</i> = 10.56 Hz), 2.72 (1 H, d, <i>J</i> = 7.92 Hz), 2.51 (1 H, dd, <i>J</i> = 12.32, 3.52 Hz), 2.32 (1 H, dd, <i>J</i> = 12.43, 10.67 Hz), 2.20–2.26 (2 H, m), 2.01–2.20 (3 H, m), 1.70–1.85 (2 H, m), 1.52–1.68 (1 H, m), 1.26 (3 H, t, <i>J</i> = 7.15 Hz), 1.00–1.13 (1 H, m). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 317. HPLC purity: 94.1% with >99% de; <i>t</i><sub>r</sub> = 4.84 min (method: Chiralpak AD-H (0.46 cm × 25 cm, 5 μm); temp, 40 °C; flow rate, 3 mL/min; mobile phase, CO<sub>2</sub>/ MeOH w 0.1%DEA in 7:3 isocratic ratio).</div></div><div id="sec3_6_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (3<i>S</i>)-Ethyl-1-(2-hydroxy-2-(4-((<i>Z</i>)-<i>N</i>′-hydroxycarbamimidoyl)phenyl)ethyl)piperidine-3-carboxylate<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of <b>14</b> (2.34 g, 7.74 mmol) and hydroxylamine hydrochloride (1.076 g, 15.48 mmol) in 2-propanol (50 mL) was added sodium bicarbonate (2.60 g, 31.0 mmol) and heated at 80 °C overnight. The reaction mixture was diluted with ethyl acetate and washed with satd NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. Recovered 2.4 g of (3<i>S</i>)-ethyl-1-(2-hydroxy-2-(4-((<i>Z</i>)-<i>N</i>′-hydroxycarbamimidoyl)phenyl)ethyl)piperidine-3-carboxylate (92%). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 336. HPLC <i>t</i><sub>r</sub> = 0.46 min (<a class="ref internalNav" href="#sec3_6_1_1" aria-label="method A">method A</a>).</div></div><div id="sec3_6_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (3<i>S</i>)-1-(2-Hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (<b>16</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of 3-phenyl-4-(trifluoromethyl)isoxazole-5-carbonyl fluoride (102 mg, 0.39 mmol) and (3<i>S</i>)-ethyl 1-(2-hydroxy-2-(4-((<i>Z</i>)-<i>N</i>′-hydroxycarbamimidoyl)phenyl)ethyl)piperidine-3-carboxylate (130 mg, 0.39 mmol) in CH<sub>3</sub>CN (5 mL) was added DIEA (0.136 mL, 0.778 mmol) and stirred at rt for 2 h. Then 1 M TBAF in THF (0.389 mL, 0.389 mmol) was added and the reaction was stirred at rt overnight. The reaction mixture was diluted with ethyl acetate and washed with satd NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. To this product was added dioxane (2 mL) and 6 N HCL (2 mL). The reaction mixture was gently warmed with a heat gun for a few minutes and then stirred overnight at rt. The reaction mixture was filtered and purified by HPLC. HPLC conditions: Phenomenex Luna C18 5 μm column (250 mm × 30 mm); 25–100% CH<sub>3</sub>CN/water (0.1% TFA); 25 min gradient; 30 mL/min. Isolated fractions with correct mass and freeze-dried overnight. Recovered 52 mg of (3<i>S</i>)-1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid, TFA salt (<b>16</b>, 20%) as a white solid. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) d 8.23 (d, <i>J</i> = 8.5 Hz, 2H), 7.74–7.65 (m, 4H), 7.65–7.54 (m, 3H), 5.27 (dd, <i>J</i> = 9.8, 4.5 Hz, 1H), 4.02 (d, <i>J</i> = 11.8 Hz, 1H), 3.94–3.78 (m, 1H), 3.42–3.34 (m, 2H), 3.14 (dt, <i>J</i> = 19.0, 12.5 Hz, 1H), 3.07–2.80 (m, 1H), 2.26 (d, <i>J</i> = 12.6 Hz, 1H), 2.13 (d, <i>J</i> = 15.4 Hz, 1H), 2.07–1.80 (m, 2H), 1.72–1.53 (m, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 529. HPLC <i>t</i><sub>r</sub> = 3.23 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 99.2%, <i>t</i><sub>r</sub> = 8.70 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>).</div></div><div id="sec3_6_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Ethyl 2-((3<i>R</i>)-1-(2-Hydroxy-2-(4-((<i>Z</i>)-<i>N</i>′-hydroxycarbamimidoyl)phenyl)ethyl)piperidin-3-yl)acetate<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of <b>15</b> (356 mg, 1.125 mmol) and sodium bicarbonate (378 mg, 4.50 mmol) in 2-propanol (10 mL) was added hydroxylamine hydrochloride (156 mg, 2.250 mmol) and heated at 85 °C overnight. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. Recovered 346 mg of ethyl 2-((3<i>R</i>)-1-(2-hydroxy-2-(4-((<i>Z</i>)-<i>N</i>′-hydroxycarbamimidoyl)phenyl)ethyl)piperidin-3-yl)acetate (88%). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 350. HPLC <i>t</i><sub>r</sub> = 1.06 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>).</div></div><div id="sec3_6_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 2-((3<i>R</i>)-1-(2-Hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic Acid (<b>17</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">To a mixture of 3-phenyl-4-(trifluoromethyl)isoxazole-5-carbonyl fluoride (75 mg, 0.29 mmol) and ethyl 2-((3<i>R</i>)-1-(2-hydroxy-2-(4-((<i>Z</i>)-<i>N</i>′-hydroxycarbamimidoyl)phenyl)ethyl)piperidin-3-yl)acetate (98 mg, 0.29 mmol) in CH<sub>3</sub>CN (5 mL) was added DIEA (0.102 mL, 0.583 mmol) and stirred at 25 °C for 3 h. TBAF in THF (0.292 mL, 0.292 mmol) was added, and the reaction was stirred at rt overnight. The reaction mixture was diluted with ethyl acetate and washed with satd NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. This product was dissolved in dioxane (2 mL), and 6 N HCl was added. The reaction mixture was gently heated to solublize and then stirred overnight at rt. The reaction mixture was filtered and purified by HPLC. HPLC conditions: Phenomenex Luna C18 5 μm column (250 mm × 30 mm); 25–100% CH<sub>3</sub>CN/water (0.1% TFA); 25 min gradient; 30 mL/min. Isolated fractions with correct mass and freeze-dried overnight. Recovered 27 mg of 2-((3<i>R</i>)-1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid, TFA salt (<b>17</b>, 20%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.22 (d, <i>J</i> = 8.35 Hz, 2H), 7.75–7.65 (m, 4H), 7.65–7.51 (m, 3H), 5.31–5.20 (m, 1H), 4.00–3.79 (m, 1H), 3.76–3.57 (m, 1H), 3.26–3.17 (m, 1H), 2.49–2.27 (m, 3H), 2.09–1.86 (m, 3H), 1.41 (sxt, <i>J</i> = 7.38 Hz, 1H), 1.34–1.26 (m, 1H), 1.02(t <i>J</i> = 7.36 Hz, 2H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 543. HPLC <i>t</i><sub>r</sub> = 3.23 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 99.2%, <i>t</i><sub>r</sub> = 8.81 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>).</div></div><div id="sec3_6_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (<i>S</i>)-1-((<i>S</i>)-2-Hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl) isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic Acid (<b>18a</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p">To a mixture of <b>14a</b> (5.2 g, 17.2 mmol) and hydroxylamine hydrochloride (1.4 g, 20.6 mmol) in 2-propanol (50 mL) was added sodium bicarbonate (2.9 g, 84 mmol). The reaction mixture was heated at 85 °C. The reaction mixture was diluted with EtOAc and washed with satd NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated to afford 5.35 g of (<i>S</i>)-ethyl 1-((<i>S</i>)-2-hydroxy-2-(4-((<i>Z</i>)-<i>N</i>′-hydroxycarbamimidoyl)phenyl)ethyl)piperidine-3-carboxylate (93%)</div><div class="NLM_p">To a solution of 3-phenyl-4-(trifluoromethyl)isoxazole-5-carbonyl fluoride<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (214 mg, 0.78 mmol) in CH<sub>3</sub>CN (5 mL) was added DIEA (0.27 mL, 1.56 mmol) and (<i>S</i>)-ethyl-1-((<i>S</i>)-2-hydroxy-2-(4-((<i>Z</i>)-<i>N</i>′-hydroxycarbamimidoyl) phenyl) ethyl)piperidine-3-carboxylate (260 mg, 0.78 mmol). The reaction mixture was stirred for 2 h, and then 1 M TBAF in THF (0.78 mL, 0.78 mmol) was added. The reaction mixture was stirred overnight at room temperature. The reaction mixture was filtered and purified by HPLC in three batches. HPLC conditions: Phenomenex Luna C18 5 μm column (250 mm × 30 mm); 25–100% CH<sub>3</sub>CN/water (0.1% TFA); 25 min gradient; 30 mL/min. Isolated fractions with correct mass were partitioned between EtOAc and saturated NaHCO<sub>3.</sub> The aqueous layer was back-extracted once. The combined organic layers were dried with MgSO<sub>4</sub>, filtered, and concentrated to afford 155 mg of (<i>S</i>)-ethyl 1-((<i>S</i>)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylate (36%). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ ppm 8.04 (2 H, d, <i>J</i> = 8.13 Hz), 7.55–7.60 (2 H, m), 7.41–7.54 (5 H, m), 4.81 (1 H, ddd, <i>J</i> = 8.35, 4.06, 3.84 Hz), 3.96–4.10 (2 H, m), 2.82–3.08 (1 H, m), 2.67–2.82 (1 H, m), 2.36–2.61 (3 H, m), 2.08–2.33 (2 H, m), 1.73–1.87 (1 H, m, <i>J</i> = 8.54, 8.54, 4.45, 4.17 Hz), 1.32–1.70 (3 H, m), 1.09–1.19 (3 H, m). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 557. HPLC purity: 99%, <i>t</i><sub>r</sub> = 3.36 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>).</div><div class="NLM_p last">(<i>S</i>)-Ethyl 1-((<i>S</i>)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylate (35 mg, 0.063 mmol) was then heated at 50 °C in 6 N HCl (1 mL) and dioxane (1 mL). The reaction mixture was stirred overnight then filtered and purified by HPLC. HPLC conditions: Phenomenex Luna C18 5 μm column (250 mm × 30 mm); 25–100% CH<sub>3</sub>CN/water (0.1% TFA); 25 min gradient; 30 mL/min. Isolated fractions with correct mass were freeze-dried overnight to afford 25 mg of (<i>S</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid, TFA salt (<b>18a</b>, 61%) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ ppm 8.23 (2 H, d, <i>J</i> = 8.35 Hz), 7.65–7.74 (4 H, m), 7.54–7.65 (3 H, m), 5.29 (1 H, t, <i>J</i> = 7.03 Hz), 4.00 (1 H, br s), 3.43–3.75 (1 H, m), 3.34–3.41 (2 H, m), 2.82–3.24 (2 H, m), 2.26 (1 H, d, <i>J</i> = 11.86 Hz), 1.84–2.14 (2 H, m), 1.52–1.75 (1 H, m). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 529. HPLC <i>t</i><sub>r</sub> = 3.27 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 99.4%, <i>t</i><sub>r</sub> = 8.78 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 99.0%, <i>t</i><sub>r</sub> = 7.29 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>). This material was converted to the HCl salt for the following analyses: mp: 219.2 °C. Anal. Calcd for C<sub>26</sub>H<sub>23</sub>N<sub>4</sub>O<sub>5</sub>F<sub>3</sub>·HCl: 0.14% water: C, 55.2; H, 4.31; N, 9.87; Cl, 6.25. Found: C, 55.39; H, 4.10; N, 9.88; Cl, 6.34. [α]<sub>D</sub><sup>20</sup> + 30.47 (<i>c</i> 0.336, MeOH). HPLC with chiral stationary phase (A linear gradient using CO<sub>2</sub> (solvent A) and IPA with 0.1% DEA (solvent B); <i>t</i> = 0 min, 30% B, <i>t</i> = 10 min, 55% B was employed on a Chiralcel AD-H 250 mm × 4.6 mm ID, 5 μm column; flow rate was 2.0 mL/min): <i>t</i><sub>r</sub> = 5.38 min with >99% ee.</div></div><div id="sec3_6_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (<i>S</i>)-1-((<i>R</i>)-2-Hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic Acid (<b>18b</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Compound <b>18b</b> was synthesized by the same route as used for <b>18a</b> but using (<i>S</i>)-ethyl 1-((<i>R</i>)-2-(4-cyanophenyl)-2-hydroxyethyl)piperidine-3-carboxylate (<b>14b</b>) to give (<i>S</i>)-1-((<i>R</i>)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid, TFA salt (<b>18b</b>, 23%) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ ppm 8.14 (2 H, d, <i>J</i> = 8.35 Hz), 7.57–7.66 (4 H, m), 7.44–7.56 (3 H, m), 5.17 (1 H, dd, <i>J</i> = 9.67, 4.39 Hz), 3.65–4.02 (2 H, m), 3.25–3.46 (2 H, m), 2.77–3.13 (3 H, m), 1.98–2.29 (2 H, m), 1.70–1.91 (2 H, m), 1.42–1.64 (1 H, m). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 529. HPLC <i>t</i><sub>r</sub> = 3.27 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 99.7%, <i>t</i><sub>r</sub> = 8.77 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 99.7%, <i>t</i><sub>r</sub> = 7.26 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>).</div></div><div id="sec3_6_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 2-((<i>R</i>)-1-((<i>S</i>)-2-Hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic Acid (<b>19a</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p">To a mixture of <b>15a</b> (346 mg, 1.13 mmol) and sodium bicarbonate (378 mg, 4.5 mmol) in 2-propanol (10 mL) was added hydroxylamine hydrochloride (156 mg, 2.25 mmol). The reaction mixture was heated at 85 °C overnight. The reaction mixture was diluted with EtOAc and washed with H<sub>2</sub>O. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated to yield 346 mg of ethyl 2-((3<i>R</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-((<i>Z</i>)-<i>N</i>′-hydroxycarbamimidoyl) phenyl)ethyl)piperidin-3-yl)acetate. MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 350. HPLC <i>t</i><sub>r</sub> = 1.02 min (<a class="ref internalNav" href="#sec3_6_1_1" aria-label="method A">method A</a>).</div><div class="NLM_p last">To a mixture of ethyl 2-((3<i>R</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-((<i>Z</i>)-<i>N</i>′-hydroxycarbamimidoyl) phenyl)ethyl)piperidin-3-yl)acetate (198 mg, 0.57 mmol) and DIEA (0.198 mL, 1.1 mmol) in CH<sub>3</sub>CN (10 mL) was added 3-phenyl-4-(trifluoromethyl)isoxazole-5-carbonyl fluoride (147 mg, 0.57 mmol). The reaction mixture was stirred at room temperature. After 1 h, 1 M TBAF in THF (0.57 mL, 0.57 mmol) was added and the reaction mixture was stirred overnight. The reaction mixture was diluted with EtOAc and washed with H<sub>2</sub>O. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The resulting solids were purified on a silica gel cartridge using an EtOAc/hexanes gradient to afford ethyl 2-((<i>R</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetate. This product was then treated with 6 N HCl/dioxane (1:1, 6 mL) at 50 °C overnight. The reaction mixture was filtered and purified by HPLC. HPLC conditions: Phenomenex Luna C18 5 μm column (250 mm × 30 mm); 25–100% CH<sub>3</sub>CN/water (0.1% TFA); 25 min gradient; 30 mL/min. Isolated fractions with correct mass were freeze-dried overnight to yield 107 mg of 2-((<i>R</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid, TFA salt (<b>19a</b>, 28%, 2 steps) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ ppm 8.13 (2 H, d, <i>J</i> = 8.35 Hz), 7.57–7.64 (4 H, m), 7.44–7.55 (3 H, m), 5.17 (1 H, dd, <i>J</i> = 9.23, 4.39 Hz), 3.81 (1 H, d, <i>J</i> = 11.86 Hz), 3.56 (1 H, d, <i>J</i> = 11.42 Hz), 3.24–3.31 (2 H, m), 2.82–2.95 (1 H, m), 2.72 (1 H, t, <i>J</i> = 11.86 Hz), 2.16–2.40 (3 H, m), 1.79–1.95 (3 H, m), 1.10–1.34 (1 H, m). <sup>13</sup>C NMR (126 MHz, MeOD) δ ppm 174.69, 170.46, 165.65, 163.52, 156.94 (1 C, q, <i>J</i> = 2.90 Hz), 146.62, 132.16, 130.19 (2 C, s), 130.00 (3 C, s), 129.08 (2 C, s), 128.15 (2 C, s), 127.49, 127.01, 121.91 (1 C, q, <i>J</i> = 265.10 Hz), 113.84 (1 C, q, <i>J</i> = 42.90 Hz), 68.14 (1 C, br s), 64.19 (1 C, br s), 56.95 (1 C, br s), 55.91 (1 C, br s), 38.49 (1 C, br s), 31.87–33.03 (1 C, m), 29.12, 23.85 (1 C, br s). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 543. HPLC <i>t</i><sub>r</sub> = 3.26 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 99.6%, <i>t</i><sub>r</sub> = 5.73 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 99.9%, <i>t</i><sub>r</sub> = 4.47 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>). This material was converted to the HCl salt for the following analyses: mp: 185.9 °C. Anal. Calcd for C<sub>27</sub>H<sub>25</sub>N<sub>4</sub>O<sub>4</sub> F<sub>3</sub>·1.06HCl: 0.26% water: C, 55.68; H, 4.54; N, 9.67; Cl, 6.59. Found: C, 55.51; H, 4.79; N, 9.45; Cl, 6.59. [α]<sub>D</sub><sup>20</sup> + 14.29 (<i>c</i> 0.319, MeOH). HPLC with chiral stationary phase (an isocratic run using 80% CO<sub>2</sub> (solvent A) and 20% IPA with 0.1% DEA was employed on a Chiralcel AS-H 250 mm × 4.6 mm ID column; flow rate was 2.0 mL/min): <i>t</i><sub>r</sub> = 4.29 min with >99.8% ee.</div></div><div id="sec3_6_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 2-((<i>R</i>)-1-((<i>R</i>)-2-Hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic Acid (<b>19b</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last"><b>19b</b> was synthesized by the same route as used for <b>19a</b> but using ethyl 2-((<i>R</i>)-1-((<i>R</i>)-2-(4-cyanophenyl)-2-hydroxyethyl)-piperidin-3-yl)acetate (<b>15b</b>) to give 2-((<i>R</i>)-1-((<i>R</i>)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid, TFA salt (<b>19b,</b> 41%) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ ppm 8.14 (2 H, d, <i>J</i> = 8.35 Hz), 7.57–7.63 (4 H, m), 7.45–7.56 (3 H, m), 5.16 (1 H, dd, <i>J</i> = 8.79, 4.83 Hz), 3.54–3.81 (2 H, m), 2.83–2.97 (1 H, m), 2.66–2.78 (1 H, m), 2.64–2.96 (2 H, m), 2.14–2.46 (3 H, m), 1.67–2.02 (3 H, m), 1.11–1.42 (1 H, m). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 543. HPLC <i>t</i><sub>r</sub> = 3.26 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 99.6%, <i>t</i><sub>r</sub> = 5.62 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 99.5%, <i>t</i><sub>r</sub> = 4.35 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>).</div></div><div id="sec3_6_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (<i>S</i>)-1-((<i>S</i>)-2-Hydroxy-2-(4-(5-(3-(pyridin-2-yl)-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic Acid (<b>20a</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p">To a mixture of 3-(pyridin-2-yl)-4-(trifluoromethyl)isoxazole-5-carboxylic acid<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (45 mg, 0.174 mmol), (<i>S</i>)-ethyl 1-((<i>S</i>)-2-hydroxy-2-(4-((<i>Z</i>)-<i>N</i>′-hydroxycarbamimidoyl)phenyl)ethyl)piperidine-3-carboxylate (70 mg, 0.21 mmol), and BOP-Cl (53 mg, 0.21 mmol) in DMF (5 mL) was added TEA (0.073 mL, 0.52 mmol). The reaction mixture was stirred at room temperature for 2 h and then 1 M TBAF (0.17 mL, 0.17 mmol) was added. Next, the reaction mixture was stirred for 3 days. The reaction mixture was diluted with EtOAc and washed with saturated NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The crude residue was purified by a silica gel cartridge using an EtOAc/hexanes gradient to yield 37 mg of ethyl (<i>S</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-(5-(3-(pyridin-2-yl)-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylate (38%).</div><div class="NLM_p last">To a mixture of ethyl (<i>S</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-(5-(3-(pyridin-2-yl)-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylate (37 mg, 0.066 mmol) in CH<sub>3</sub>CN (1 mL) was added water (1 mL) and hydrochloric acid, 37% (1 mL). The reaction mixture was heated at 50 °C overnight, then filtered and purified by HPLC. HPLC conditions: Phenomenex Luna C18 5 μm column (250 mm × 30 mm); 20–100% CH<sub>3</sub>CN/water (0.1% TFA); 25 min gradient; 30 mL/min. Isolated fractions with correct mass were freeze-dried overnight to afford 30 mg of (<i>S</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-(5-(3-(pyridin-2-yl)-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid, TFA salt (<b>20a</b>, 68%) as a pale-yellow oil. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ ppm 8.78 (1 H, d, <i>J</i> = 4.39 Hz), 8.23 (2 H, d, <i>J</i> = 8.35 Hz), 8.00–8.09 (1 H, m), 7.95 (1 H, d, <i>J</i> = 7.91 Hz), 7.71 (2 H, d, <i>J</i> = 8.35 Hz), 7.57–7.65 (1 H, m), 5.20–5.34 (1 H, m), 3.80–4.08 (1 H, m), 3.43–3.73 (1 H, m), 3.34–3.43 (2 H, m), 2.81–3.22 (3 H, m), 1.83–2.37 (4 H, m), 1.53–1.75 (1 H, m). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 530. HPLC <i>t</i><sub>r</sub> = 2.80 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 97.6%, <i>t</i><sub>r</sub> = 7.68 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 97.1%, <i>t</i><sub>r</sub> = 6.73 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>).</div></div><div id="sec3_6_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 2-((<i>R</i>)-1-((<i>S</i>)-2-Hydroxy-2-(4-(5-(3-(pyridin-2-yl)-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic Acid (<b>20b</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p">3-(Pyridin-2-yl)-4-(trifluoromethyl)isoxazole-5-carboxylic acid<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (40 mg, 0.16 mmol) was suspended in dichloromethane (1.5 mL) with sonication, then DMF (5 μL, 0.065 mmol) was added. Oxalyl chloride (54 μL, 0.62 mmol) was added dropwise over 1–2 min. The reaction vial was flushed with argon and sealed. After 3 h, the contents were concentrated in vacuo. The material was reconstituted in dichloromethane, and a solution of ethyl 2-((<i>3R</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-((<i>Z</i>)-<i>N</i>′-hydroxycarbamimidoyl)phenyl)ethyl)piperidin-3-yl)acetate (54 mg, 0.16 mmol) in DCM (1–2 mL) was added. The reaction mixture was stirred for 3 days at room temperature and then purified by Prep HPLC to afford ethyl 2-((<i>R</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-(5-(3-(pyridin-2-yl)-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetate, which was suspended in dioxane (2–3 mL) and 3 N aq HCl (1 mL) was added. The mixture was heated to 50 °C overnight. The solution was evaporated and then placed under high vacuum to afford 10 mg of 2-((<i>R</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-(5-(3-(pyridin-2-yl)-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid, HCl (<b>20b</b>, 10%) as an off-white solid. <sup>1</sup>H NMR (500 MHz, MeOD) δ ppm 8.69 (1 H, d, <i>J</i> = 4.72 Hz), 8.14 (2 H, d, <i>J</i> = 8.32 Hz), 7.95 (1 H, td, <i>J</i> = 7.70, 1.80 Hz), 7.86 (1 H, d, <i>J</i> = 7.77 Hz), 7.61 (2 H, d, <i>J</i> = 8.32 Hz), 7.49–7.56 (1 H, m), 5.17 (1 H, dd, <i>J</i> = 9.71, 4.16 Hz), 3.80 (1 H, br s), 3.52–3.67 (4 H, m), 2.89 (1 H, br s), 2.73 (1 H, t, <i>J</i> = 11.93 Hz), 2.18–2.39 (3 H, m), 1.79–1.94 (3 H, m). HPLC <i>t</i><sub>r</sub> = 2.54 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 95.4%, <i>t</i><sub>r</sub> = 8.27 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 98.4%, <i>t</i><sub>r</sub> = 8.27 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>).</div><div class="NLM_p last">The following compounds were synthesized using the same routes as described above for <b>18a</b>, <b>19a</b>, <b>20a</b>, and <b>20b</b>.</div></div><div id="sec3_6_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (<i>S</i>)-1-((<i>S</i>)-2-Hydroxy-2-(4-(5-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic Acid (<b>21a</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 55 mg of (<i>S</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-(5-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid, TFA salt (<b>21a</b>, 28%) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.13 (2 H, d, <i>J</i> = 8.36 Hz), 7.71 (2 H, d, <i>J</i> = 7.48 Hz), 7.58–7.65 (3 H, m), 7.49–7.58 (2 H, m), 5.19 (1 H, t, <i>J</i> = 6.93 Hz), 3.93 (1 H, d, <i>J</i> = 11.44 Hz), 3.57 (1 H, d, <i>J</i> = 12.54 Hz), 3.28 (2 H, d, <i>J</i> = 6.82 Hz), 3.07 (1 H, t, <i>J</i> = 12.21 Hz), 2.93 (1 H, td, <i>J</i> = 12.54, 3.52 Hz), 2.81 (1 H, t, <i>J</i> = 12.32 Hz), 2.17 (1 H, d, <i>J</i> = 12.10 Hz), 1.86–2.06 (2 H, m), 1.45–1.64 (1 H, m, <i>J</i> = 13.09, 12.82, 12.82, 3.74 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 529. HPLC <i>t</i><sub>r</sub> = 3.19 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 97.7%, <i>t</i><sub>r</sub> = 7.67 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 98.3%, <i>t</i><sub>r</sub> = 6.47 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>).</div></div><div id="sec3_6_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 2-((<i>R</i>)-1-((<i>S</i>)-2-Hydroxy-2-(4-(5-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic Acid (<b>21b</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 66 mg of 2-((<i>R</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-(5-(5-phenyl-4-(trifluoromethyl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid, TFA salt (<b>21b</b>, 19%) as a white solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>3</sub>) δ ppm 8.12 (2 H, d, <i>J</i> = 8.35 Hz), 7.71 (2 H, d, <i>J</i> = 7.47 Hz), 7.49–7.66 (5 H, m), 5.16 (1 H, dd, <i>J</i> = 9.67, 4.39 Hz), 3.81 (1 H, d, <i>J</i> = 11.86 Hz), 3.56 (1 H, d, <i>J</i> = 11.42 Hz), 3.14–3.33 (2 H, m), 2.83–2.94 (1 H, m), 2.72 (1 H, t, <i>J</i> = 11.86 Hz), 2.16–2.38 (3 H, m), 1.78–1.92 (3 H, m), 1.10–1.33 (1 H, m). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 543. HPLC <i>t</i><sub>r</sub> = 3.24 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 99.5%, <i>t</i><sub>r</sub> = 7.66 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 100%, <i>t</i><sub>r</sub> = 6.43 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>).</div></div><div id="sec3_6_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (<i>S</i>)-1-((<i>S</i>)-2-Hydroxy-2-(4-(5-(5-isobutyl-4-(trifluoromethyl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic Acid (<b>22a</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 24 mg of (<i>S</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-(5-(5-isobutyl-4-(trifluoromethyl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid (<b>22a</b>, 52%) as a tan solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.19 (2 H, d, <i>J</i> = 8.36 Hz), 7.70 (2 H, d, <i>J</i> = 8.36 Hz), 5.26 (1H, dd, <i>J</i> = 10.45, 2.97 Hz), 3.25–3.40 (6 H, m), 3.02 (2 H, dd, <i>J</i> = 7.26, 1.10 Hz), 2.80–2.88 (1 H, m), 2.14–2.26 (1 H, m), 1.89–2.08 (4 H, m), 1.05 (3 H, s), 1.04 (3 H, s). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 509. HPLC <i>t</i><sub>r</sub> = 3.78 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 98.9%, <i>t</i><sub>r</sub> = 8.71 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 98.7%, <i>t</i><sub>r</sub> = 7.71 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>).</div></div><div id="sec3_6_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 2-((<i>R</i>)-1-((<i>S</i>)-2-Hydroxy-2-(4-(5-(5-isobutyl-4-(trifluoromethyl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic Acid (<b>22b</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 17 mg of 2-((<i>R</i>)-1-((<i>S</i>)-2-hydroxy-2-(4-(5-(5-isobutyl-4-(trifluoromethyl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)acetic acid, TFA salt (<b>22b</b>, 15%) as a clear oil. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.09 (2 H, m, <i>J</i> = 8.36 Hz), 7.58 (2 H, d, <i>J</i> = 8.36 Hz), 5.16 (1 H, dd, <i>J</i> = 9.24, 4.62 Hz), 3.80 (1 H, d, <i>J</i> = 11.22 Hz), 3.57 (1 H, d, <i>J</i> = 13.42 Hz), 2.91 (2 H, dd, <i>J</i> = 7.26, 1.10 Hz), 2.79–2.90 (1 H, m), 2.73 (1 H, t, <i>J</i> = 11.77 Hz), 2.18–2.39 (3 H, m), 2.09 (1 H, dt, <i>J</i> = 13.64, 6.82 Hz), 1.82–1.93 (3 H, m), 1.14–1.31 (1 H, m), 0.94 (6 H, d, <i>J</i> = 6.60 Hz). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 523. HPLC <i>t</i><sub>r</sub> = 3.28 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 97.9%, <i>t</i><sub>r</sub> = 8.95 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>); 96.7%, <i>t</i><sub>r</sub> = 7.83 min (<a class="ref internalNav" href="#sec3_6_1_5" aria-label="method F">method F</a>).</div></div><div id="sec3_6_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 2-((<i>R</i>)-1-((<i>S</i>)-2-(4-(5-(5-Cyclohexyl-4-(trifluoromethyl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl)acetic Acid (<b>23</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h4><div class="NLM_p last">Recovered 15 mg of 2-((<i>R</i>)-1-((<i>S</i>)-2-(4-(5-(5-cyclohexyl-4-(trifluoromethyl)isoxazol-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)-2-hydroxyethyl)piperidin-3-yl)acetic acid, HCL (<b>23</b>, 21%) as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ ppm 8.09 (2 H, d, <i>J</i> = 8.36 Hz), 7.59 (2 H, d, <i>J</i> = 8.36 Hz), 5.13–5.22 (1 H, m), 3.80 (1 H, d, <i>J</i> = 10.56 Hz), 3.53–3.62 (2 H, m), 2.91 (1 H, br s), 2.75 (1 H, t, <i>J</i> = 11.44 Hz), 2.17–2.39 (3 H, m), 1.79–1.97 (7 H, m), 1.58–1.78 (3 H, m), 1.19–1.44 (4 H, m). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 549. HPLC <i>t</i><sub>r</sub> = 3.52 min (<a class="ref internalNav" href="#sec3_6_1_2" aria-label="method B">method B</a>). HPLC purity: 96.8%, <i>t</i><sub>r</sub> = 9.71 min (<a class="ref internalNav" href="#sec3_6_1_4" aria-label="method E">method E</a>).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00373">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11534" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11534" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00373" class="ext-link">10.1021/acs.jmedchem.6b00373</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">X-ray crystallographic structure of <b>14a</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">X-ray crystallographic structure of <b>14a</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Docking of <b>19a</b> into the crystal structure of S1P<sub>1</sub> in complex with ML056 (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_004.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_001.pdf">jm6b00373_si_001.pdf (208.49 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_002.pdb">jm6b00373_si_002.pdb (6.63 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_003.pdb">jm6b00373_si_003.pdb (529.67 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_004.csv">jm6b00373_si_004.csv (2.85 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00373" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24517" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24517" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John L. Gilmore</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#92f8fdfafcbcf5fbfefffde0f7d2f0ffe1bcf1fdff"><span class="__cf_email__" data-cfemail="d0babfb8befeb7b9bcbdbfa2b590b2bda3feb3bfbd">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James E. Sheppeck</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott H. Watterson</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lauren Haque</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Parag Mukhopadhyay</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew J. Tebben</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael A. Galella</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ding Ren Shen</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa Yarde</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary Ellen Cvijic</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Virna Borowski</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathleen Gillooly</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tracy Taylor</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kim W. McIntyre</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bethanne Warrack</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul C. Levesque</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julia P. Li</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Georgia Cornelius</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Celia D’Arienzo</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony Marino</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Praveen Balimane</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luisa Salter-Cid</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joel C. Barrish</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William J. Pitts</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Percy H. Carter</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jenny Xie</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alaric J. Dyckman</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb,
P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i78" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i78"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i79" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i79"> Abbreviations Used</h2><tr><td class="NLM_term">S1P</td><td class="NLM_def"><p class="first last">sphingosine-1-phosphate</p></td></tr><tr><td class="NLM_term">S1P<sub>1–5</sub></td><td class="NLM_def"><p class="first last">sphingosine-1-phosphate receptors 1–5</p></td></tr><tr><td class="NLM_term">BLR</td><td class="NLM_def"><p class="first last">rat blood lymphocyte reduction</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">transmembrane</p></td></tr><tr><td class="NLM_term">AA</td><td class="NLM_def"><p class="first last">adjuvant induced arthritis</p></td></tr><tr><td class="NLM_term">EAE</td><td class="NLM_def"><p class="first last">experimental autoimmune encephalomyelitis</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04254" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04254" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 27 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Billich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornancin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechtcheriakova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urtz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumruker, T.</span><span> </span><span class="NLM_article-title">Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">47408</span><span class="NLM_x">–</span> <span class="NLM_lpage">47415</span><span class="refDoi"> DOI: 10.1074/jbc.M307687200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1074%2Fjbc.M307687200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=13129923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1Cqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=47408-47415&author=A.+Billichauthor=F.+Bornancinauthor=P.+Devayauthor=D.+Mechtcheriakovaauthor=N.+Urtzauthor=T.+Baumruker&title=Phosphorylation+of+the+immunomodulatory+drug+FTY720+by+sphingosine+kinases&doi=10.1074%2Fjbc.M307687200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases</span></div><div class="casAuthors">Billich, Andreas; Bornancin, Frederic; Devay, Piroska; Mechtcheriakova, Diana; Urtz, Nicole; Baumruker, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">47408-47415</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The immunomodulatory drug FTY720 is phosphorylated in vivo, and the resulting FTY720 phosphate as a ligand for sphingosine-1-phosphate receptors is responsible for the unique biol. effects of the compd.  So far, phosphorylation of FTY720 by murine sphingosine kinase (SPHK) 1a had been documented.  We found that, while FTY720 is also phosphorylated by human SPHK1, the human type 2 isoform phosphorylates the drug 30-fold more efficiently, because of a lower Km of FTY720 for SPHK2.  Similarly, murine SPHK2 was more efficient than SPHK1a.  Among splice variants of the human SPHKs, an N-terminally extended SPHK2 isoform was even more active than SPHK2 itself.  Further SPHK superfamily members, namely ceramide kinase and a "SPHK-like" protein, failed to phosphorylate sphingosine and FTY720.  Thus, only SPHK1 and 2 appear to be capable of phosphorylating FTY720.  Using selective assay conditions, SPHK1 and 2 activities in murine tissues were measured.  While activity of SPHK2 toward sphingosine was generally lower than of SPHK1, FTY720 phosphorylation was higher under conditions favoring SPHK2.  In human endothelial cells, while activity of SPHK1 toward sphingosine was 2-fold higher than of SPHK2, FTY720 phosphorylation was 7-fold faster under SPHK2 assay conditions.  Finally, FTY720 was poorly phosphorylated in human blood as compared with rodent blood, in line with the low activity of SPHK1 and in particular of SPHK2 in human blood.  To conclude, both SPHK1 and 2 are capable of phosphorylating FTY720, but SPHK2 is quant. more important than SPHK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR5e-dVWnBT7Vg90H21EOLACvtfcHk0lgOp1TocMnn2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1Cqtr0%253D&md5=26820503680682863dc76a69ea02fc7e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M307687200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M307687200%26sid%3Dliteratum%253Aachs%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DBornancin%26aufirst%3DF.%26aulast%3DDevay%26aufirst%3DP.%26aulast%3DMechtcheriakova%26aufirst%3DD.%26aulast%3DUrtz%26aufirst%3DN.%26aulast%3DBaumruker%26aufirst%3DT.%26atitle%3DPhosphorylation%2520of%2520the%2520immunomodulatory%2520drug%2520FTY720%2520by%2520sphingosine%2520kinases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D47408%26epage%3D47415%26doi%3D10.1074%2Fjbc.M307687200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Albert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinterding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Hartwieg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knecht, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simeon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streiff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welzenbach, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zécri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zollinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francotte, E.</span><span> </span><span class="NLM_article-title">Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. identification, chemical proof, and biological characterization of the biologically active species and its enantiomer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5373</span><span class="NLM_x">–</span> <span class="NLM_lpage">5377</span><span class="refDoi"> DOI: 10.1021/jm050242f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050242f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtVWisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5373-5377&author=R.+Albertauthor=K.+Hinterdingauthor=V.+Brinkmannauthor=D.+Gueriniauthor=C.+Muller-Hartwiegauthor=H.+Knechtauthor=C.+Simeonauthor=M.+Streiffauthor=T.+Wagnerauthor=K.+Welzenbachauthor=F.+Z%C3%A9criauthor=M.+Zollingerauthor=N.+Cookeauthor=E.+Francotte&title=Novel+immunomodulator+FTY720+is+phosphorylated+in+rats+and+humans+to+form+a+single+stereoisomer.+identification%2C+chemical+proof%2C+and+biological+characterization+of+the+biologically+active+species+and+its+enantiomer&doi=10.1021%2Fjm050242f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Immunomodulator FTY720 Is Phosphorylated in Rats and Humans To Form a Single Stereoisomer. Identification, Chemical Proof, and Biological Characterization of the Biologically Active Species and Its Enantiomer</span></div><div class="casAuthors">Albert, Rainer; Hinterding, Klaus; Brinkmann, Volker; Guerini, Danilo; Mueller-Hartwieg, Constanze; Knecht, Helmut; Simeon, Corinne; Streiff, Markus; Wagner, Trixie; Welzenbach, Karl; Zecri, Frederic; Zollinger, Markus; Cooke, Nigel; Francotte, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5373-5377</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In vivo phosphorylation of FTY720 (1) in rats and humans resulted exclusively in the biol. active (S)-configured enantiomer, which was proven by an ex vivo o-phthaldialdehyde derivatization protocol esp. elaborated for phosphates of 1.  Starting from the prochiral amino alc. 1, racemic and enantiomerically pure phosphates of 1 were synthesized.  Pure enantiomers were obtained after purifn. of a partially protected key intermediate on an enantioselective support.  The abs. stereochem. was detd. by x-ray diffraction.  Data on human and rat studies are given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh0U1_F0bQtLVg90H21EOLACvtfcHk0liKSp9hDgMJWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtVWisr4%253D&md5=34b956ad7d7e60c2013e66320a88560e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm050242f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050242f%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DR.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DMuller-Hartwieg%26aufirst%3DC.%26aulast%3DKnecht%26aufirst%3DH.%26aulast%3DSimeon%26aufirst%3DC.%26aulast%3DStreiff%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DWelzenbach%26aufirst%3DK.%26aulast%3DZ%25C3%25A9cri%26aufirst%3DF.%26aulast%3DZollinger%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DN.%26aulast%3DFrancotte%26aufirst%3DE.%26atitle%3DNovel%2520immunomodulator%2520FTY720%2520is%2520phosphorylated%2520in%2520rats%2520and%2520humans%2520to%2520form%2520a%2520single%2520stereoisomer.%2520identification%252C%2520chemical%2520proof%252C%2520and%2520biological%2520characterization%2520of%2520the%2520biologically%2520active%2520species%2520and%2520its%2520enantiomer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5373%26epage%3D5377%26doi%3D10.1021%2Fjm050242f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartung, H.</span><span> </span><span class="NLM_article-title">Mechanism of action of oral fingolimod (FTY720) in multiple schlerosis</span> <span class="citation_source-journal">Clin. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span><span class="refDoi"> DOI: 10.1097/WNF.0b013e3181cbf825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1097%2FWNF.0b013e3181cbf825" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=91-101&author=J.+Chunauthor=H.+Hartung&title=Mechanism+of+action+of+oral+fingolimod+%28FTY720%29+in+multiple+schlerosis&doi=10.1097%2FWNF.0b013e3181cbf825"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1097%2FWNF.0b013e3181cbf825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FWNF.0b013e3181cbf825%26sid%3Dliteratum%253Aachs%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DHartung%26aufirst%3DH.%26atitle%3DMechanism%2520of%2520action%2520of%2520oral%2520fingolimod%2520%2528FTY720%2529%2520in%2520multiple%2520schlerosis%26jtitle%3DClin.%2520Neuropharmacol.%26date%3D2010%26volume%3D33%26spage%3D91%26epage%3D101%26doi%3D10.1097%2FWNF.0b013e3181cbf825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Mandala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quackenbush, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupprecht, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">296</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span><span class="refDoi"> DOI: 10.1126/science.1070238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1126%2Fscience.1070238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=11923495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=346-349&author=S.+Mandalaauthor=R.+Hajduauthor=J.+Bergstromauthor=E.+Quackenbushauthor=J.+Xieauthor=J.+Milliganauthor=R.+Thorntonauthor=G.-J.+Sheiauthor=D.+Cardauthor=C.+A.+Keohaneauthor=M.+Rosenbachauthor=J.+Haleauthor=C.+L.+Lynchauthor=K.+Rupprechtauthor=W.+Parsonsauthor=H.+Rosen&title=Alteration+of+lymphocyte+trafficking+by+sphingosine-1-phosphate+receptor+agonists&doi=10.1126%2Fscience.1070238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</span></div><div class="casAuthors">Mandala, Suzanne; Hajdu, Richard; Bergstrom, James; Quackenbush, Elizabeth; Xie, Jenny; Milligan, James; Thornton, Rosemary; Shei, Gan-Ju; Card, Deborah; Keohane, Carolann; Rosenbach, Mark; Hale, Jeffrey; Lynch, Christopher L.; Rupprecht, Kathleen; Parsons, William; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5566</span>),
    <span class="NLM_cas:pages">346-349</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Blood lymphocyte nos., essential for the development of efficient immune responses, are maintained by recirculation through secondary Lymphoid organs.  We show that lymphocyte trafficking is altered by the lysophospholipid sphingosine-1-phosphate (S1P) and by a phosphoryl metabolite of the immunosuppressive agent FTY720.  Both species were high-affinity agonists of at least four of the five S1P receptors.  These agonists produce lymphopenia in blood and thoracic duct lymph by sequestration of lymphocytes in lymph nodes, but not spleen.  S1P receptor agonists induced emptying of lymphoid sinuses by retention of lymphocytes on the abluminal side of sinus-lining endothelium and inhibition of egress into lymph.  Inhibition of lymphocyte recirculation by activation of S1P receptors may result in therapeutically useful immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPvwG_lLsA8LVg90H21EOLACvtfcHk0lgtR5lKVpdxkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D&md5=b57cbcffe41d144e701dbd42459cf38a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1070238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1070238%26sid%3Dliteratum%253Aachs%26aulast%3DMandala%26aufirst%3DS.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DQuackenbush%26aufirst%3DE.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DMilligan%26aufirst%3DJ.%26aulast%3DThornton%26aufirst%3DR.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DRupprecht%26aufirst%3DK.%26aulast%3DParsons%26aufirst%3DW.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DAlteration%2520of%2520lymphocyte%2520trafficking%2520by%2520sphingosine-1-phosphate%2520receptor%2520agonists%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D346%26epage%3D349%26doi%3D10.1126%2Fscience.1070238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hof, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruns, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prieschl, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumruker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiestand, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zollinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, K. R.</span><span> </span><span class="NLM_article-title">The immune modulator FTY720 targets sphingosine 1-phosphate receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">21453</span><span class="NLM_x">–</span> <span class="NLM_lpage">21457</span><span class="refDoi"> DOI: 10.1074/jbc.C200176200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1074%2Fjbc.C200176200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=11967257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD38Xkslyqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=21453-21457&author=V.+Brinkmannauthor=M.+D.+Davisauthor=C.+E.+Heiseauthor=R.+Albertauthor=S.+Cottensauthor=R.+Hofauthor=C.+Brunsauthor=E.+Prieschlauthor=T.+Baumrukerauthor=P.+Hiestandauthor=C.+A.+Fosterauthor=M.+Zollingerauthor=K.+R.+Lynch&title=The+immune+modulator+FTY720+targets+sphingosine+1-phosphate+receptors&doi=10.1074%2Fjbc.C200176200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The immune modulator FTY720 targets sphingosine 1-phosphate receptors</span></div><div class="casAuthors">Brinkmann, Volker; Davis, Michael D.; Heise, Christopher E.; Albert, Rainer; Cottens, Sylvain; Hof, Robert; Bruns, Christian; Prieschl, Eva; Baumruker, Thomas; Hiestand, Peter; Foster, Carolyn A.; Zollinger, Markus; Lynch, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">21453-21457</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Immunosuppressant drugs such as cyclosporin have allowed widespread organ transplantation, but their utility remains limited by toxicities, and they are ineffective in chronic management of autoimmune diseases such as multiple sclerosis.  In contrast, the immune modulating drug FTY720 is efficacious in a variety of transplant and autoimmune models without inducing a generalized immunosuppressed state and is effective in human kidney transplantation.  FTY720 elicits a lymphopenia resulting from a reversible redistribution of lymphocytes from circulation to secondary lymphoid tissues by unknown mechanisms.  Using FTY720 and several analogs, we show now that FTY720 is phosphorylated by sphingosine kinase; the phosphorylated compd. is a potent agonist at four sphingosine 1-phosphate receptors and represents the therapeutic principle in a rodent model of multiple sclerosis.  Our results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_6zyZnHOYNbVg90H21EOLACvtfcHk0lgtR5lKVpdxkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xkslyqtb4%253D&md5=b59856fffa9ebae7fb8182d18daa025f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C200176200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C200176200%26sid%3Dliteratum%253Aachs%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DM.%2BD.%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DAlbert%26aufirst%3DR.%26aulast%3DCottens%26aufirst%3DS.%26aulast%3DHof%26aufirst%3DR.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DPrieschl%26aufirst%3DE.%26aulast%3DBaumruker%26aufirst%3DT.%26aulast%3DHiestand%26aufirst%3DP.%26aulast%3DFoster%26aufirst%3DC.%2BA.%26aulast%3DZollinger%26aufirst%3DM.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26atitle%3DThe%2520immune%2520modulator%2520FTY720%2520targets%2520sphingosine%25201-phosphate%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D21453%26epage%3D21457%26doi%3D10.1074%2Fjbc.C200176200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Cyster, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, S. R.</span><span> </span><span class="NLM_article-title">Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs</span> <span class="citation_source-journal">Annu. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span><span class="refDoi"> DOI: 10.1146/annurev-immunol-020711-075011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1146%2Fannurev-immunol-020711-075011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=22149932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=69-94&author=J.+G.+Cysterauthor=S.+R.+Schwab&title=Sphingosine-1-phosphate+and+lymphocyte+egress+from+lymphoid+organs&doi=10.1146%2Fannurev-immunol-020711-075011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs</span></div><div class="casAuthors">Cyster, Jason G.; Schwab, Susan R.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-94</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Much has been learned about how cells enter lymphoid tissues.  But how do they leave.  Sphingosine-1-phosphate (S1P) has emerged over the past decade as a central mediator of lymphocyte egress.  In this review, we summarize the current understanding of how S1P promotes exit from the secondary lymphoid organs and thymus.  We review what is known about addnl. requirements for emigration and summarize the mostly distinct requirements for exit from the bone marrow.  Egress from lymphoid organs is limited during immune responses, and we examine how this regulation works.  There is accumulating evidence for roles of S1P in directing immune cell behavior within lymphoid tissues.  How such actions can fit together with the egress-promoting role of S1P is discussed.  Finally, we examine current understanding of how FTY720, a drug that targets S1P receptors and is approved for the treatment of multiple sclerosis, causes immune suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhvMroRvgkZrVg90H21EOLACvtfcHk0liZ1a2YpnPY8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKmtLY%253D&md5=c9f9ef63f2248594b0f9ce4d06024bba</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev-immunol-020711-075011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-immunol-020711-075011%26sid%3Dliteratum%253Aachs%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26aulast%3DSchwab%26aufirst%3DS.%2BR.%26atitle%3DSphingosine-1-phosphate%2520and%2520lymphocyte%2520egress%2520from%2520lymphoid%2520organs%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2012%26volume%3D30%26spage%3D69%26epage%3D94%26doi%3D10.1146%2Fannurev-immunol-020711-075011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendataraman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaud, J.</span><span> </span><span class="NLM_article-title">The vascular S1P gradient: cellular sources and biological significance</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">1781</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">482</span><span class="refDoi"> DOI: 10.1016/j.bbalip.2008.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1016%2Fj.bbalip.2008.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=18674637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKjtbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1781&publication_year=2008&pages=477-482&author=T.+Hlaauthor=K.+Vendataramanauthor=J.+Michaud&title=The+vascular+S1P+gradient%3A+cellular+sources+and+biological+significance&doi=10.1016%2Fj.bbalip.2008.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">The vascular S1P gradient-Cellular sources and biological significance</span></div><div class="casAuthors">Hla, Timothy; Venkataraman, Krishnan; Michaud, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1781</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">477-482</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P), a product of sphingomyelin metab., is enriched in the circulatory system whereas it is estd. to be much lower in interstitial fluids of tissues.  This concn. gradient, termed the vascular S1P gradient appears to form as a result of substrate availability and the action of metabolic enzymes.  S1P levels in blood and lymph are estd. to be in the μM range.  In the immune system, the S1P gradient is needed as a spatial cue for lymphocyte and hematopoietic cell trafficking.  During inflammatory reactions in which enhanced vascular permeability occurs, a burst of S1P becomes available to its receptors in the extravascular compartment, which likely contributes to the tissue reactions.  Thus, the presence of the vascular S1P gradient is thought to contribute to physiol. and pathol. conditions.  From an evolutionary perspective, S1P receptors may have co-evolved with the advent of a closed vascular system and the trafficking paradigms for hematopoietic cells to navigate in and out of the vascular system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosbyXvTWrRf7Vg90H21EOLACvtfcHk0liZ1a2YpnPY8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKjtbrF&md5=a9c4420dff6764f71060b18149669767</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2008.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2008.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DHla%26aufirst%3DT.%26aulast%3DVendataraman%26aufirst%3DK.%26aulast%3DMichaud%26aufirst%3DJ.%26atitle%3DThe%2520vascular%2520S1P%2520gradient%253A%2520cellular%2520sources%2520and%2520biological%2520significance%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2008%26volume%3D1781%26spage%3D477%26epage%3D482%26doi%3D10.1016%2Fj.bbalip.2008.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schwab, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cyster, J. G.</span><span> </span><span class="NLM_article-title">Finding a way out: lymphocyte egress from lymphoid organs</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1295</span><span class="NLM_x">–</span> <span class="NLM_lpage">1301</span><span class="refDoi"> DOI: 10.1038/ni1545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1038%2Fni1545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=18026082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlajtr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=1295-1301&author=S.+R.+Schwabauthor=J.+G.+Cyster&title=Finding+a+way+out%3A+lymphocyte+egress+from+lymphoid+organs&doi=10.1038%2Fni1545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Finding a way out: lymphocyte egress from lymphoid organs</span></div><div class="casAuthors">Schwab, Susan R.; Cyster, Jason G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1295-1301</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The egress of lymphocytes from the thymus and secondary lymphoid organs into circulatory fluids is essential for normal immune function.  The discovery that a small-mol. inhibitor of lymphocyte exit, FTY720, is a ligand for sphingosine 1-phosphate (S1P) receptors led to studies demonstrating that S1P receptor type 1 (S1P1) is needed in T cells and B cells for their egress from lymphoid organs.  S1P exists in higher concns. in blood and lymph than in lymphoid organs, and this differential is also required for lymphocyte exit.  Transcriptional and post-translational mechanisms regulate S1P1 and thus the egress of lymphocytes.  In this review we discuss the body of evidence supporting a model in which lymphocyte egress is promoted by encounter with S1P at exit sites.  We relate this model to work examg. the effects of S1P receptor agonists on endothelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWY-Rk111SmLVg90H21EOLACvtfcHk0lhc0YNcEZM0bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlajtr7J&md5=ccf7ef06130d3ebd218707ac92618f36</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1038%2Fni1545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1545%26sid%3Dliteratum%253Aachs%26aulast%3DSchwab%26aufirst%3DS.%2BR.%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26atitle%3DFinding%2520a%2520way%2520out%253A%2520lymphocyte%2520egress%2520from%2520lymphoid%2520organs%26jtitle%3DNat.%2520Immunol.%26date%3D2007%26volume%3D8%26spage%3D1295%26epage%3D1301%26doi%3D10.1038%2Fni1545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetzl, E. J.</span><span> </span><span class="NLM_article-title">Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">560</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span><span class="refDoi"> DOI: 10.1038/nri1650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1038%2Fnri1650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=15999095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsl2itr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=560-570&author=H.+Rosenauthor=E.+J.+Goetzl&title=Sphingosine+1-phosphate+and+its+receptors%3A+an+autocrine+and+paracrine+network&doi=10.1038%2Fnri1650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network</span></div><div class="casAuthors">Rosen, Hugh; Goetzl, Edward J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">560-570</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P) is a biol. active lysophospholipid that transmits signals through a family of G-protein-coupled receptors to control cellular differentiation and survival, as well as the vital functions of several types of immune cell.  In this Review article, the authors discuss recent results that indicate that S1P and its receptors are required for the emigration of thymocytes from the thymus, the trafficking of lymphocytes in secondary lymphoid organs and the migration of B cells into splenic follicles.  In an autocrine manner, through interactions with different G-protein-coupled receptors, S1P also enhances optimal mast-cell migration and release of pro-inflammatory mediators in allergic reactions.  S1P-S1P-receptor regulatory systems might therefore be novel targets for the therapy of diverse immunol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6-Zo0R14YILVg90H21EOLACvtfcHk0lhc0YNcEZM0bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsl2itr4%253D&md5=b680f6c9e29d407579ab7f056209d853</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1038%2Fnri1650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1650%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DGoetzl%26aufirst%3DE.%2BJ.%26atitle%3DSphingosine%25201-phosphate%2520and%2520its%2520receptors%253A%2520an%2520autocrine%2520and%2520paracrine%2520network%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2005%26volume%3D5%26spage%3D560%26epage%3D570%26doi%3D10.1038%2Fnri1650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Pappu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelissen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regard, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camerer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Y.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cyster, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coughlin, S. R.</span><span> </span><span class="NLM_article-title">Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span><span class="refDoi"> DOI: 10.1126/science.1139221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1126%2Fscience.1139221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=17363629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktVeku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=295-298&author=R.+Pappuauthor=S.+R.+Schwabauthor=I.+Cornelissenauthor=J.+P.+Pereiraauthor=J.+B.+Regardauthor=Y.+Xuauthor=E.+Camererauthor=Y.-W.+Zhengauthor=Y.+Huangauthor=J.+G.+Cysterauthor=S.+R.+Coughlin&title=Promotion+of+lymphocyte+egress+into+blood+and+lymph+by+distinct+sources+of+sphingosine-1-phosphate&doi=10.1126%2Fscience.1139221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate</span></div><div class="casAuthors">Pappu, Rajita; Schwab, Susan R.; Cornelissen, Ivo; Pereira, Joao P.; Regard, Jean B.; Xu, Ying; Camerer, Eric; Zheng, Yao-Wu; Huang, Yong; Cyster, Jason G.; Coughlin, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5822</span>),
    <span class="NLM_cas:pages">295-298</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Lymphocytes require sphingosine-1-phosphate (S1P) receptor-1 to exit lymphoid organs, but the source(s) of extracellular S1P and whether S1P directly promotes egress are unknown.  By using mice in which the two kinases that generate S1P were conditionally ablated, we find that plasma S1P is mainly hematopoietic in origin, with erythrocytes a major contributor, whereas lymph S1P is from a distinct radiation-resistant source.  Lymphocyte egress from thymus and secondary lymphoid organs was markedly reduced in kinase-deficient mice.  Restoration of S1P to plasma rescued egress to blood but not lymph, and the rescue required lymphocyte expression of S1P-receptor-1.  Thus, sep. sources provide S1P to plasma and lymph to help lymphocytes exit the low-S1P environment of lymphoid organs.  Disruption of compartmentalized S1P signaling is a plausible mechanism by which S1P-receptor-1 agonists function as immunosuppressives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMH4WVYwTIX7Vg90H21EOLACvtfcHk0lg1L5aaZqLO2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktVeku70%253D&md5=6c658296c3b1d34543c193987092506b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.1139221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1139221%26sid%3Dliteratum%253Aachs%26aulast%3DPappu%26aufirst%3DR.%26aulast%3DSchwab%26aufirst%3DS.%2BR.%26aulast%3DCornelissen%26aufirst%3DI.%26aulast%3DPereira%26aufirst%3DJ.%2BP.%26aulast%3DRegard%26aufirst%3DJ.%2BB.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DCamerer%26aufirst%3DE.%26aulast%3DZheng%26aufirst%3DY.-W.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26aulast%3DCoughlin%26aufirst%3DS.%2BR.%26atitle%3DPromotion%2520of%2520lymphocyte%2520egress%2520into%2520blood%2520and%2520lymph%2520by%2520distinct%2520sources%2520of%2520sphingosine-1-phosphate%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D295%26epage%3D298%26doi%3D10.1126%2Fscience.1139221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Singer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobias, K.</span><span> </span><span class="NLM_article-title">Oral fingolomid for the treatment of patients with relapsing forms of multiple sclerosis</span> <span class="citation_source-journal">Int. J. Clin. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">887</span><span class="NLM_x">–</span> <span class="NLM_lpage">895</span><span class="refDoi"> DOI: 10.1111/j.1742-1241.2011.02721.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1111%2Fj.1742-1241.2011.02721.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=21679286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsV2hsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2011&pages=887-895&author=B.+Singerauthor=A.+P.+Rossauthor=K.+Tobias&title=Oral+fingolomid+for+the+treatment+of+patients+with+relapsing+forms+of+multiple+sclerosis&doi=10.1111%2Fj.1742-1241.2011.02721.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis</span></div><div class="casAuthors">Singer, B.; Ross, A. P.; Tobias, K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">887-895</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1742-1241</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Fingolimod, a sphingosine 1-phosphate receptor modulator, is the first oral treatment approved by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (MS).  The aim of this review was to provide a concise, comprehensive overview of the clin. relevant mechanism of action, efficacy and safety information available for fingolimod.  Key data were derived from two international, Phase III, double-blind, randomised trials (TRANSFORMS and FREEDOMS) performed over 12 and 24 mo, resp., which evaluated fingolimod 0.5 and 1.25 mg daily in 1703 patients with relapsing forms of MS.  In TRANSFORMS, there was a 52% redn. in the annualised relapse rate (ARR) with fingolimod 0.5 mg vs. 30 μg i.m. interferon beta-1a (0.16 vs. 0.33; p < 0.001) at 1 yr.  In FREEDOMS, there was a 55% decrease in ARR at 2 years with fingolimod 0.5 mg vs. placebo (0.18 vs. 0.40; p < 0.001).  Risk of disability progression, confirmed at 3 mo, was also reduced by 30% over the 2-yr study period with fingolimod vs. placebo (p = 0.02).  Significantly fewer new or enlarged lesions on T2-weighted images were seen in both studies (TRANSFORMS, p = 0.002 vs. interferon beta-1a at 1 yr; FREEDOMS, p < 0.001 vs. placebo at 2 years).  Overall, fingolimod 0.5 mg was well tolerated by patients.  Transient, generally asymptomatic bradycardia and infrequent atrioventricular block were seen with the administration of the first dose.  Macular edema and serious infections occurred infrequently.  Reversible, asymptomatic elevations of liver enzymes could also occur.  As the first approved oral disease-modifying treatment, fingolimod offers patients a convenient alternative to regular self-injection for the treatment of relapsing forms of MS.  In addn. to high efficacy with a relatively acceptable safety profile, fingolimod provides a therapy with a new mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVKs1Biiz177Vg90H21EOLACvtfcHk0lg1L5aaZqLO2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsV2hsbY%253D&md5=8be8ad56fc253ddccb59597c041b9ff8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-1241.2011.02721.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-1241.2011.02721.x%26sid%3Dliteratum%253Aachs%26aulast%3DSinger%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DA.%2BP.%26aulast%3DTobias%26aufirst%3DK.%26atitle%3DOral%2520fingolomid%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520relapsing%2520forms%2520of%2520multiple%2520sclerosis%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2011%26volume%3D65%26spage%3D887%26epage%3D895%26doi%3D10.1111%2Fj.1742-1241.2011.02721.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Sanchez, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada-Hernandez, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paik, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, M.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkataraman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claffey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span> </span><span class="NLM_article-title">Phosphorylation and action of the immunomodulatory FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">47281</span><span class="NLM_x">–</span> <span class="NLM_lpage">47290</span><span class="refDoi"> DOI: 10.1074/jbc.M306896200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1074%2Fjbc.M306896200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=47281-47290&author=T.+Sanchezauthor=T.+Estrada-Hernandezauthor=J.-H.+Paikauthor=M.-T.+Wuauthor=K.+Venkataramanauthor=V.+Brinkmannauthor=K.+Claffeyauthor=T.+Hla&title=Phosphorylation+and+action+of+the+immunomodulatory+FTY720+inhibits+vascular+endothelial+cell+growth+factor-induced+vascular+permeability&doi=10.1074%2Fjbc.M306896200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M306896200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M306896200%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DT.%26aulast%3DEstrada-Hernandez%26aufirst%3DT.%26aulast%3DPaik%26aufirst%3DJ.-H.%26aulast%3DWu%26aufirst%3DM.-T.%26aulast%3DVenkataraman%26aufirst%3DK.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DClaffey%26aufirst%3DK.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DPhosphorylation%2520and%2520action%2520of%2520the%2520immunomodulatory%2520FTY720%2520inhibits%2520vascular%2520endothelial%2520cell%2520growth%2520factor-induced%2520vascular%2520permeability%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D47281%26epage%3D47290%26doi%3D10.1074%2Fjbc.M306896200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Kappos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montalban, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polman, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korn, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radue, E. W.</span><span> </span><span class="NLM_article-title">Oral fingolimod (FTY720) for relapsing multiple sclerosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">1124</span><span class="NLM_x">–</span> <span class="NLM_lpage">1140</span><span class="refDoi"> DOI: 10.1056/NEJMoa052643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1056%2FNEJMoa052643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=16971719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsFKku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=1124-1140&author=L.+Kapposauthor=J.+Antelauthor=G.+Comiauthor=X.+Montalbanauthor=P.+O%E2%80%99Connorauthor=C.+H.+Polmanauthor=T.+Haasauthor=A.+A.+Kornauthor=G.+Karlssonauthor=E.+W.+Radue&title=Oral+fingolimod+%28FTY720%29+for+relapsing+multiple+sclerosis&doi=10.1056%2FNEJMoa052643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Oral fingolimod (FTY720) for relapsing multiple sclerosis</span></div><div class="casAuthors">Kappos, Ludwig; Antel, Jack; Comi, Giancarlo; Montalban, Xavier; O'Connor, Paul; Polman, Chris H.; Haas, Tomas; Korn, Alexander A.; Karlsson, Goeril; Radue, Ernst W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1124-1140</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis.  We randomly assigned 281 patients to receive oral fingolimod, at a dose of 1.25 mg or 5.0 mg, or a placebo once daily, and we followed these patients for 6 mo with magnetic resonance imaging (MRI) and clin. evaluations (core study, months 0 to 6).  The primary end point was the total no. of gadolinium-enhanced lesions recorded on T1-weighted MRI at monthly intervals for 6 mo.  In an extension study in which the investigators and patients remained unaware of the dose assignments (months 7 to 12), patients who received placebo underwent randomization again to one of the fingolimod doses.  A total of 255 patients completed the core study.  The median total no. of gadolinium-enhanced lesions on MRI was lower with 1.25 mg of fingolimod (1 lesion, P < 0.001) and 5.0 mg of fingolimod (3 lesions, P = 0.006) than with placebo (5 lesions).  The annualized relapse rate was 0.77 in the placebo group, as compared with 0.35 in the group given 1.25 mg of fingolimod (P = 0.009) and 0.36 in the group given 5.0 mg of fingolimod (P = 0.01).  For the 227 patients who completed the extension study, the no. of gadolinium-enhanced lesions and relapse rates remained low in the groups that received continuous fingolimod, and both measures decreased in patients who switched from placebo to fingolimod.  Adverse events included nasopharyngitis, dyspnea, headache, diarrhea, and nausea.  Clin. asymptomatic elevations of alanine aminotransferase levels were more frequent with fingolimod (10 to 12%, vs. 1% in the placebo group).  One case of the posterior reversible encephalopathy syndrome occurred in the 5.0-mg group.  Fingolimod was also assocd. with an initial redn. in the heart rate and a modest decrease in the forced expiratory vol. in 1 s.  In this proof-of-concept study, fingolimod reduced the no. of lesions detected on MRI and clin. disease activity in patients with multiple sclerosis.  Evaluation in larger, longer-term studies is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA4MSvDIuvV7Vg90H21EOLACvtfcHk0ljt6rKTb2XG3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsFKku78%253D&md5=2a84e8f5fb92091782406da9dcbc1453</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa052643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa052643%26sid%3Dliteratum%253Aachs%26aulast%3DKappos%26aufirst%3DL.%26aulast%3DAntel%26aufirst%3DJ.%26aulast%3DComi%26aufirst%3DG.%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DP.%26aulast%3DPolman%26aufirst%3DC.%2BH.%26aulast%3DHaas%26aufirst%3DT.%26aulast%3DKorn%26aufirst%3DA.%2BA.%26aulast%3DKarlsson%26aufirst%3DG.%26aulast%3DRadue%26aufirst%3DE.%2BW.%26atitle%3DOral%2520fingolimod%2520%2528FTY720%2529%2520for%2520relapsing%2520multiple%2520sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D1124%26epage%3D1140%26doi%3D10.1056%2FNEJMoa052643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Sanna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfonso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Sphingosine 1-phosphate (S1P) receptor subtypes S1P<sub>1</sub> and S1P<sub>3</sub>, respectively, regulate lymphocyte recirculation and heart rate</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">13839</span><span class="NLM_x">–</span> <span class="NLM_lpage">13848</span><span class="refDoi"> DOI: 10.1074/jbc.M311743200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1074%2Fjbc.M311743200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=14732717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1elsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=13839-13848&author=M.+G.+Sannaauthor=J.+Liaoauthor=E.+Joauthor=C.+Alfonsoauthor=M.-Y.+Ahnauthor=M.+S.+Petersonauthor=B.+Webbauthor=S.+Lefebvreauthor=J.+Chunauthor=N.+Grayauthor=H.+Rosen&title=Sphingosine+1-phosphate+%28S1P%29+receptor+subtypes+S1P1+and+S1P3%2C+respectively%2C+regulate+lymphocyte+recirculation+and+heart+rate&doi=10.1074%2Fjbc.M311743200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate</span></div><div class="casAuthors">Sanna, M. Germana; Liao, Jiayu; Jo, Euijung; Alfonso, Christopher; Ahn, Min-Young; Peterson, Melissa S.; Webb, Bill; Lefebvre, Sophie; Chun, Jerold; Gray, Nathanael; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">13839-13848</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) influences heart rate, coronary artery caliber, endothelial integrity, and lymphocyte recirculation through five related high affinity G-protein-coupled receptors.  Inhibition of lymphocyte recirculation by non-selective S1P receptor agonists produces clin. immunosuppression preventing transplant rejection but is assocd. with transient bradycardia.  Understanding the contribution of individual receptors has been limited by the embryonic lethality of the S1P1 knock-out and the unavailability of selective agonists or antagonists.  A potent, S1P1-receptor selective agonist structurally unrelated to S1P was found to activate multiple signals triggered by S1P, including guanosine 5'-3-O-(thio)triphosphate binding, calcium flux, Akt and ERK1/2 phosphorylation, and stimulation of migration of S1P1- but not S1P3-expressing cells in vitro.  The agonist also alters lymphocyte trafficking in vivo.  Use of selective agonism together with deletant mice lacking S1P3 receptor reveals that agonism of S1P1 receptor alone is sufficient to control lymphocyte recirculation.  Moreover, S1P1 receptor agonist plasma levels are causally assocd. with induction and maintenance of lymphopenia.  S1P3, and not S1P1, is directly implicated in sinus bradycardia.  The sustained bradycardia induced by S1P receptor non-selective immunosuppressive agonists in wild-type mice is abolished in S1P3-/- mice, whereas S1P1-selective agonist does not produce bradycardia.  Sepn. of receptor subtype usage for control of lymphocyte recirculation and heart rate may allow the identification of selective immunosuppressive S1P1 receptor agonists with an enhanced therapeutic window.  S1P1-selective agonists will be of broad utility in understanding cell functions in vitro, and vascular physiol. in vivo, and the success of the chem. approach for S1P1 suggests that selective tools for the resoln. of function across this broad lipid receptor family are now possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoztTB58pXPA7Vg90H21EOLACvtfcHk0ljt6rKTb2XG3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1elsb8%253D&md5=5b720513c7c550bfdf55e5344efc8f16</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M311743200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M311743200%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DM.%2BG.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DAlfonso%26aufirst%3DC.%26aulast%3DAhn%26aufirst%3DM.-Y.%26aulast%3DPeterson%26aufirst%3DM.%2BS.%26aulast%3DWebb%26aufirst%3DB.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DSphingosine%25201-phosphate%2520%2528S1P%2529%2520receptor%2520subtypes%2520S1P1%2520and%2520S1P3%252C%2520respectively%252C%2520regulate%2520lymphocyte%2520recirculation%2520and%2520heart%2520rate%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D13839%26epage%3D13848%26doi%3D10.1074%2Fjbc.M311743200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Forrest, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, I. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">309</span><span class="NLM_x">, </span> <span class="NLM_fpage">758</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span><span class="refDoi"> DOI: 10.1124/jpet.103.062828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1124%2Fjpet.103.062828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=14747617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1ygsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2004&pages=758-768&author=M.+Forrestauthor=S.-Y.+Sunauthor=R.+Hajduauthor=J.+Bergstromauthor=D.+Cardauthor=G.+Dohertyauthor=J.+Haleauthor=C.+Keohaneauthor=C.+Meyersauthor=J.+Milliganauthor=S.+Millsauthor=N.+Nomuraauthor=H.+Rosenauthor=M.+Rosenbachauthor=G.-J.+Sheiauthor=I.+I.+Singerauthor=M.+Tianauthor=S.+Westauthor=V.+Whiteauthor=J.+Xieauthor=R.+L.+Proiaauthor=S.+Mandala&title=Immune+cell+regulation+and+cardiovascular+effects+of+sphingosine+1-phosphate+receptor+agonists+in+rodents+are+mediated+via+distinct+receptor+subtypes&doi=10.1124%2Fjpet.103.062828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes</span></div><div class="casAuthors">Forrest, M.; Sun, S.-Y.; Hajdu, R.; Bergstrom, J.; Card, D.; Doherty, G.; Hale, J.; Keohane, C.; Meyers, C.; Milligan, J.; Mills, S.; Nomura, N.; Rosen, H.; Rosenbach, M.; Shei, G.-J.; Singer, I. I.; Tian, M.; West, S.; White, V.; Xie, J.; Proia, R. L.; Mandala, S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">758-768</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) is a bioactive lysolipid with pleiotropic functions mediated through a family of G protein-coupled receptors, S1P1,2,3,4,5.  Physiol. effects of S1P receptor agonists include regulation of cardiovascular function and immunosuppression via redistribution of lymphocytes from blood to secondary lymphoid organs.  The phosphorylated metabolite of the immunosuppressant agent FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol) and other phosphonate analogs with differential receptor selectivity were investigated.  No significant species differences in compd. potency or rank order of activity on receptors cloned from human, murine, and rat sources were obsd.  All synthetic analogs were high-affinity agonists on S1P1, with IC50 values for ligand binding between 0.3 and 14 nM.  The correlation between S1P1 receptor activation and the ED50 for lymphocyte redn. was highly significant (p < 0.001) and lower for the other receptors.  In contrast to S1P1-mediated effects on lymphocyte recirculation, three lines of evidence link S1P3 receptor activity with acute toxicity and cardiovascular regulation: compd. potency on S1P3 correlated with toxicity and bradycardia; the shift in potency of phosphorylated-FTY720 for inducing lymphopenia vs. bradycardia and hypertension was consistent with affinity for S1P1 relative to S1P3; and toxicity, bradycardia, and hypertension were absent in S1P3-/- mice.  Blood pressure effects of agonists in anesthetized rats were complex, whereas hypertension was the predominant effect in conscious rats and mice.  Immunolocalization of S1P3 in rodent heart revealed abundant expression on myocytes and perivascular smooth muscle cells consistent with regulation of bradycardia and hypertension, whereas S1P1 expression was restricted to the vascular endothelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKo2vpih4eoLVg90H21EOLACvtfcHk0ljOpKHsN4bM5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1ygsrg%253D&md5=27183d4991bffbc5d2b88174b1386d5a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.062828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.062828%26sid%3Dliteratum%253Aachs%26aulast%3DForrest%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DS.-Y.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DDoherty%26aufirst%3DG.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DKeohane%26aufirst%3DC.%26aulast%3DMeyers%26aufirst%3DC.%26aulast%3DMilligan%26aufirst%3DJ.%26aulast%3DMills%26aufirst%3DS.%26aulast%3DNomura%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DSinger%26aufirst%3DI.%2BI.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DV.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DProia%26aufirst%3DR.%2BL.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DImmune%2520cell%2520regulation%2520and%2520cardiovascular%2520effects%2520of%2520sphingosine%25201-phosphate%2520receptor%2520agonists%2520in%2520rodents%2520are%2520mediated%2520via%2520distinct%2520receptor%2520subtypes%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D309%26spage%3D758%26epage%3D768%26doi%3D10.1124%2Fjpet.103.062828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrebet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parent, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quackenbush, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickham, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P<sub>1</sub>) receptor agonists with exceptional selectivity against S1P<sub>2</sub> and S1P<sub>3</sub></span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6169</span><span class="NLM_x">–</span> <span class="NLM_lpage">6173</span><span class="refDoi"> DOI: 10.1021/jm0503244</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0503244" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6169-6173&author=Z.+Liauthor=W.+Chenauthor=J.+J.+Haleauthor=C.+L.+Lynchauthor=S.+G.+Millsauthor=R.+Hajduauthor=C.+A.+Keohaneauthor=M.+J.+Rosenbachauthor=J.+A.+Milliganauthor=G.-J.+Sheiauthor=G.+Chrebetauthor=S.+A.+Parentauthor=J.+Bergstromauthor=D.+Cardauthor=M.+Forrestauthor=E.+J.+Quackenbushauthor=L.+A.+Wickhamauthor=H.+Vargasauthor=R.+M.+Evansauthor=H.+Rosenauthor=S.+Mandala&title=Discovery+of+potent+3%2C5-diphenyl-1%2C2%2C4-oxadiazole+sphingosine-1-phosphate-1+%28S1P1%29+receptor+agonists+with+exceptional+selectivity+against+S1P2+and+S1P3&doi=10.1021%2Fjm0503244"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm0503244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0503244%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%2BJ.%26aulast%3DMilligan%26aufirst%3DJ.%2BA.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DChrebet%26aufirst%3DG.%26aulast%3DParent%26aufirst%3DS.%2BA.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DForrest%26aufirst%3DM.%26aulast%3DQuackenbush%26aufirst%3DE.%2BJ.%26aulast%3DWickham%26aufirst%3DL.%2BA.%26aulast%3DVargas%26aufirst%3DH.%26aulast%3DEvans%26aufirst%3DR.%2BM.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520potent%25203%252C5-diphenyl-1%252C2%252C4-oxadiazole%2520sphingosine-1-phosphate-1%2520%2528S1P1%2529%2520receptor%2520agonists%2520with%2520exceptional%2520selectivity%2520against%2520S1P2%2520and%2520S1P3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6169%26epage%3D6173%26doi%3D10.1021%2Fjm0503244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Buzard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrader, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moody, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span> </span><span class="NLM_article-title">Design and synthesis of new trycyclic indoles as potent modulators of the S1P1 receptor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">659</span><span class="NLM_x">–</span> <span class="NLM_lpage">663</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.11.089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1016%2Fj.bmcl.2014.11.089" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=659-663&author=D.+J.+Buzardauthor=O.+Schraderauthor=X.+Zhuauthor=J.+Lehmannauthor=B.+Johnsonauthor=M.+Kasemauthor=S.-H.+Kimauthor=A.+Kawasakiauthor=L.+Lopezauthor=J.+Moodyauthor=S.+Hanauthor=Y.+Gaoauthor=J.+Edwardsauthor=J.+Bardenauthor=J.+Thatteauthor=J.+Gatlinauthor=R.+M.+Jones&title=Design+and+synthesis+of+new+trycyclic+indoles+as+potent+modulators+of+the+S1P1+receptor&doi=10.1016%2Fj.bmcl.2014.11.089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.11.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.11.089%26sid%3Dliteratum%253Aachs%26aulast%3DBuzard%26aufirst%3DD.%2BJ.%26aulast%3DSchrader%26aufirst%3DO.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLehmann%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DB.%26aulast%3DKasem%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DKawasaki%26aufirst%3DA.%26aulast%3DLopez%26aufirst%3DL.%26aulast%3DMoody%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DEdwards%26aufirst%3DJ.%26aulast%3DBarden%26aufirst%3DJ.%26aulast%3DThatte%26aufirst%3DJ.%26aulast%3DGatlin%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DR.%2BM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520new%2520trycyclic%2520indoles%2520as%2520potent%2520modulators%2520of%2520the%2520S1P1%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D659%26epage%3D663%26doi%3D10.1016%2Fj.bmcl.2014.11.089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Buzard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moody, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrader, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoresen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gharbaoui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sengupta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvano, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usmani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadeque, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopher, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whelan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Shamma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaidarov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unett, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackburn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span> </span><span class="NLM_article-title">(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acids as S1P1 functional agonists</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1334</span><span class="NLM_x">–</span> <span class="NLM_lpage">1339</span><span class="refDoi"> DOI: 10.1021/ml500422m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500422m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1334-1339&author=D.+J.+Buzardauthor=L.+Lopezauthor=J.+Moodyauthor=A.+Kawasakiauthor=T.+O.+Schraderauthor=M.+Kasemauthor=B.+Johnsonauthor=X.+Zhuauthor=L.+Thoresenauthor=S.+H.+Kimauthor=T.+Gharbaouiauthor=D.+Senguptaauthor=L.+Calvanoauthor=A.+Krishnanauthor=Y.+Gaoauthor=G.+Sempleauthor=J.+Edwardsauthor=J.+Bardenauthor=M.+Morganauthor=K.+Usmaniauthor=C.+Chenauthor=A.+Sadequeauthor=W.+Chenauthor=R.+J.+Christopherauthor=J.+Thatteauthor=L.+Fuauthor=M.+Solomonauthor=K.+Whelanauthor=H.+Al-Shammaauthor=J.+Gatlinauthor=I.+Gaidarovauthor=T.+Anthonyauthor=M.+Leauthor=D.+J.+Unettauthor=S.+Stirnauthor=A.+Blackburnauthor=D.+P.+Behanauthor=R.+M.+Jones&title=%287-Benzyloxy-2%2C3-dihydro-1H-pyrrolo%5B1%2C2-a%5Dindol-1-yl%29acetic+acids+as+S1P1+functional+agonists&doi=10.1021%2Fml500422m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1021%2Fml500422m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500422m%26sid%3Dliteratum%253Aachs%26aulast%3DBuzard%26aufirst%3DD.%2BJ.%26aulast%3DLopez%26aufirst%3DL.%26aulast%3DMoody%26aufirst%3DJ.%26aulast%3DKawasaki%26aufirst%3DA.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DKasem%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DThoresen%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DGharbaoui%26aufirst%3DT.%26aulast%3DSengupta%26aufirst%3DD.%26aulast%3DCalvano%26aufirst%3DL.%26aulast%3DKrishnan%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DEdwards%26aufirst%3DJ.%26aulast%3DBarden%26aufirst%3DJ.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DUsmani%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DSadeque%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DChristopher%26aufirst%3DR.%2BJ.%26aulast%3DThatte%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DSolomon%26aufirst%3DM.%26aulast%3DWhelan%26aufirst%3DK.%26aulast%3DAl-Shamma%26aufirst%3DH.%26aulast%3DGatlin%26aufirst%3DJ.%26aulast%3DGaidarov%26aufirst%3DI.%26aulast%3DAnthony%26aufirst%3DT.%26aulast%3DLe%26aufirst%3DM.%26aulast%3DUnett%26aufirst%3DD.%2BJ.%26aulast%3DStirn%26aufirst%3DS.%26aulast%3DBlackburn%26aufirst%3DA.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DJones%26aufirst%3DR.%2BM.%26atitle%3D%25287-Benzyloxy-2%252C3-dihydro-1H-pyrrolo%255B1%252C2-a%255Dindol-1-yl%2529acetic%2520acids%2520as%2520S1P1%2520functional%2520agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D1334%26epage%3D1339%26doi%3D10.1021%2Fml500422m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Skidmore, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redshaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeting, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cridland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vesey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myatt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giblin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bit, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haynes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witherington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demont, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heightman, T. D.</span><span> </span><span class="NLM_article-title">Optimization of sphingosine-1-phosphate receptor agonists: effects of acidic, basic, and zwitterionic chemotypes on pharmacokinetic and pharmacodynamics profiles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">10424</span><span class="NLM_x">–</span> <span class="NLM_lpage">10442</span><span class="refDoi"> DOI: 10.1021/jm5010336</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5010336" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10424-10442&author=J.+Skidmoreauthor=J.+Heerauthor=C.+N.+Johnsonauthor=D.+Nortonauthor=S.+Redshawauthor=J.+Sweetingauthor=D.+Hurstauthor=A.+Cridlandauthor=D.+Veseyauthor=I.+Wallauthor=M.+Ahmedauthor=D.+Riversauthor=J.+Myattauthor=G.+Giblinauthor=K.+Philpottauthor=U.+Kumarauthor=A.+Stevensauthor=R.+A.+Bitauthor=A.+Haynesauthor=S.+Taylorauthor=R.+Watsonauthor=J.+Witheringtonauthor=E.+Demontauthor=T.+D.+Heightman&title=Optimization+of+sphingosine-1-phosphate+receptor+agonists%3A+effects+of+acidic%2C+basic%2C+and+zwitterionic+chemotypes+on+pharmacokinetic+and+pharmacodynamics+profiles&doi=10.1021%2Fjm5010336"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1021%2Fjm5010336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5010336%26sid%3Dliteratum%253Aachs%26aulast%3DSkidmore%26aufirst%3DJ.%26aulast%3DHeer%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DNorton%26aufirst%3DD.%26aulast%3DRedshaw%26aufirst%3DS.%26aulast%3DSweeting%26aufirst%3DJ.%26aulast%3DHurst%26aufirst%3DD.%26aulast%3DCridland%26aufirst%3DA.%26aulast%3DVesey%26aufirst%3DD.%26aulast%3DWall%26aufirst%3DI.%26aulast%3DAhmed%26aufirst%3DM.%26aulast%3DRivers%26aufirst%3DD.%26aulast%3DMyatt%26aufirst%3DJ.%26aulast%3DGiblin%26aufirst%3DG.%26aulast%3DPhilpott%26aufirst%3DK.%26aulast%3DKumar%26aufirst%3DU.%26aulast%3DStevens%26aufirst%3DA.%26aulast%3DBit%26aufirst%3DR.%2BA.%26aulast%3DHaynes%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DR.%26aulast%3DWitherington%26aufirst%3DJ.%26aulast%3DDemont%26aufirst%3DE.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26atitle%3DOptimization%2520of%2520sphingosine-1-phosphate%2520receptor%2520agonists%253A%2520effects%2520of%2520acidic%252C%2520basic%252C%2520and%2520zwitterionic%2520chemotypes%2520on%2520pharmacokinetic%2520and%2520pharmacodynamics%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10424%26epage%3D10442%26doi%3D10.1021%2Fjm5010336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Bolli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abele, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kanter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimont, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lescop, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathys, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seifert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, T.</span><span> </span><span class="NLM_article-title">Novel S1P1 receptor agonists – part 3: from thiophenes to pyridines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">130</span><span class="refDoi"> DOI: 10.1021/jm4014696</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4014696" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=110-130&author=M.+H.+Bolliauthor=S.+Abeleauthor=M.+Birkerauthor=R.+Bravoauthor=D.+Burauthor=R.+de+Kanterauthor=C.+Kohlauthor=J.+Grimontauthor=P.+Hessauthor=C.+Lescopauthor=B.+Mathysauthor=C.+Mullerauthor=O.+Naylerauthor=M.+Reyauthor=M.+Scherzauthor=G.+Schmidtauthor=J.+Seifertauthor=B.+Steinerauthor=J.+Velkerauthor=T.+Weller&title=Novel+S1P1+receptor+agonists+%E2%80%93+part+3%3A+from+thiophenes+to+pyridines&doi=10.1021%2Fjm4014696"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1021%2Fjm4014696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4014696%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DAbele%26aufirst%3DS.%26aulast%3DBirker%26aufirst%3DM.%26aulast%3DBravo%26aufirst%3DR.%26aulast%3DBur%26aufirst%3DD.%26aulast%3Dde%2BKanter%26aufirst%3DR.%26aulast%3DKohl%26aufirst%3DC.%26aulast%3DGrimont%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DLescop%26aufirst%3DC.%26aulast%3DMathys%26aufirst%3DB.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DRey%26aufirst%3DM.%26aulast%3DScherz%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DG.%26aulast%3DSeifert%26aufirst%3DJ.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DVelker%26aufirst%3DJ.%26aulast%3DWeller%26aufirst%3DT.%26atitle%3DNovel%2520S1P1%2520receptor%2520agonists%2520%25E2%2580%2593%2520part%25203%253A%2520from%2520thiophenes%2520to%2520pyridines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D110%26epage%3D130%26doi%3D10.1021%2Fjm4014696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Bolli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathys, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kanter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B.</span><span> </span><span class="NLM_article-title">Novel S1P1 receptor agonists – part 2: from bicylco[3.1.0]hexane-fused thiophenes to isobutyl substituted thiophenes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">97</span><span class="refDoi"> DOI: 10.1021/jm401456d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401456d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=78-97&author=M.+H.+Bolliauthor=J.+Velkerauthor=C.+Mullerauthor=B.+Mathysauthor=M.+Birkerauthor=R.+Bravoauthor=D.+Burauthor=R.+de+Kanterauthor=P.+Hessauthor=C.+Kohlauthor=D.+Lehmannauthor=S.+Meyerauthor=O.+Naylerauthor=M.+Reyauthor=M.+Scherzauthor=B.+Steiner&title=Novel+S1P1+receptor+agonists+%E2%80%93+part+2%3A+from+bicylco%5B3.1.0%5Dhexane-fused+thiophenes+to+isobutyl+substituted+thiophenes&doi=10.1021%2Fjm401456d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15e&amp;dbid=16384&amp;doi=10.1021%2Fjm401456d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401456d%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DVelker%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DMathys%26aufirst%3DB.%26aulast%3DBirker%26aufirst%3DM.%26aulast%3DBravo%26aufirst%3DR.%26aulast%3DBur%26aufirst%3DD.%26aulast%3Dde%2BKanter%26aufirst%3DR.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DKohl%26aufirst%3DC.%26aulast%3DLehmann%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DRey%26aufirst%3DM.%26aulast%3DScherz%26aufirst%3DM.%26aulast%3DSteiner%26aufirst%3DB.%26atitle%3DNovel%2520S1P1%2520receptor%2520agonists%2520%25E2%2580%2593%2520part%25202%253A%2520from%2520bicylco%255B3.1.0%255Dhexane-fused%2520thiophenes%2520to%2520isobutyl%2520substituted%2520thiophenes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D78%26epage%3D97%26doi%3D10.1021%2Fjm401456d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Horan, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanyal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill-Drzewi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaude, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gueneva-Boucheva, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bannen, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mac, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modis, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemieux, R. M.</span><span> </span><span class="NLM_article-title">Piperazinyl-oxadiazoles as selective sphingosine-1-phosphate receptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4807</span><span class="NLM_x">–</span> <span class="NLM_lpage">4811</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1016%2Fj.bmcl.2014.09.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4807-4811&author=J.+C.+Horanauthor=S.+Sanyalauthor=Y.+Choiauthor=M.+Hill-Drzewiauthor=L.+Patnaudeauthor=S.+Andersonauthor=S.+Fogalauthor=C.+Maoauthor=B.+N.+Cookauthor=K.+Gueneva-Bouchevaauthor=M.+B.+Fisherauthor=E.+Hickeyauthor=E.+Packauthor=L.+C.+Bannenauthor=D.+S.+Chanauthor=M.+B.+Macauthor=S.+M.+Ngauthor=Y.+Wangauthor=W.+Xuauthor=L.+K.+Modisauthor=R.+M.+Lemieux&title=Piperazinyl-oxadiazoles+as+selective+sphingosine-1-phosphate+receptor+agonists&doi=10.1016%2Fj.bmcl.2014.09.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15f&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DHoran%26aufirst%3DJ.%2BC.%26aulast%3DSanyal%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DHill-Drzewi%26aufirst%3DM.%26aulast%3DPatnaude%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DFogal%26aufirst%3DS.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DB.%2BN.%26aulast%3DGueneva-Boucheva%26aufirst%3DK.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHickey%26aufirst%3DE.%26aulast%3DPack%26aufirst%3DE.%26aulast%3DBannen%26aufirst%3DL.%2BC.%26aulast%3DChan%26aufirst%3DD.%2BS.%26aulast%3DMac%26aufirst%3DM.%2BB.%26aulast%3DNg%26aufirst%3DS.%2BM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DModis%26aufirst%3DL.%2BK.%26aulast%3DLemieux%26aufirst%3DR.%2BM.%26atitle%3DPiperazinyl-oxadiazoles%2520as%2520selective%2520sphingosine-1-phosphate%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4807%26epage%3D4811%26doi%3D10.1016%2Fj.bmcl.2014.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dyckman, A.</span><span> </span><span class="NLM_article-title">Recent advances in the discovery and development of sphingosine-1-phosphate-1 receptor agonists</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span><span class="refDoi"> DOI: 10.1016/B978-0-12-396492-2.00013-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1016%2FB978-0-12-396492-2.00013-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=195-207&author=A.+Dyckman&title=Recent+advances+in+the+discovery+and+development+of+sphingosine-1-phosphate-1+receptor+agonists&doi=10.1016%2FB978-0-12-396492-2.00013-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396492-2.00013-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396492-2.00013-8%26sid%3Dliteratum%253Aachs%26aulast%3DDyckman%26aufirst%3DA.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520and%2520development%2520of%2520sphingosine-1-phosphate-1%2520receptor%2520agonists%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2012%26volume%3D47%26spage%3D195%26epage%3D207%26doi%3D10.1016%2FB978-0-12-396492-2.00013-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">and references cited therein.</p></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Roberts, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Sphingosine 1-phosphate receptor agonists: a patent review (2010–2012)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">841</span><div class="note"><p class="first last">and references cited therein.</p></div><span class="refDoi"> DOI: 10.1517/13543776.2013.783022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1517%2F13543776.2013.783022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=23541049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslCks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=817-841&issue=7&author=E.+Robertsauthor=M.+Guerreroauthor=M.+Urbanoauthor=H.+Rosen&title=Sphingosine+1-phosphate+receptor+agonists%3A+a+patent+review+%282010%E2%80%932012%29&doi=10.1517%2F13543776.2013.783022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate receptor agonists: a patent review (2010 - 2012)</span></div><div class="casAuthors">Roberts, Edward; Guerrero, Miguel; Urbano, Mariangela; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">817-841</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The sphingosine-1-phosphate (S1P)-driven signaling regulates fundamental biol. functions, including cell proliferation, angiogenesis, endothelial cell chemotaxis, immune cell trafficking and mitogenesis.  A large body of research has been focusing on the development of immunosuppressive S1P1 receptor (S1P1-R) agonist mols.  The S1P1,3 - 5-R pan-agonist fingolimod (FTY720) has been approved by the FDA for the treatment of relapsing-remitting multiple sclerosis.  However, FTY720 is now contraindicated in patients with compromised cardiac function.  Although the main adverse effect bradycardia has been linked to the S1P3-R activation, cardiovascular liabilities persist with more selective S1P1-R agonists that have entered clin. trials.  In contrast to the S1P1-R, the therapeutic application of the S1P2 - 5-Rs remains poorly explored.  Areas covered: This review provides the patent literature from 2010 to date on S1P-R agonist mols. and their relevant biol. properties.  Expert opinion: Limited progress has been made on agonists at S1P4,5-R subtypes, with some families of S1P5-R agonists showing promising results in animal models of age-related cognitive disorders.  A discrete no. of reviewed mols. are S1P1-R agonists with a promising clin. outlook in transplantation, inflammation, cancer and autoimmune settings.  Further preclin. and clin. studies will det. whether the new developed S1P1-R agonists do indeed improve the safety profile of FTY720.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIrASpSMDS37Vg90H21EOLACvtfcHk0lgq6BkhHain2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslCks7o%253D&md5=405b6350b777d3040e2be21adf85d440</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.783022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.783022%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DE.%26aulast%3DGuerrero%26aufirst%3DM.%26aulast%3DUrbano%26aufirst%3DM.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DSphingosine%25201-phosphate%2520receptor%2520agonists%253A%2520a%2520patent%2520review%2520%25282010%25E2%2580%25932012%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26issue%3D7%26spage%3D817%26epage%3D841%26doi%3D10.1517%2F13543776.2013.783022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Blaho, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span> </span><span class="NLM_article-title">An update on the biology of sphingosine 1-phosphate receptors</span> <span class="citation_source-journal">J. Lipid Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1596</span><span class="NLM_x">–</span> <span class="NLM_lpage">1608</span><span class="refDoi"> DOI: 10.1194/jlr.R046300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1194%2Fjlr.R046300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=24459205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1agsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1596-1608&author=V.+A.+Blahoauthor=T.+Hla&title=An+update+on+the+biology+of+sphingosine+1-phosphate+receptors&doi=10.1194%2Fjlr.R046300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">An update on the biology of sphingosine 1-phosphate receptors</span></div><div class="casAuthors">Blaho, Victoria A.; Hla, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1596-1608</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P) is a membrane-derived lysophospholipid that acts primarily as an extracellular signaling mol.  Signals initiated by S1P are transduced by five G protein-coupled receptors, named S1P1-5.  Cellular and temporal expression of the S1P receptors (S1PRs) det. their specific roles in various organ systems, but they are particularly crit. for regulation of the cardiovascular, immune, and nervous systems, with the most well-known contributions of S1PR signaling being modulation of vascular barrier function, vascular tone, and regulation of lymphocyte trafficking.  However, our knowledge of S1PR biol. is rapidly increasing as they become attractive therapeutic targets in several diseases, such as chronic inflammatory pathologies, autoimmunity, and cancer.  Understanding how the S1PRs regulate interactions between biol. systems will allow for greater efficacy in this novel therapeutic strategy as well as characterization of complex physiol. networks.  Because of the rapidly expanding body of research, this review will focus on the most recent advances in S1PRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIZfnE0tv0rbVg90H21EOLACvtfcHk0lgq6BkhHain2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1agsrnP&md5=3939398b28359c3be8d38b3b49be3d4c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R046300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R046300%26sid%3Dliteratum%253Aachs%26aulast%3DBlaho%26aufirst%3DV.%2BA.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DAn%2520update%2520on%2520the%2520biology%2520of%2520sphingosine%25201-phosphate%2520receptors%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2014%26volume%3D55%26spage%3D1596%26epage%3D1608%26doi%3D10.1194%2Fjlr.R046300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Gergely, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuesslein-Hildesheim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traebert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruns, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinterding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groenewegen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitaliti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sing, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttringer, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumb, W. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallstrom, E.</span><span> </span><span class="NLM_article-title">The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">1035</span><span class="NLM_x">–</span> <span class="NLM_lpage">1047</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.02061.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1111%2Fj.1476-5381.2012.02061.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=22646698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2012&pages=1035-1047&author=P.+Gergelyauthor=B.+Nuesslein-Hildesheimauthor=D.+Gueriniauthor=V.+Brinkmannauthor=M.+Traebertauthor=C.+Brunsauthor=S.+Panauthor=N.+S.+Grayauthor=K.+Hinterdingauthor=N.+G.+Cookeauthor=A.+Groenewegenauthor=A.+Vitalitiauthor=T.+Singauthor=O.+Luttringerauthor=J.+Yangauthor=A.+Gardinauthor=N.+Wangauthor=W.+J.+Crumbauthor=M.+Saltzmanauthor=M.+Rosenbergauthor=E.+Wallstrom&title=The+selective+sphingosine+1-phosphate+receptor+modulator+BAF312+redirects+lymphocyte+distribution+and+has+species-specific+effects+on+heart+rate&doi=10.1111%2Fj.1476-5381.2012.02061.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate</span></div><div class="casAuthors">Gergely, P.; Nuesslein-Hildesheim, B.; Guerini, D.; Brinkmann, V.; Traebert, M.; Bruns, C.; Pan, S.; Gray, N. S.; Hinterding, K.; Cooke, N. G.; Groenewegen, A.; Vitaliti, A.; Sing, T.; Luttringer, O.; Yang, J.; Gardin, A.; Wang, N.; Crumb, W. J., Jr.; Saltzman, M.; Rosenberg, M.; Wallstrom, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1035-1047</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose BAF312 is a next-generation sphingosine 1-phosphate (S1P) receptor modulator, selective for S1P1 and S1P5 receptors.  S1P1 receptors are essential for lymphocyte egress from lymph nodes and a drug target in immune-mediated diseases.  Here, we have characterized the immunomodulatory potential of BAF312 and the S1P receptor-mediated effects on heart rate using preclin. and human data.  Exptl. Approach BAF312 was tested in a rat exptl. autoimmune encephalomyelitis (EAE) model.  Electrophysiol. recordings of G-protein-coupled inwardly rectifying potassium (GIRK) channels were carried out in human atrial myocytes.  A Phase I multiple-dose trial studied the pharmacokinetics, pharmacodynamics and safety of BAF312 in 48 healthy subjects.  Key Results BAF312 effectively suppressed EAE in rats by internalizing S1P1 receptors, rendering them insensitive to the egress signal from lymph nodes.  In healthy volunteers, BAF312 caused preferential decreases in CD4+ T cells, Tnaive, Tcentral memory and B cells within 4-6 h.  Cell counts returned to normal ranges within a week after stopping treatment, in line with the elimination half-life of BAF312.  Despite sparing S1P3 receptors (assocd. with bradycardia in mice), BAF312 induced rapid, transient (day 1 only) bradycardia in humans.  BAF312-mediated activation of GIRK channels in human atrial myocytes can fully explain the bradycardia.  Conclusion and Implications This study illustrates species-specific differences in S1P receptor specificity for first-dose cardiac effects.  Based on its profound but rapidly reversible inhibition of lymphocyte trafficking, BAF312 may have potential as a treatment for immune-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42VfW58NMyLVg90H21EOLACvtfcHk0lgq6BkhHain2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7bE&md5=0034be62fb68b10abefff50f0220be2a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.02061.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.02061.x%26sid%3Dliteratum%253Aachs%26aulast%3DGergely%26aufirst%3DP.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DTraebert%26aufirst%3DM.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DCooke%26aufirst%3DN.%2BG.%26aulast%3DGroenewegen%26aufirst%3DA.%26aulast%3DVitaliti%26aufirst%3DA.%26aulast%3DSing%26aufirst%3DT.%26aulast%3DLuttringer%26aufirst%3DO.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGardin%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DCrumb%26aufirst%3DW.%2BJ.%26aulast%3DSaltzman%26aufirst%3DM.%26aulast%3DRosenberg%26aufirst%3DM.%26aulast%3DWallstrom%26aufirst%3DE.%26atitle%3DThe%2520selective%2520sphingosine%25201-phosphate%2520receptor%2520modulator%2520BAF312%2520redirects%2520lymphocyte%2520distribution%2520and%2520has%2520species-specific%2520effects%2520on%2520heart%2520rate%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D167%26spage%3D1035%26epage%3D1047%26doi%3D10.1111%2Fj.1476-5381.2012.02061.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">David, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovarik, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmouder, R. L.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetics of fingolimod</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span><span class="refDoi"> DOI: 10.2165/11596550-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.2165%2F11596550-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=22149256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1OqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=15-28&author=O.+J.+Davidauthor=J.+M.+Kovarikauthor=R.+L.+Schmouder&title=Clinical+pharmacokinetics+of+fingolimod&doi=10.2165%2F11596550-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of fingolimod</span></div><div class="casAuthors">David, Olivier J.; Kovarik, John M.; Schmouder, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-28</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review.  Fingolimod (FTY720), a sphingosine 1-phosphate receptor modulator, is the first in a new class of therapeutic compds. and is the first oral therapy approved for the treatment of relapsing forms of multiple sclerosis (MS).  Fingolimod is a structural analog of endogenous sphingosine and undergoes phosphorylation to produce fingolimod phosphate, the active moiety.  Fingolimod targets MS via effects on the immune system, and evidence from animal models indicates that it may also have actions in the central nervous system.  In phase III studies in patients with relapsing-remitting MS, fingolimod has demonstrated efficacy superior to that of an approved first-line therapy, i.m. interferon-β-1a, as well as placebo, with benefits extending across clin. and magnetic resonance imaging measures.  The pharmacokinetic profiles of fingolimod and fingolimod phosphate have been extensively investigated in studies in healthy volunteers, renal transplant recipients (the indication for which fingolimod was initially under clin. development, but the development was subsequently discontinued) and MS patients.  Results from these studies have demonstrated that fingolimod is efficiently absorbed, with an oral bioavailability of >90%, and its absorption is unaffected by dietary intake, therefore it can be taken without regard to meals.  Fingolimod and fingolimod phosphate have a half-life of 6-9 days, and steady-state pharmacokinetics are reached after 1-2 mo of daily dosing.  The long half-life of fingolimod, together with its slow absorption, means that fingolimod has a fiat concn. profile over time with once-daily dosing.  Fingolimod and fingolimod phosphate show dose-proportional exposure in single- and multiple-dose studies over a range of 0.125-5 mg; hence, there is a predictable relationship between dose and systemic exposure.  Furthermore, fingolimod and fingolimod phosphate exhibit low to moderate intersubject pharmacokinetic variability.  Fingolimod is extensively metabolized, with biotransformation occurring via three main pathways: (i) reversible phosphorylation to fingolimod phosphate; (ii) hydroxylation and oxidn. to yield a series of inactive carboxylic acid metabolites; and (iii) formation of non-polar ceramides.  Fingolimod is largely cleared through metab. by cytochrome P 450 (CYP) 4F2.  Since few drugs are metabolized by CYP4F2, fingolimod would be expected to have a relatively low potential for drug-drug interactions.  This is supported by data from in vitro studies indicating that fingolimod and fingolimod phosphate have little or no capacity to inhibit and no capacity to induce other major drug-metabolizing CYP enzymes at therapeutically relevant steady-state blood concns.  Population pharmacokinetic evaluations indicate that CYP3A inhibitors and CYP3A inducers have no effect or only a weak effect on the pharmacokinetics of fingolimod and fingolimod phosphate.  However, blood concns. of fingolimod and fingolimod phosphate are increased moderately when fingolimod is coadministered with ketoconazole, an inhibitor of CYP4F2.  The pharmacokinetics of fingolimod are unaffected by renal impairment or mild-to-moderate hepatic impairment.  However, exposure to fingolimod is increased in patients with severe hepatic impairment.  No clin. relevant effects of age, sex or ethnicity on the pharmacokinetics of fingolimod have been obsd.  Fingolimod is thus a promising new therapy for eligible patients with MS, with a predictable pharmacokinetic profile that allows effective once-daily oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoxIUshcr8m7Vg90H21EOLACvtfcHk0liulnM3k0OEuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1OqtLg%253D&md5=a1a6d271470f6c297892ef00f0fe6ec6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2165%2F11596550-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11596550-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DDavid%26aufirst%3DO.%2BJ.%26aulast%3DKovarik%26aufirst%3DJ.%2BM.%26aulast%3DSchmouder%26aufirst%3DR.%2BL.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520fingolimod%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2012%26volume%3D51%26spage%3D15%26epage%3D28%26doi%3D10.2165%2F11596550-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hale, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neway, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parent, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrebet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strulovici, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">A rational utilization of high-throughput screening affords selective, orally bioavailable 1- benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6662</span><span class="NLM_x">–</span> <span class="NLM_lpage">6665</span><span class="refDoi"> DOI: 10.1021/jm0492507</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0492507" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6662-6665&author=J.+J.+Haleauthor=C.+L.+Lynchauthor=W.+Newayauthor=S.+G.+Millsauthor=R.+Hajduauthor=C.+A.+Keohaneauthor=M.+J.+Rosenbachauthor=J.+A.+Milliganauthor=G.+J.+Sheiauthor=S.+A.+Parentauthor=G.+Chrebetauthor=J.+Bergstromauthor=D.+Cardauthor=M.+Ferrerauthor=P.+Hodderauthor=B.+Struloviciauthor=H.+Rosenauthor=S.+Mandala&title=A+rational+utilization+of+high-throughput+screening+affords+selective%2C+orally+bioavailable+1-+benzyl-3-carboxyazetidine+sphingosine-1-phosphate-1+receptor+agonists&doi=10.1021%2Fjm0492507"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1021%2Fjm0492507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0492507%26sid%3Dliteratum%253Aachs%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DNeway%26aufirst%3DW.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%2BJ.%26aulast%3DMilligan%26aufirst%3DJ.%2BA.%26aulast%3DShei%26aufirst%3DG.%2BJ.%26aulast%3DParent%26aufirst%3DS.%2BA.%26aulast%3DChrebet%26aufirst%3DG.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DStrulovici%26aufirst%3DB.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DA%2520rational%2520utilization%2520of%2520high-throughput%2520screening%2520affords%2520selective%252C%2520orally%2520bioavailable%25201-%2520benzyl-3-carboxyazetidine%2520sphingosine-1-phosphate-1%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6662%26epage%3D6665%26doi%3D10.1021%2Fjm0492507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinterding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">End, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heining, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruns, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuesslein-Hildesheim, B.</span><span> </span><span class="NLM_article-title">Discovery of BAF312 (siponimod), a potent and selective S1P receptor modulator</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span><span class="refDoi"> DOI: 10.1021/ml300396r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300396r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVynug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=333-337&author=S.+Panauthor=N.-S.+Grayauthor=W.+Gaoauthor=Y.+Miauthor=Y.+Fanauthor=X.+Wangauthor=T.+Tuntlandauthor=J.+Cheauthor=S.+Lefebvreauthor=Y.+Chenauthor=A.+Chuauthor=K.+Hinterdingauthor=A.+Gardinauthor=P.+Endauthor=P.+Heiningauthor=C.+Brunsauthor=N.+G.+Cookeauthor=B.+Nuesslein-Hildesheim&title=Discovery+of+BAF312+%28siponimod%29%2C+a+potent+and+selective+S1P+receptor+modulator&doi=10.1021%2Fml300396r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator</span></div><div class="casAuthors">Pan, Shifeng; Gray, Nathanael S.; Gao, Wenqi; Mi, Yuan; Fan, Yi; Wang, Xing; Tuntland, Tove; Che, Jianwei; Lefebvre, Sophie; Chen, Yu; Chu, Alan; Hinterding, Klaus; Gardin, Anne; End, Peter; Heining, Peter; Bruns, Christian; Cooke, Nigel G.; Nuesslein-Hildesheim, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">333-337</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of alkoxyimino derivs. as S1P1 agonists were discovered through de novo design using FTY720 as the chem. starting point.  Extensive structure-activity relationship studies led to the discovery of (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid (I, BAF312, Siponimod), which has recently completed phase 2 clin. trials in patients with relapsing-remitting multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV0CukK1Qn3bVg90H21EOLACvtfcHk0ljRNjBZxbkfIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVynug%253D%253D&md5=a410b8b34f28380a51b3ffb63ae23161</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1021%2Fml300396r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300396r%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.-S.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DMi%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DChe%26aufirst%3DJ.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DA.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DGardin%26aufirst%3DA.%26aulast%3DEnd%26aufirst%3DP.%26aulast%3DHeining%26aufirst%3DP.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DCooke%26aufirst%3DN.%2BG.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520BAF312%2520%2528siponimod%2529%252C%2520a%2520potent%2520and%2520selective%2520S1P%2520receptor%2520modulator%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D333%26epage%3D337%26doi%3D10.1021%2Fml300396r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lanman, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheruku, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marantz, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neira, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickrell, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivenzon-Segal, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schutz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharadendu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buys, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElvain, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrag, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bürli, R. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent, S1P3-sparing benzothiazole agonist of sphingosine-1-phosphate receptor 1 (S1P1)</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span><span class="refDoi"> DOI: 10.1021/ml100228m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100228m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=102-106&author=B.+A.+Lanmanauthor=V.+J.+Ceeauthor=S.+R.+Cherukuauthor=M.+Frohnauthor=J.+Goldenauthor=J.+Linauthor=M.+Loberaauthor=Y.+Marantzauthor=K.+M.+Mullerauthor=S.+C.+Neiraauthor=A.+J.+Pickrellauthor=D.+Rivenzon-Segalauthor=N.+Schutzauthor=A.+Sharadenduauthor=X.+Yuauthor=Z.+Zhangauthor=J.+Buysauthor=M.+Fiorinoauthor=A.+Goreauthor=M.+Hornerauthor=A.+Itanoauthor=M.+McElvainauthor=S.+Middletonauthor=M.+Schragauthor=H.+M.+Vargasauthor=H.+Xuauthor=Y.+Xuauthor=X.+Zhangauthor=J.+Siuauthor=R.+W.+B%C3%BCrli&title=Discovery+of+a+potent%2C+S1P3-sparing+benzothiazole+agonist+of+sphingosine-1-phosphate+receptor+1+%28S1P1%29&doi=10.1021%2Fml100228m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1021%2Fml100228m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100228m%26sid%3Dliteratum%253Aachs%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DCheruku%26aufirst%3DS.%2BR.%26aulast%3DFrohn%26aufirst%3DM.%26aulast%3DGolden%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLobera%26aufirst%3DM.%26aulast%3DMarantz%26aufirst%3DY.%26aulast%3DMuller%26aufirst%3DK.%2BM.%26aulast%3DNeira%26aufirst%3DS.%2BC.%26aulast%3DPickrell%26aufirst%3DA.%2BJ.%26aulast%3DRivenzon-Segal%26aufirst%3DD.%26aulast%3DSchutz%26aufirst%3DN.%26aulast%3DSharadendu%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DBuys%26aufirst%3DJ.%26aulast%3DFiorino%26aufirst%3DM.%26aulast%3DGore%26aufirst%3DA.%26aulast%3DHorner%26aufirst%3DM.%26aulast%3DItano%26aufirst%3DA.%26aulast%3DMcElvain%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DS.%26aulast%3DSchrag%26aufirst%3DM.%26aulast%3DVargas%26aufirst%3DH.%2BM.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSiu%26aufirst%3DJ.%26aulast%3DB%25C3%25BCrli%26aufirst%3DR.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520S1P3-sparing%2520benzothiazole%2520agonist%2520of%2520sphingosine-1-phosphate%2520receptor%25201%2520%2528S1P1%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D102%26epage%3D106%26doi%3D10.1021%2Fml100228m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ren, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, J.-N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X.</span><span> </span><span class="NLM_article-title">Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P1)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4286</span><span class="NLM_x">–</span> <span class="NLM_lpage">4296</span><span class="refDoi"> DOI: 10.1021/jm2016107</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2016107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4286-4296&author=F.+Renauthor=G.+Dengauthor=H.+Wangauthor=L.+Luanauthor=Q.+Mengauthor=Q.+Xuauthor=H.+Xuauthor=X.+Xuauthor=H.+Zhangauthor=B.+Zhaoauthor=C.+Liauthor=T.+B.+Guoauthor=J.+Yangauthor=W.+Zhangauthor=Y.+Zhaoauthor=Q.+Jiaauthor=H.+Luauthor=J.-N.+Xiangauthor=J.+D.+Elliottauthor=X.+Lin&title=Discovery+of+novel+1%2C2%2C4-thiadiazole+derivatives+as+potent%2C+orally+active+agonists+of+sphingosine+1-phosphate+receptor+subtype+1+%28S1P1%29&doi=10.1021%2Fjm2016107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=10.1021%2Fjm2016107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2016107%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DF.%26aulast%3DDeng%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLuan%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DT.%2BB.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DXiang%26aufirst%3DJ.-N.%26aulast%3DElliott%26aufirst%3DJ.%2BD.%26aulast%3DLin%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520novel%25201%252C2%252C4-thiadiazole%2520derivatives%2520as%2520potent%252C%2520orally%2520active%2520agonists%2520of%2520sphingosine%25201-phosphate%2520receptor%2520subtype%25201%2520%2528S1P1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4286%26epage%3D4296%26doi%3D10.1021%2Fjm2016107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanman, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neira, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickrell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnett, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buys, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElvain, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrag, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivenzon-Segal, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buerli, R. W.</span><span> </span><span class="NLM_article-title">Discovery of AMG 369, a thiazolo[5,4-b]pyridine agonist of S1P1 and S1P5</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1021/ml100306h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100306h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=107-112&author=V.+J.+Ceeauthor=M.+Frohnauthor=B.+A.+Lanmanauthor=J.+Goldenauthor=K.+Mullerauthor=S.+Neiraauthor=A.+Pickrellauthor=H.+Arnettauthor=J.+Buysauthor=A.+Goreauthor=M.+Fiorinoauthor=M.+Hornerauthor=A.+Itanoauthor=M.+R.+Leeauthor=M.+McElvainauthor=S.+Middletonauthor=M.+Schragauthor=D.+Rivenzon-Segalauthor=H.+M.+Vargasauthor=H.+Xuauthor=Y.+Xuauthor=X.+Zhangauthor=J.+Siuauthor=M.+Wongauthor=R.+W.+Buerli&title=Discovery+of+AMG+369%2C+a+thiazolo%5B5%2C4-b%5Dpyridine+agonist+of+S1P1+and+S1P5&doi=10.1021%2Fml100306h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20e&amp;dbid=16384&amp;doi=10.1021%2Fml100306h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100306h%26sid%3Dliteratum%253Aachs%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DFrohn%26aufirst%3DM.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DGolden%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DK.%26aulast%3DNeira%26aufirst%3DS.%26aulast%3DPickrell%26aufirst%3DA.%26aulast%3DArnett%26aufirst%3DH.%26aulast%3DBuys%26aufirst%3DJ.%26aulast%3DGore%26aufirst%3DA.%26aulast%3DFiorino%26aufirst%3DM.%26aulast%3DHorner%26aufirst%3DM.%26aulast%3DItano%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DMcElvain%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DS.%26aulast%3DSchrag%26aufirst%3DM.%26aulast%3DRivenzon-Segal%26aufirst%3DD.%26aulast%3DVargas%26aufirst%3DH.%2BM.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSiu%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DBuerli%26aufirst%3DR.%2BW.%26atitle%3DDiscovery%2520of%2520AMG%2520369%252C%2520a%2520thiazolo%255B5%252C4-b%255Dpyridine%2520agonist%2520of%2520S1P1%2520and%2520S1P5%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D107%26epage%3D112%26doi%3D10.1021%2Fml100306h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Watterson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spergel, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langevine, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moquin, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yarde, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cvijic, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suchard, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">RexRabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuster, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D'Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balimane, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrack, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salter-Cid, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinnon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitts, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyckman, A. J.</span><span> </span><span class="NLM_article-title">Potent and selective agonists of sphingosine-1-phosphate 1 (S1P<sub>1</sub>): the discovery and SAR of a novel isoxazole based series</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">2820</span><span class="NLM_x">–</span> <span class="NLM_lpage">2840</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00089</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00089" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2820-2840&author=S.+H.+Wattersonauthor=J.+Guoauthor=S.+H.+Spergelauthor=C.+M.+Langevineauthor=R.+V.+Moquinauthor=D.+R.+Shenauthor=M.+Yardeauthor=M.+E.+Cvijicauthor=D.+Banasauthor=R.+Liuauthor=S.+J.+Suchardauthor=K.+Gilloolyauthor=T.+Taylorauthor=S.+RexRabeauthor=D.+J.+Shusterauthor=K.+W.+McIntyreauthor=G.+Corneliusauthor=C.+D%27Arienzoauthor=A.+Marinoauthor=P.+Balimaneauthor=B.+Warrackauthor=L.+Salter-Cidauthor=M.+McKinnonauthor=J.+C.+Barrishauthor=P.+C.+Carterauthor=W.+J.+Pittsauthor=J.+Xieauthor=A.+J.+Dyckman&title=Potent+and+selective+agonists+of+sphingosine-1-phosphate+1+%28S1P1%29%3A+the+discovery+and+SAR+of+a+novel+isoxazole+based+series&doi=10.1021%2Facs.jmedchem.6b00089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00089%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DSpergel%26aufirst%3DS.%2BH.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DBanas%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DSuchard%26aufirst%3DS.%2BJ.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%26aulast%3DRexRabe%26aufirst%3DS.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DD%2527Arienzo%26aufirst%3DC.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DWarrack%26aufirst%3DB.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DMcKinnon%26aufirst%3DM.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BC.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26atitle%3DPotent%2520and%2520selective%2520agonists%2520of%2520sphingosine-1-phosphate%25201%2520%2528S1P1%2529%253A%2520the%2520discovery%2520and%2520SAR%2520of%2520a%2520novel%2520isoxazole%2520based%2520series%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2820%26epage%3D2840%26doi%3D10.1021%2Facs.jmedchem.6b00089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Watterson, S. H.; Dyckman, A. J.; Pitts, W. J.; Spergel, S. H.</span><span> </span><span class="NLM_article-title">Substituted isoxazole derivatives as S1P agonists in the treatment of autoimmune and inflammatory diseases and their preparation</span>. WO 2010085581,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">, </span>(US Patent 8354398, 2013);</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+H.+Watterson&author=A.+J.+Dyckman&author=W.+J.+Pitts&author=S.+H.+Spergel&title=Substituted+isoxazole+derivatives+as+S1P+agonists+in+the+treatment+of+autoimmune+and+inflammatory+diseases+and+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26atitle%3DSubstituted%2520isoxazole%2520derivatives%2520as%2520S1P%2520agonists%2520in%2520the%2520treatment%2520of%2520autoimmune%2520and%2520inflammatory%2520diseases%2520and%2520their%2520preparation%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="ref21_3"><span> <span class="citation_source-journal">Chem. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">153</span><span class="NLM_x">, </span> <span class="NLM_fpage">232588</span> .</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chem.+Abstr.+2010%2C+153%2C+232588+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref21_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Abstr.%26date%3D2010%26volume%3D153%26spage%3D232588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="note"><p class="first last">The absolute and relative stereochemistry of compound <b>14a</b> was unambiguously assigned (<i>S</i>,<i>S</i>) by X-ray crystal structure. Crystallographic data for the structures <b>14a</b> reported in this paper has been deposited with the Cambridge Crystallographic Data Centre as supplementary publication nos. CCDC 1452864. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: (+44) 1223-336-033; e-mail: <a href="/cdn-cgi/l/email-protection#244041544b574d5064474740470a4745490a45470a514f"><span class="__cf_email__" data-cfemail="422627322d312b3602212126216c21232f6c23216c3729">[email protected]</span></a>). The absolute and relative stereochemistry of <b>14b</b> was assigned (<i>S</i>,<i>R</i>) based on the crystal structure of <b>14a</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="note"><p class="first last">The stereochemical assignment of <b>15a</b> was made by preparation of the material using the procedures described in WO2009005646. The starting (2-bromoacetyl)benzonitrile was reduced with (<i>S</i>)-2-methyl-CBS-oxazaborolidine followed by BH<sub>3</sub>-SMe<sub>2</sub>, yielding a 10:1 mixture of the <i>S</i>:<i>R</i> isomer. Subsequent HPLC chiral separation removed the minor isomer and coupling with the commercially available (<i>R</i>)-ethyl 2-(piperidin-3-yl)acetate afforded <b>15a</b>, which was assigned as the (<i>R</i>,<i>S</i>) isomer.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desale, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemons, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahalan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuerer, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">Crystal structure of a lipid G-protein coupled receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">851</span><span class="NLM_x">–</span> <span class="NLM_lpage">855</span><span class="refDoi"> DOI: 10.1126/science.1215904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1126%2Fscience.1215904" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2012&pages=851-855&author=M.+A.+Hansonauthor=C.+B.+Rothauthor=E.+Joauthor=M.+T.+Griffithauthor=F.+L.+Scottauthor=G.+Reinhartauthor=H.+Desaleauthor=B.+Clemonsauthor=S.+M.+Cahalanauthor=S.+C.+Schuererauthor=M.+G.+Sannaauthor=G.+W.+Hanauthor=P.+Kuhnauthor=H.+Rosenauthor=R.+C.+Stevens&title=Crystal+structure+of+a+lipid+G-protein+coupled+receptor&doi=10.1126%2Fscience.1215904"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1126%2Fscience.1215904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1215904%26sid%3Dliteratum%253Aachs%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DRoth%26aufirst%3DC.%2BB.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DGriffith%26aufirst%3DM.%2BT.%26aulast%3DScott%26aufirst%3DF.%2BL.%26aulast%3DReinhart%26aufirst%3DG.%26aulast%3DDesale%26aufirst%3DH.%26aulast%3DClemons%26aufirst%3DB.%26aulast%3DCahalan%26aufirst%3DS.%2BM.%26aulast%3DSchuerer%26aufirst%3DS.%2BC.%26aulast%3DSanna%26aufirst%3DM.%2BG.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DCrystal%2520structure%2520of%2520a%2520lipid%2520G-protein%2520coupled%2520receptor%26jtitle%3DScience%26date%3D2012%26volume%3D335%26spage%3D851%26epage%3D855%26doi%3D10.1126%2Fscience.1215904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="note"><p class="first last">The des-hydroxy version of <b>11l</b> was prepared and this resulted in >380-fold loss of activity in the S1P<sub>1</sub> binding assay. Additionally, the methoxy version of <b>11b</b> resulted in a >700-fold loss of activity in the S1P<sub>1</sub> binding assay.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Bendele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McComb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAbee, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennello, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chlipala, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guy, M.</span><span> </span><span class="NLM_article-title">Animal models of arthritis: relevance to human disease</span> <span class="citation_source-journal">Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span><span class="refDoi"> DOI: 10.1177/019262339902700125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1177%2F019262339902700125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10367688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A280%3ADyaK1M3psVWjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=134-142&author=A.+Bendeleauthor=J.+McCombauthor=T.+Gouldauthor=T.+McAbeeauthor=G.+Sennelloauthor=E.+Chlipalaauthor=M.+Guy&title=Animal+models+of+arthritis%3A+relevance+to+human+disease&doi=10.1177%2F019262339902700125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of arthritis: relevance to human disease</span></div><div class="casAuthors">Bendele A; McComb J; Gould T; McAbee T; Sennello G; Chlipala E; Guy M</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic pathology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-42</span>
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    </div><div class="casAbstract">Animal models of arthritis are used to evaluate potential antiarthritis drugs for clinical use.  Therefore capacity of the model to predict efficacy in human disease is one of the most important criteria in model selection.  Animal models of rheumatoid arthritis (RA) with a proven track record of predictability include rat adjuvant arthritis, rat type II collagen arthritis, mouse type II collagen arthritis, and antigen-induced arthritis in several species.  Agents currently in clinical use (or trials) that are active in these models include corticosteroids, methotrexate, nonsteroidal anti-inflammatory drugs, cyclosporin A, leflunomide, interleukin-1 receptor antagonist, and soluble tumor necrosis factor receptors.  For some of these agents, the models also predict that toxicities seen at higher doses for prolonged periods would preclude dosing in humans at levels that might provide disease-modifying effects.  Animal models of osteoarthritis (OA) include mouse and guinea pig spontaneous OA, meniscectomy and ligament transection in guinea pigs, meniscectomy in rabbits, and meniscectomy and cruciate transection in dogs.  None of these models have a proven track record of predictability in human disease because there are no agents that have been proven to provide anything other than symptomatic relief in human OA.  Efficacy data and features of the various models of RA and OA are discussed with emphasis on their proven relevance to human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSl_Wv0PotC6OkdrW1FkXG-fW6udTcc2eYz2lasNIFMh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3psVWjug%253D%253D&md5=1b6484ca61fd10dbb07f090d376730a4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1177%2F019262339902700125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F019262339902700125%26sid%3Dliteratum%253Aachs%26aulast%3DBendele%26aufirst%3DA.%26aulast%3DMcComb%26aufirst%3DJ.%26aulast%3DGould%26aufirst%3DT.%26aulast%3DMcAbee%26aufirst%3DT.%26aulast%3DSennello%26aufirst%3DG.%26aulast%3DChlipala%26aufirst%3DE.%26aulast%3DGuy%26aufirst%3DM.%26atitle%3DAnimal%2520models%2520of%2520arthritis%253A%2520relevance%2520to%2520human%2520disease%26jtitle%3DToxicol.%2520Pathol.%26date%3D1999%26volume%3D27%26spage%3D134%26epage%3D142%26doi%3D10.1177%2F019262339902700125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Gilmore, John L.; Sheppeck, James E</span>; <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate receptor agonists</span>. WO201117578,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">, </span>(US Patent 8399451, 2013);</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=John+L.+Gilmore&author=James+E+Sheppeck&title=Sphingosine-1-phosphate+receptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGilmore%26aufirst%3DJohn%2BL.%26atitle%3DSphingosine-1-phosphate%2520receptor%2520agonists%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="ref27_2"><span> <span class="citation_source-journal">Chem. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">259630</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chem.+Abstr.+2011%2C+154%2C+259630."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref27_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Abstr.%26date%3D2011%26volume%3D154%26spage%3D259630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c','cit15d','cit15e','cit15f'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20a','cit20b','cit20c','cit20d','cit20e'],'ref21':['cit21a','cit21b','ref21_3'],'ref22':[],'ref23':[],'ref24':['cit24'],'ref25':[],'ref26':['cit26'],'ref27':['cit27','ref27_2']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 17 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">John L. Gilmore, Hai-Yun Xiao, T. G. Murali Dhar, Michael G. Yang, Zili Xiao, Jenny Xie, Lois D. Lehman-McKeeman, Lei Gong, Huadong Sun, Lloyd Lecureux, Cliff Chen, Dauh-Rurng Wu, Marta Dabros, Xiaoxia Yang, Tracy L. Taylor, Xia D. Zhou, Elizabeth M. Heimrich, Rochelle Thomas, Kim W. McIntyre, Virna Borowski, Bethanne M. Warrack, Yuwen Li, Hong Shi, Paul C. Levesque, Zheng Yang, Anthony M. Marino, Georgia Cornelius, Celia J. D’Arienzo, Arvind Mathur, Richard Rampulla, Anuradha Gupta, Bala Pragalathan, Ding Ren Shen, Mary Ellen Cvijic, Luisa M. Salter-Cid, Percy H. Carter, <span class="NLM_string-name hlFld-ContribAuthor">Alaric J. Dyckman</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and Preclinical Pharmacology of ((1R,3S)-1-Amino-3-((S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P1) Modulator Advanced into Clinical Trials. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (5)
                                     , 2265-2285. <a href="https://doi.org/10.1021/acs.jmedchem.8b01695" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01695</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01695%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Band%252BPreclinical%252BPharmacology%252Bof%252B%252528%2525281R%25252C3S%252529-1-Amino-3-%252528%252528S%252529-6-%2525282-methoxyphenethyl%252529-5%25252C6%25252C7%25252C8-tetrahydronaphthalen-2-yl%252529cyclopentyl%252529methanol%252B%252528BMS-986166%252529%25253A%252BA%252BDifferentiated%252BSphingosine-1-phosphate%252BReceptor%252B1%252B%252528S1P1%252529%252BModulator%252BAdvanced%252Binto%252BClinical%252BTrials%26aulast%3DGilmore%26aufirst%3DJohn%2BL.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D31102018%26date%3D06032019%26date%3D20022019%26volume%3D62%26issue%3D5%26spage%3D2265%26epage%3D2285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">John Jin Lim, <span class="NLM_string-name hlFld-ContribAuthor">David C. Leitch</span>. </span><span class="cited-content_cbyCitation_article-title">Lewis Acid-Catalyzed Addition of Benzophenone Imine to Epoxides Enables the Selective Synthesis and Derivatization of Primary 1,2-Amino Alcohols. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2018,</strong> <em>22 </em>
                                    (5)
                                     , 641-649. <a href="https://doi.org/10.1021/acs.oprd.8b00133" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00133</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00133%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DLewis%252BAcid-Catalyzed%252BAddition%252Bof%252BBenzophenone%252BImine%252Bto%252BEpoxides%252BEnables%252Bthe%252BSelective%252BSynthesis%252Band%252BDerivatization%252Bof%252BPrimary%252B1%25252C2-Amino%252BAlcohols%26aulast%3DLim%26aufirst%3DJohn%2BJin%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D25042018%26date%3D02052018%26date%3D27042018%26volume%3D22%26issue%3D5%26spage%3D641%26epage%3D649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haruto  Kurata</span>, <span class="hlFld-ContribAuthor ">Kensuke  Kusumi</span>, <span class="hlFld-ContribAuthor ">Kazuhiro  Otsuki</span>, <span class="hlFld-ContribAuthor ">Ryo  Suzuki</span>, <span class="hlFld-ContribAuthor ">Masakuni  Kurono</span>, <span class="hlFld-ContribAuthor ">Takaki  Komiya</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Hagiya</span>, <span class="hlFld-ContribAuthor ">Hirotaka  Mizuno</span>, <span class="hlFld-ContribAuthor ">Hiroki  Shioya</span>, <span class="hlFld-ContribAuthor ">Takeji  Ono</span>, <span class="hlFld-ContribAuthor ">Yuka  Takada</span>, <span class="hlFld-ContribAuthor ">Tatsuo  Maeda</span>, <span class="hlFld-ContribAuthor ">Norikazu  Matsunaga</span>, <span class="hlFld-ContribAuthor ">Tetsu  Kondo</span>, <span class="hlFld-ContribAuthor ">Sachiko  Tominaga</span>, <span class="hlFld-ContribAuthor ">Ken-ici  Nunoya</span>, <span class="hlFld-ContribAuthor ">Hidekazu  Kiyoshi</span>, <span class="hlFld-ContribAuthor ">Masaharu  Komeno</span>, <span class="hlFld-ContribAuthor ">Shinji  Nakade</span>, and <span class="hlFld-ContribAuthor ">Hiromu  Habashita</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P1 and S1P5 Selective Agonist for the Treatment of Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (23)
                                     , 9508-9530. <a href="https://doi.org/10.1021/acs.jmedchem.7b00785" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00785</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00785%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252B1-Methyl-3%25252C4-dihydronaphthalene-Based%252BSphingosine-1-Phosphate%252B%252528S1P%252529%252BReceptor%252BAgonist%252BCeralifimod%252B%252528ONO-4641%252529.%252BA%252BS1P1%252Band%252BS1P5%252BSelective%252BAgonist%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%26aulast%3DKurata%26aufirst%3DHaruto%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D29052017%26date%3D21112017%26date%3D14122017%26date%3D09112017%26volume%3D60%26issue%3D23%26spage%3D9508%26epage%3D9530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alaric J.  Dyckman</span>  . </span><span class="cited-content_cbyCitation_article-title">Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P1) Agonists and Future Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (13)
                                     , 5267-5289. <a href="https://doi.org/10.1021/acs.jmedchem.6b01575" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01575%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DModulators%252Bof%252BSphingosine-1-phosphate%252BPathway%252BBiology%25253A%252BRecent%252BAdvances%252Bof%252BSphingosine-1-phosphate%252BReceptor%252B1%252B%252528S1P1%252529%252BAgonists%252Band%252BFuture%252BPerspectives%26aulast%3DDyckman%26aufirst%3DAlaric%2BJ.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D24102016%26date%3D30032017%26date%3D13072017%26date%3D14032017%26volume%3D60%26issue%3D13%26spage%3D5267%26epage%3D5289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoping  Hou</span>, <span class="hlFld-ContribAuthor ">Huiping  Zhang</span>, <span class="hlFld-ContribAuthor ">Bang-Chi  Chen</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Guo</span>, <span class="hlFld-ContribAuthor ">Amarjit  Singh</span>, <span class="hlFld-ContribAuthor ">Animesh  Goswami</span>, <span class="hlFld-ContribAuthor ">John L.  Gilmore</span>, <span class="hlFld-ContribAuthor ">James E.  Sheppeck</span>, <span class="hlFld-ContribAuthor ">Alaric J.  Dyckman</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, and <span class="hlFld-ContribAuthor ">Arvind  Mathur</span>  . </span><span class="cited-content_cbyCitation_article-title">Regioselective Epoxide Ring Opening for the Stereospecific Scale-Up Synthesis of BMS-960, A Potent and Selective Isoxazole-Containing S1P1 Receptor Agonist. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2017,</strong> <em>21 </em>
                                    (2)
                                     , 200-207. <a href="https://doi.org/10.1021/acs.oprd.6b00366" title="DOI URL">https://doi.org/10.1021/acs.oprd.6b00366</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.6b00366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.6b00366%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DRegioselective%252BEpoxide%252BRing%252BOpening%252Bfor%252Bthe%252BStereospecific%252BScale-Up%252BSynthesis%252Bof%252BBMS-960%25252C%252BA%252BPotent%252Band%252BSelective%252BIsoxazole-Containing%252BS1P1%252BReceptor%252BAgonist%26aulast%3DHou%26aufirst%3DXiaoping%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D02112016%26date%3D25012017%26date%3D17022017%26date%3D12012017%26volume%3D21%26issue%3D2%26spage%3D200%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hai-Yun  Xiao</span>, <span class="hlFld-ContribAuthor ">Scott H.  Watterson</span>, <span class="hlFld-ContribAuthor ">Charles M.  Langevine</span>, <span class="hlFld-ContribAuthor ">Anurag S.  Srivastava</span>, <span class="hlFld-ContribAuthor ">Soo S.  Ko</span>, <span class="hlFld-ContribAuthor ">Yanlei  Zhang</span>, <span class="hlFld-ContribAuthor ">Robert J.  Cherney</span>, <span class="hlFld-ContribAuthor ">Wei-Wei  Guo</span>, <span class="hlFld-ContribAuthor ">John L.  Gilmore</span>, <span class="hlFld-ContribAuthor ">James E.  Sheppeck, II</span>, <span class="hlFld-ContribAuthor ">Dauh-Rurng  Wu</span>, <span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Duraisamy  Ramasamy</span>, <span class="hlFld-ContribAuthor ">Piramanayagam  Arunachalam</span>, <span class="hlFld-ContribAuthor ">Arvind  Mathur</span>, <span class="hlFld-ContribAuthor ">Tracy L.  Taylor</span>, <span class="hlFld-ContribAuthor ">David J.  Shuster</span>, <span class="hlFld-ContribAuthor ">Kim W.  McIntyre</span>, <span class="hlFld-ContribAuthor ">Ding-Ren  Shen</span>, <span class="hlFld-ContribAuthor ">Melissa  Yarde</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Cvijic</span>, <span class="hlFld-ContribAuthor ">Anthony M.  Marino</span>, <span class="hlFld-ContribAuthor ">Praveen V.  Balimane</span>, <span class="hlFld-ContribAuthor ">Zheng  Yang</span>, <span class="hlFld-ContribAuthor ">Dana M.  Banas</span>, <span class="hlFld-ContribAuthor ">Georgia  Cornelius</span>, <span class="hlFld-ContribAuthor ">Celia J.  D’Arienzo</span>, <span class="hlFld-ContribAuthor ">Bethanne M.  Warrack</span>, <span class="hlFld-ContribAuthor ">Lois  Lehman-McKeeman</span>, <span class="hlFld-ContribAuthor ">Luisa M.  Salter-Cid</span>, <span class="hlFld-ContribAuthor ">Jenny  Xie</span>, <span class="hlFld-ContribAuthor ">Joel C.  Barrish</span>, <span class="hlFld-ContribAuthor ">Percy H.  Carter</span>, <span class="hlFld-ContribAuthor ">Alaric J.  Dyckman</span>, and <span class="hlFld-ContribAuthor ">T. G. Murali  Dhar</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of Tricyclic Agonists of Sphingosine-1-phosphate Receptor 1 (S1P1) Employing Ligand-Based Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (21)
                                     , 9837-9854. <a href="https://doi.org/10.1021/acs.jmedchem.6b01099" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01099</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01099%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BTricyclic%252BAgonists%252Bof%252BSphingosine-1-phosphate%252BReceptor%252B1%252B%252528S1P1%252529%252BEmploying%252BLigand-Based%252BDrug%252BDesign%26aulast%3DXiao%26aufirst%3DHai-Yun%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D25072016%26date%3D20102016%26date%3D10112016%26date%3D11102016%26volume%3D59%26issue%3D21%26spage%3D9837%26epage%3D9854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minhua  Jiang</span>, <span class="hlFld-ContribAuthor ">Yuxin  Tuo</span>, <span class="hlFld-ContribAuthor ">Mingzhong  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">Immobilization of copper(II) on mesoporous MCM-41: a highly efficient and recyclable catalyst for tandem oxidative annulation of amidines and methylarenes. </span><span class="cited-content_cbyCitation_journal-name">Journal of Porous Materials</span><span> <strong>2020,</strong> <em>27 </em>
                                    (4)
                                     , 1039-1049. <a href="https://doi.org/10.1007/s10934-020-00880-6" title="DOI URL">https://doi.org/10.1007/s10934-020-00880-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10934-020-00880-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10934-020-00880-6%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Porous%2520Materials%26atitle%3DImmobilization%252Bof%252Bcopper%252528II%252529%252Bon%252Bmesoporous%252BMCM-41%25253A%252Ba%252Bhighly%252Befficient%252Band%252Brecyclable%252Bcatalyst%252Bfor%252Btandem%252Boxidative%252Bannulation%252Bof%252Bamidines%252Band%252Bmethylarenes%26aulast%3DJiang%26aufirst%3DMinhua%26date%3D2020%26date%3D2020%26volume%3D27%26issue%3D4%26spage%3D1039%26epage%3D1049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sergey  Baykov</span>, <span class="hlFld-ContribAuthor ">Marina  Tarasenko</span>, <span class="hlFld-ContribAuthor ">Lev E.  Zelenkov</span>, <span class="hlFld-ContribAuthor ">Svetlana  Kasatkina</span>, <span class="hlFld-ContribAuthor ">Polina  Savko</span>, <span class="hlFld-ContribAuthor ">Anton  Shetnev</span>. </span><span class="cited-content_cbyCitation_article-title">Diastereoselective Opening of Bridged Anhydrides by Amidoximes Providing Access to 1,2,4-Oxadiazole/Norborna(e)ne Hybrids. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (33)
                                     , 5685-5693. <a href="https://doi.org/10.1002/ejoc.201900843" title="DOI URL">https://doi.org/10.1002/ejoc.201900843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201900843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201900843%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDiastereoselective%252BOpening%252Bof%252BBridged%252BAnhydrides%252Bby%252BAmidoximes%252BProviding%252BAccess%252Bto%252B1%25252C2%25252C4-Oxadiazole%25252FNorborna%252528e%252529ne%252BHybrids%26aulast%3DBaykov%26aufirst%3DSergey%26date%3D2019%26date%3D2019%26volume%3D2019%26issue%3D33%26spage%3D5685%26epage%3D5693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shiuhang Henry  Yip</span>, <span class="hlFld-ContribAuthor ">Dauh‐Rurng  Wu</span>, <span class="hlFld-ContribAuthor ">James  Kempson</span>, <span class="hlFld-ContribAuthor ">Andres  Hernandez</span>, <span class="hlFld-ContribAuthor ">Huiping  Zhang</span>, <span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Dawn  Sun</span>, <span class="hlFld-ContribAuthor ">Arvind  Mathur</span>. </span><span class="cited-content_cbyCitation_article-title">Large‐scale chiral supercritical fluid chromatography of a key intermediate in the synthesis of two S1P
              1
              final active pharmaceutical ingredients. </span><span class="cited-content_cbyCitation_journal-name">SEPARATION SCIENCE PLUS</span><span> <strong>2019,</strong> <em>2 </em>
                                    (9)
                                     , 343-352. <a href="https://doi.org/10.1002/sscp.201900047" title="DOI URL">https://doi.org/10.1002/sscp.201900047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/sscp.201900047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fsscp.201900047%26sid%3Dliteratum%253Aachs%26jtitle%3DSEPARATION%2520SCIENCE%2520PLUS%26atitle%3DLarge%2525E2%252580%252590scale%252Bchiral%252Bsupercritical%252Bfluid%252Bchromatography%252Bof%252Ba%252Bkey%252Bintermediate%252Bin%252Bthe%252Bsynthesis%252Bof%252Btwo%252BS1P%252B1%252Bfinal%252Bactive%252Bpharmaceutical%252Bingredients%26aulast%3DYip%26aufirst%3DShiuhang%2BHenry%26date%3D2019%26date%3D2019%26volume%3D2%26issue%3D9%26spage%3D343%26epage%3D352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zonghua  Luo</span>, <span class="hlFld-ContribAuthor ">Junbin  Han</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Adam J.  Rosenberg</span>, <span class="hlFld-ContribAuthor ">Delphine L.  Chen</span>, <span class="hlFld-ContribAuthor ">Robert J.  Gropler</span>, <span class="hlFld-ContribAuthor ">Joel S.  Perlmutter</span>, <span class="hlFld-ContribAuthor ">Zhude  Tu</span>. </span><span class="cited-content_cbyCitation_article-title">Syntheses and
              in vitro
              biological evaluation of S1PR1 ligands and PET studies of four F-18 labeled radiotracers in the brain of nonhuman primates. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (47)
                                     , 9171-9184. <a href="https://doi.org/10.1039/C8OB02609B" title="DOI URL">https://doi.org/10.1039/C8OB02609B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB02609B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB02609B%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DSyntheses%252Band%252Bin%252Bvitro%252Bbiological%252Bevaluation%252Bof%252BS1PR1%252Bligands%252Band%252BPET%252Bstudies%252Bof%252Bfour%252BF-18%252Blabeled%252Bradiotracers%252Bin%252Bthe%252Bbrain%252Bof%252Bnonhuman%252Bprimates%26aulast%3DLuo%26aufirst%3DZonghua%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D47%26spage%3D9171%26epage%3D9184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">V. E.  Pankrat’eva</span>, <span class="hlFld-ContribAuthor ">T. V.  Sharonova</span>, <span class="hlFld-ContribAuthor ">M. V.  Tarasenko</span>, <span class="hlFld-ContribAuthor ">S. V.  Baikov</span>, <span class="hlFld-ContribAuthor ">E. R.  Kofanov</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot Synthesis of 3,5-Disubstituted 1,2,4-Oxadiazoles Using Catalytic System NaOH‒DMSO. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>54 </em>
                                    (8)
                                     , 1250-1255. <a href="https://doi.org/10.1134/S1070428018080213" title="DOI URL">https://doi.org/10.1134/S1070428018080213</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428018080213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428018080213%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BSynthesis%252Bof%252B3%25252C5-Disubstituted%252B1%25252C2%25252C4-Oxadiazoles%252BUsing%252BCatalytic%252BSystem%252BNaOH%2525E2%252580%252592DMSO%26aulast%3DPankrat%25E2%2580%2599eva%26aufirst%3DV.%2BE.%26date%3D2018%26date%3D2018%26volume%3D54%26issue%3D8%26spage%3D1250%26epage%3D1255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tatyana  Sharonova</span>, <span class="hlFld-ContribAuthor ">Vitalina  Pankrat'eva</span>, <span class="hlFld-ContribAuthor ">Polyna  Savko</span>, <span class="hlFld-ContribAuthor ">Sergey  Baykov</span>, <span class="hlFld-ContribAuthor ">Anton  Shetnev</span>. </span><span class="cited-content_cbyCitation_article-title">Facile room-temperature assembly of the 1,2,4-oxadiazole core from readily available amidoximes and carboxylic acids. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2018,</strong> <em>59 </em>
                                    (29)
                                     , 2824-2827. <a href="https://doi.org/10.1016/j.tetlet.2018.06.019" title="DOI URL">https://doi.org/10.1016/j.tetlet.2018.06.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2018.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2018.06.019%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DFacile%252Broom-temperature%252Bassembly%252Bof%252Bthe%252B1%25252C2%25252C4-oxadiazole%252Bcore%252Bfrom%252Breadily%252Bavailable%252Bamidoximes%252Band%252Bcarboxylic%252Bacids%26aulast%3DSharonova%26aufirst%3DTatyana%26date%3D2018%26volume%3D59%26issue%3D29%26spage%3D2824%26epage%3D2827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zonghua  Luo</span>, <span class="hlFld-ContribAuthor ">Adam J.  Rosenberg</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Junbin  Han</span>, <span class="hlFld-ContribAuthor ">Zhude  Tu</span>. </span><span class="cited-content_cbyCitation_article-title">Syntheses and in vitro evaluation of new S1PR1 compounds and initial evaluation of a lead F-18 radiotracer in rodents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>150 </em>, 796-808. <a href="https://doi.org/10.1016/j.ejmech.2018.03.035" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.035%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSyntheses%252Band%252Bin%2525C2%2525A0vitro%252Bevaluation%252Bof%252Bnew%252BS1PR1%252Bcompounds%252Band%252Binitial%252Bevaluation%252Bof%252Ba%252Blead%252BF-18%252Bradiotracer%252Bin%252Brodents%26aulast%3DLuo%26aufirst%3DZonghua%26date%3D2018%26volume%3D150%26spage%3D796%26epage%3D808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui-Zhen  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhi-Long  Zhao</span>, <span class="hlFld-ContribAuthor ">Cheng-He  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advance in oxazole-based medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>144 </em>, 444-492. <a href="https://doi.org/10.1016/j.ejmech.2017.12.044" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.12.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.12.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.12.044%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvance%252Bin%252Boxazole-based%252Bmedicinal%252Bchemistry%26aulast%3DZhang%26aufirst%3DHui-Zhen%26date%3D2018%26volume%3D144%26spage%3D444%26epage%3D492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">В.Е.  Панкратьева</span>, <span class="hlFld-ContribAuthor ">Т.В.  Шаронова</span>, <span class="hlFld-ContribAuthor ">М.В.  Тарасенко</span>, <span class="hlFld-ContribAuthor ">С.В.  Байков</span>, <span class="hlFld-ContribAuthor ">Е.Р.  Кофанов</span>. </span><span class="cited-content_cbyCitation_article-title">ОДНОРЕАКТОРНЫЙ СИНТЕЗ 3,5-ДИЗАМЕЩЁННЫХ 1,2,4-ОКСАДИАЗОЛОВ С ПРИМЕНЕНИЕМ КАТАЛИТИЧЕСКОЙ СИСТЕМЫ NaOH-ДМСО, "Журнал органической химии". </span><span class="cited-content_cbyCitation_journal-name">Журнал органической химии</span><span> <strong>2018,</strong> <em> </em>
                                    (8)
                                     , 1236-1241. <a href="https://doi.org/10.7868/S0514749218080216" title="DOI URL">https://doi.org/10.7868/S0514749218080216</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7868/S0514749218080216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7868%2FS0514749218080216%26sid%3Dliteratum%253Aachs%26jtitle%3D%25D0%2596%25D1%2583%25D1%2580%25D0%25BD%25D0%25B0%25D0%25BB%2520%25D0%25BE%25D1%2580%25D0%25B3%25D0%25B0%25D0%25BD%25D0%25B8%25D1%2587%25D0%25B5%25D1%2581%25D0%25BA%25D0%25BE%25D0%25B9%2520%25D1%2585%25D0%25B8%25D0%25BC%25D0%25B8%25D0%25B8%26atitle%3D%2525D0%25259E%2525D0%252594%2525D0%25259D%2525D0%25259E%2525D0%2525A0%2525D0%252595%2525D0%252590%2525D0%25259A%2525D0%2525A2%2525D0%25259E%2525D0%2525A0%2525D0%25259D%2525D0%2525AB%2525D0%252599%252B%2525D0%2525A1%2525D0%252598%2525D0%25259D%2525D0%2525A2%2525D0%252595%2525D0%252597%252B3%25252C5-%2525D0%252594%2525D0%252598%2525D0%252597%2525D0%252590%2525D0%25259C%2525D0%252595%2525D0%2525A9%2525D0%252581%2525D0%25259D%2525D0%25259D%2525D0%2525AB%2525D0%2525A5%252B1%25252C2%25252C4-%2525D0%25259E%2525D0%25259A%2525D0%2525A1%2525D0%252590%2525D0%252594%2525D0%252598%2525D0%252590%2525D0%252597%2525D0%25259E%2525D0%25259B%2525D0%25259E%2525D0%252592%252B%2525D0%2525A1%252B%2525D0%25259F%2525D0%2525A0%2525D0%252598%2525D0%25259C%2525D0%252595%2525D0%25259D%2525D0%252595%2525D0%25259D%2525D0%252598%2525D0%252595%2525D0%25259C%252B%2525D0%25259A%2525D0%252590%2525D0%2525A2%2525D0%252590%2525D0%25259B%2525D0%252598%2525D0%2525A2%2525D0%252598%2525D0%2525A7%2525D0%252595%2525D0%2525A1%2525D0%25259A%2525D0%25259E%2525D0%252599%252B%2525D0%2525A1%2525D0%252598%2525D0%2525A1%2525D0%2525A2%2525D0%252595%2525D0%25259C%2525D0%2525AB%252BNaOH-%2525D0%252594%2525D0%25259C%2525D0%2525A1%2525D0%25259E%25252C%252B%252522%2525D0%252596%2525D1%252583%2525D1%252580%2525D0%2525BD%2525D0%2525B0%2525D0%2525BB%252B%2525D0%2525BE%2525D1%252580%2525D0%2525B3%2525D0%2525B0%2525D0%2525BD%2525D0%2525B8%2525D1%252587%2525D0%2525B5%2525D1%252581%2525D0%2525BA%2525D0%2525BE%2525D0%2525B9%252B%2525D1%252585%2525D0%2525B8%2525D0%2525BC%2525D0%2525B8%2525D0%2525B8%252522%26aulast%3D%25D0%259F%25D0%25B0%25D0%25BD%25D0%25BA%25D1%2580%25D0%25B0%25D1%2582%25D1%258C%25D0%25B5%25D0%25B2%25D0%25B0%26aufirst%3D%25D0%2592.%25D0%2595.%26date%3D2018%26issue%3D8%26spage%3D1236%26epage%3D1241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianquan  Hong</span>, <span class="hlFld-ContribAuthor ">Guifu  Wang</span>, <span class="hlFld-ContribAuthor ">Lianguang  Huo</span>, <span class="hlFld-ContribAuthor ">Changge  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-Promoted Conversion of Aromatic Amines into Trifluoromethylated Arenes: One-Pot Sandmeyer Trifluoromethylation. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Chemistry</span><span> <strong>2017,</strong> <em>35 </em>
                                    (11)
                                     , 1761-1767. <a href="https://doi.org/10.1002/cjoc.201700311" title="DOI URL">https://doi.org/10.1002/cjoc.201700311</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cjoc.201700311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcjoc.201700311%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Chemistry%26atitle%3DCopper-Promoted%252BConversion%252Bof%252BAromatic%252BAmines%252Binto%252BTrifluoromethylated%252BArenes%25253A%252BOne-Pot%252BSandmeyer%252BTrifluoromethylation%26aulast%3DHong%26aufirst%3DJianquan%26date%3D2017%26date%3D2017%26volume%3D35%26issue%3D11%26spage%3D1761%26epage%3D1767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Romina E.  Avanzo</span>, <span class="hlFld-ContribAuthor ">José M.  Padrón</span>, <span class="hlFld-ContribAuthor ">Norma B.  D'Accorso</span>, <span class="hlFld-ContribAuthor ">Mirta L.  Fascio</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and in vitro antiproliferative activities of (5-aryl-1,2,4-oxadiazole-3-yl) methyl d-ribofuranosides. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (16)
                                     , 3674-3677. <a href="https://doi.org/10.1016/j.bmcl.2017.07.015" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.07.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.07.015%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bin%252Bvitro%252Bantiproliferative%252Bactivities%252Bof%252B%2525285-aryl-1%25252C2%25252C4-oxadiazole-3-yl%252529%252Bmethyl%252Bd-ribofuranosides%26aulast%3DAvanzo%26aufirst%3DRomina%2BE.%26date%3D2017%26volume%3D27%26issue%3D16%26spage%3D3674%26epage%3D3677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Propylisoxazole Ethanolamines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 160 °C, 18 h, 87%; (b) 1 M NaOH, EtOH, 75 °C, 12 h, 95%; (c) cyanuric fluoride, pyridine, DCM, rt, 1 h, 90%; (d) DIEA, CH<sub>3</sub>CN, rt then heat at 70 °C, 18 h, 45%; (e) <i>m</i>-CPBA, DCM, rt, 12 h, 62%; (f) phthalimide, cat. potassium phthalimide, 100 °C, 12 h, 85%; (g) NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, EtOH, 75 °C, 35%; (h) bromotriethylsilane, THF, −78 °C, 2 h, 50%; (i) R-Br, NaI, pyridine, 80 °C; (j) 6 N HCl, EtOH or MeOH, 70 °C, 12 h, 95% or TFA/DCM (1:1); (k) <i>RR</i>′-NH, DBU, or tetrabutylammonium hydroxide, DMSO, 80 °C, 10–50%.</p></p></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Trifluoromethyloxazole Ethanolamines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) toluene, rt, 18 h; (b) NaBH<sub>4</sub>, EtOH or MeOH, 80–95% (c) NH<sub>2</sub>OH, NaHCO<sub>3</sub>, <sup><i>i</i></sup>PrOH 85–90%; (d) 3-phenyl-4-(trifluoromethyl)isoxazole-5-carbonyl fluoride, DIEA, CH<sub>3</sub>CN, rt, 2 h then TBAF/THF, 12 h, 20–50%; (e) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1) (f) 6 N HCl, CH<sub>3</sub>CN or dioxane, 80 °C, 12 h, 80%; (g) chiral HPLC separation of isomers.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Predicted binding mode of compound <b>19a</b> in S1P<sub>1</sub>. (A) Docked conformation of compound <b>19a</b> in the S1P<sub>1</sub> crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V2W">3V2W</a>). The hydrophobic pocket is shown as a surface and the polar interactions as sticks. (B) Overlay of the crystallographic ligand <b>24</b> (blue) and <b>19a</b> (orange).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Dose response of <b>18a</b> (0.1, 0.3, and 1.0 mg/kg) and <b>19a</b> (0.03, 0.1, and 0.3 mg/kg) vs vehicle in the blood lymphocyte reduction assay in Lewis Rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Efficacy of <b>19a</b> (0.06, 0.2, and 1.0 mg/kg) vs vehicle in a rat adjuvant arthritis model. Rats (<i>n</i> = 8/group) were administered <b>19a</b> PO/QD starting on day 0 at the time of immunization. Vehicle: PEG300. <i>p</i> value <0.05 compared to vehicle treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/medium/jm-2016-00373s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Efficacy of <b>19a</b> (0.01, 0.1, and 1.0 mg/kg) and vs vehicle in a mouse experimental autoimmune encephalomyelitis model (EAE). Mice (<i>n</i> = 10/group) were administered <b>19a</b> PO/QD starting on day 0 at the time of immunization with MOG-peptide (myelin oligodendrocyte glycoprotein). Vehicle: PEG300. <i>p</i> value <0.05 compared to vehicle treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-13/acs.jmedchem.6b00373/20160708/images/large/jm-2016-00373s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00373&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87355" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87355" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 27 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Billich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornancin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechtcheriakova, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urtz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumruker, T.</span><span> </span><span class="NLM_article-title">Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">47408</span><span class="NLM_x">–</span> <span class="NLM_lpage">47415</span><span class="refDoi"> DOI: 10.1074/jbc.M307687200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1074%2Fjbc.M307687200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=13129923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1Cqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=47408-47415&author=A.+Billichauthor=F.+Bornancinauthor=P.+Devayauthor=D.+Mechtcheriakovaauthor=N.+Urtzauthor=T.+Baumruker&title=Phosphorylation+of+the+immunomodulatory+drug+FTY720+by+sphingosine+kinases&doi=10.1074%2Fjbc.M307687200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases</span></div><div class="casAuthors">Billich, Andreas; Bornancin, Frederic; Devay, Piroska; Mechtcheriakova, Diana; Urtz, Nicole; Baumruker, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">47408-47415</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The immunomodulatory drug FTY720 is phosphorylated in vivo, and the resulting FTY720 phosphate as a ligand for sphingosine-1-phosphate receptors is responsible for the unique biol. effects of the compd.  So far, phosphorylation of FTY720 by murine sphingosine kinase (SPHK) 1a had been documented.  We found that, while FTY720 is also phosphorylated by human SPHK1, the human type 2 isoform phosphorylates the drug 30-fold more efficiently, because of a lower Km of FTY720 for SPHK2.  Similarly, murine SPHK2 was more efficient than SPHK1a.  Among splice variants of the human SPHKs, an N-terminally extended SPHK2 isoform was even more active than SPHK2 itself.  Further SPHK superfamily members, namely ceramide kinase and a "SPHK-like" protein, failed to phosphorylate sphingosine and FTY720.  Thus, only SPHK1 and 2 appear to be capable of phosphorylating FTY720.  Using selective assay conditions, SPHK1 and 2 activities in murine tissues were measured.  While activity of SPHK2 toward sphingosine was generally lower than of SPHK1, FTY720 phosphorylation was higher under conditions favoring SPHK2.  In human endothelial cells, while activity of SPHK1 toward sphingosine was 2-fold higher than of SPHK2, FTY720 phosphorylation was 7-fold faster under SPHK2 assay conditions.  Finally, FTY720 was poorly phosphorylated in human blood as compared with rodent blood, in line with the low activity of SPHK1 and in particular of SPHK2 in human blood.  To conclude, both SPHK1 and 2 are capable of phosphorylating FTY720, but SPHK2 is quant. more important than SPHK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR5e-dVWnBT7Vg90H21EOLACvtfcHk0ljUbi0NnTtENQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1Cqtr0%253D&md5=26820503680682863dc76a69ea02fc7e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M307687200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M307687200%26sid%3Dliteratum%253Aachs%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DBornancin%26aufirst%3DF.%26aulast%3DDevay%26aufirst%3DP.%26aulast%3DMechtcheriakova%26aufirst%3DD.%26aulast%3DUrtz%26aufirst%3DN.%26aulast%3DBaumruker%26aufirst%3DT.%26atitle%3DPhosphorylation%2520of%2520the%2520immunomodulatory%2520drug%2520FTY720%2520by%2520sphingosine%2520kinases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D47408%26epage%3D47415%26doi%3D10.1074%2Fjbc.M307687200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Albert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinterding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Hartwieg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knecht, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simeon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streiff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welzenbach, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zécri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zollinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francotte, E.</span><span> </span><span class="NLM_article-title">Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. identification, chemical proof, and biological characterization of the biologically active species and its enantiomer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5373</span><span class="NLM_x">–</span> <span class="NLM_lpage">5377</span><span class="refDoi"> DOI: 10.1021/jm050242f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050242f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtVWisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5373-5377&author=R.+Albertauthor=K.+Hinterdingauthor=V.+Brinkmannauthor=D.+Gueriniauthor=C.+Muller-Hartwiegauthor=H.+Knechtauthor=C.+Simeonauthor=M.+Streiffauthor=T.+Wagnerauthor=K.+Welzenbachauthor=F.+Z%C3%A9criauthor=M.+Zollingerauthor=N.+Cookeauthor=E.+Francotte&title=Novel+immunomodulator+FTY720+is+phosphorylated+in+rats+and+humans+to+form+a+single+stereoisomer.+identification%2C+chemical+proof%2C+and+biological+characterization+of+the+biologically+active+species+and+its+enantiomer&doi=10.1021%2Fjm050242f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Immunomodulator FTY720 Is Phosphorylated in Rats and Humans To Form a Single Stereoisomer. Identification, Chemical Proof, and Biological Characterization of the Biologically Active Species and Its Enantiomer</span></div><div class="casAuthors">Albert, Rainer; Hinterding, Klaus; Brinkmann, Volker; Guerini, Danilo; Mueller-Hartwieg, Constanze; Knecht, Helmut; Simeon, Corinne; Streiff, Markus; Wagner, Trixie; Welzenbach, Karl; Zecri, Frederic; Zollinger, Markus; Cooke, Nigel; Francotte, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5373-5377</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In vivo phosphorylation of FTY720 (1) in rats and humans resulted exclusively in the biol. active (S)-configured enantiomer, which was proven by an ex vivo o-phthaldialdehyde derivatization protocol esp. elaborated for phosphates of 1.  Starting from the prochiral amino alc. 1, racemic and enantiomerically pure phosphates of 1 were synthesized.  Pure enantiomers were obtained after purifn. of a partially protected key intermediate on an enantioselective support.  The abs. stereochem. was detd. by x-ray diffraction.  Data on human and rat studies are given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh0U1_F0bQtLVg90H21EOLACvtfcHk0li0pWQKYYw7qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtVWisr4%253D&md5=34b956ad7d7e60c2013e66320a88560e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm050242f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050242f%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DR.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DMuller-Hartwieg%26aufirst%3DC.%26aulast%3DKnecht%26aufirst%3DH.%26aulast%3DSimeon%26aufirst%3DC.%26aulast%3DStreiff%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DWelzenbach%26aufirst%3DK.%26aulast%3DZ%25C3%25A9cri%26aufirst%3DF.%26aulast%3DZollinger%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DN.%26aulast%3DFrancotte%26aufirst%3DE.%26atitle%3DNovel%2520immunomodulator%2520FTY720%2520is%2520phosphorylated%2520in%2520rats%2520and%2520humans%2520to%2520form%2520a%2520single%2520stereoisomer.%2520identification%252C%2520chemical%2520proof%252C%2520and%2520biological%2520characterization%2520of%2520the%2520biologically%2520active%2520species%2520and%2520its%2520enantiomer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5373%26epage%3D5377%26doi%3D10.1021%2Fjm050242f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartung, H.</span><span> </span><span class="NLM_article-title">Mechanism of action of oral fingolimod (FTY720) in multiple schlerosis</span> <span class="citation_source-journal">Clin. Neuropharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span><span class="refDoi"> DOI: 10.1097/WNF.0b013e3181cbf825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1097%2FWNF.0b013e3181cbf825" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=91-101&author=J.+Chunauthor=H.+Hartung&title=Mechanism+of+action+of+oral+fingolimod+%28FTY720%29+in+multiple+schlerosis&doi=10.1097%2FWNF.0b013e3181cbf825"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1097%2FWNF.0b013e3181cbf825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FWNF.0b013e3181cbf825%26sid%3Dliteratum%253Aachs%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DHartung%26aufirst%3DH.%26atitle%3DMechanism%2520of%2520action%2520of%2520oral%2520fingolimod%2520%2528FTY720%2529%2520in%2520multiple%2520schlerosis%26jtitle%3DClin.%2520Neuropharmacol.%26date%3D2010%26volume%3D33%26spage%3D91%26epage%3D101%26doi%3D10.1097%2FWNF.0b013e3181cbf825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Mandala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quackenbush, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupprecht, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">296</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span><span class="refDoi"> DOI: 10.1126/science.1070238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1126%2Fscience.1070238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=11923495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=346-349&author=S.+Mandalaauthor=R.+Hajduauthor=J.+Bergstromauthor=E.+Quackenbushauthor=J.+Xieauthor=J.+Milliganauthor=R.+Thorntonauthor=G.-J.+Sheiauthor=D.+Cardauthor=C.+A.+Keohaneauthor=M.+Rosenbachauthor=J.+Haleauthor=C.+L.+Lynchauthor=K.+Rupprechtauthor=W.+Parsonsauthor=H.+Rosen&title=Alteration+of+lymphocyte+trafficking+by+sphingosine-1-phosphate+receptor+agonists&doi=10.1126%2Fscience.1070238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</span></div><div class="casAuthors">Mandala, Suzanne; Hajdu, Richard; Bergstrom, James; Quackenbush, Elizabeth; Xie, Jenny; Milligan, James; Thornton, Rosemary; Shei, Gan-Ju; Card, Deborah; Keohane, Carolann; Rosenbach, Mark; Hale, Jeffrey; Lynch, Christopher L.; Rupprecht, Kathleen; Parsons, William; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5566</span>),
    <span class="NLM_cas:pages">346-349</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Blood lymphocyte nos., essential for the development of efficient immune responses, are maintained by recirculation through secondary Lymphoid organs.  We show that lymphocyte trafficking is altered by the lysophospholipid sphingosine-1-phosphate (S1P) and by a phosphoryl metabolite of the immunosuppressive agent FTY720.  Both species were high-affinity agonists of at least four of the five S1P receptors.  These agonists produce lymphopenia in blood and thoracic duct lymph by sequestration of lymphocytes in lymph nodes, but not spleen.  S1P receptor agonists induced emptying of lymphoid sinuses by retention of lymphocytes on the abluminal side of sinus-lining endothelium and inhibition of egress into lymph.  Inhibition of lymphocyte recirculation by activation of S1P receptors may result in therapeutically useful immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPvwG_lLsA8LVg90H21EOLACvtfcHk0lhpXOBdl_j3pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D&md5=b57cbcffe41d144e701dbd42459cf38a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1070238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1070238%26sid%3Dliteratum%253Aachs%26aulast%3DMandala%26aufirst%3DS.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DQuackenbush%26aufirst%3DE.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DMilligan%26aufirst%3DJ.%26aulast%3DThornton%26aufirst%3DR.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DRupprecht%26aufirst%3DK.%26aulast%3DParsons%26aufirst%3DW.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DAlteration%2520of%2520lymphocyte%2520trafficking%2520by%2520sphingosine-1-phosphate%2520receptor%2520agonists%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D346%26epage%3D349%26doi%3D10.1126%2Fscience.1070238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hof, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruns, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prieschl, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumruker, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiestand, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zollinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, K. R.</span><span> </span><span class="NLM_article-title">The immune modulator FTY720 targets sphingosine 1-phosphate receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">21453</span><span class="NLM_x">–</span> <span class="NLM_lpage">21457</span><span class="refDoi"> DOI: 10.1074/jbc.C200176200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1074%2Fjbc.C200176200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=11967257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD38Xkslyqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=21453-21457&author=V.+Brinkmannauthor=M.+D.+Davisauthor=C.+E.+Heiseauthor=R.+Albertauthor=S.+Cottensauthor=R.+Hofauthor=C.+Brunsauthor=E.+Prieschlauthor=T.+Baumrukerauthor=P.+Hiestandauthor=C.+A.+Fosterauthor=M.+Zollingerauthor=K.+R.+Lynch&title=The+immune+modulator+FTY720+targets+sphingosine+1-phosphate+receptors&doi=10.1074%2Fjbc.C200176200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The immune modulator FTY720 targets sphingosine 1-phosphate receptors</span></div><div class="casAuthors">Brinkmann, Volker; Davis, Michael D.; Heise, Christopher E.; Albert, Rainer; Cottens, Sylvain; Hof, Robert; Bruns, Christian; Prieschl, Eva; Baumruker, Thomas; Hiestand, Peter; Foster, Carolyn A.; Zollinger, Markus; Lynch, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">21453-21457</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Immunosuppressant drugs such as cyclosporin have allowed widespread organ transplantation, but their utility remains limited by toxicities, and they are ineffective in chronic management of autoimmune diseases such as multiple sclerosis.  In contrast, the immune modulating drug FTY720 is efficacious in a variety of transplant and autoimmune models without inducing a generalized immunosuppressed state and is effective in human kidney transplantation.  FTY720 elicits a lymphopenia resulting from a reversible redistribution of lymphocytes from circulation to secondary lymphoid tissues by unknown mechanisms.  Using FTY720 and several analogs, we show now that FTY720 is phosphorylated by sphingosine kinase; the phosphorylated compd. is a potent agonist at four sphingosine 1-phosphate receptors and represents the therapeutic principle in a rodent model of multiple sclerosis.  Our results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_6zyZnHOYNbVg90H21EOLACvtfcHk0lhpXOBdl_j3pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xkslyqtb4%253D&md5=b59856fffa9ebae7fb8182d18daa025f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C200176200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C200176200%26sid%3Dliteratum%253Aachs%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DM.%2BD.%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DAlbert%26aufirst%3DR.%26aulast%3DCottens%26aufirst%3DS.%26aulast%3DHof%26aufirst%3DR.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DPrieschl%26aufirst%3DE.%26aulast%3DBaumruker%26aufirst%3DT.%26aulast%3DHiestand%26aufirst%3DP.%26aulast%3DFoster%26aufirst%3DC.%2BA.%26aulast%3DZollinger%26aufirst%3DM.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26atitle%3DThe%2520immune%2520modulator%2520FTY720%2520targets%2520sphingosine%25201-phosphate%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D21453%26epage%3D21457%26doi%3D10.1074%2Fjbc.C200176200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Cyster, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, S. R.</span><span> </span><span class="NLM_article-title">Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs</span> <span class="citation_source-journal">Annu. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span><span class="refDoi"> DOI: 10.1146/annurev-immunol-020711-075011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1146%2Fannurev-immunol-020711-075011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=22149932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=69-94&author=J.+G.+Cysterauthor=S.+R.+Schwab&title=Sphingosine-1-phosphate+and+lymphocyte+egress+from+lymphoid+organs&doi=10.1146%2Fannurev-immunol-020711-075011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs</span></div><div class="casAuthors">Cyster, Jason G.; Schwab, Susan R.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-94</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Much has been learned about how cells enter lymphoid tissues.  But how do they leave.  Sphingosine-1-phosphate (S1P) has emerged over the past decade as a central mediator of lymphocyte egress.  In this review, we summarize the current understanding of how S1P promotes exit from the secondary lymphoid organs and thymus.  We review what is known about addnl. requirements for emigration and summarize the mostly distinct requirements for exit from the bone marrow.  Egress from lymphoid organs is limited during immune responses, and we examine how this regulation works.  There is accumulating evidence for roles of S1P in directing immune cell behavior within lymphoid tissues.  How such actions can fit together with the egress-promoting role of S1P is discussed.  Finally, we examine current understanding of how FTY720, a drug that targets S1P receptors and is approved for the treatment of multiple sclerosis, causes immune suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhvMroRvgkZrVg90H21EOLACvtfcHk0lhpXOBdl_j3pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKmtLY%253D&md5=c9f9ef63f2248594b0f9ce4d06024bba</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev-immunol-020711-075011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-immunol-020711-075011%26sid%3Dliteratum%253Aachs%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26aulast%3DSchwab%26aufirst%3DS.%2BR.%26atitle%3DSphingosine-1-phosphate%2520and%2520lymphocyte%2520egress%2520from%2520lymphoid%2520organs%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2012%26volume%3D30%26spage%3D69%26epage%3D94%26doi%3D10.1146%2Fannurev-immunol-020711-075011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vendataraman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaud, J.</span><span> </span><span class="NLM_article-title">The vascular S1P gradient: cellular sources and biological significance</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">1781</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">482</span><span class="refDoi"> DOI: 10.1016/j.bbalip.2008.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1016%2Fj.bbalip.2008.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=18674637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKjtbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1781&publication_year=2008&pages=477-482&author=T.+Hlaauthor=K.+Vendataramanauthor=J.+Michaud&title=The+vascular+S1P+gradient%3A+cellular+sources+and+biological+significance&doi=10.1016%2Fj.bbalip.2008.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">The vascular S1P gradient-Cellular sources and biological significance</span></div><div class="casAuthors">Hla, Timothy; Venkataraman, Krishnan; Michaud, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1781</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">477-482</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P), a product of sphingomyelin metab., is enriched in the circulatory system whereas it is estd. to be much lower in interstitial fluids of tissues.  This concn. gradient, termed the vascular S1P gradient appears to form as a result of substrate availability and the action of metabolic enzymes.  S1P levels in blood and lymph are estd. to be in the μM range.  In the immune system, the S1P gradient is needed as a spatial cue for lymphocyte and hematopoietic cell trafficking.  During inflammatory reactions in which enhanced vascular permeability occurs, a burst of S1P becomes available to its receptors in the extravascular compartment, which likely contributes to the tissue reactions.  Thus, the presence of the vascular S1P gradient is thought to contribute to physiol. and pathol. conditions.  From an evolutionary perspective, S1P receptors may have co-evolved with the advent of a closed vascular system and the trafficking paradigms for hematopoietic cells to navigate in and out of the vascular system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosbyXvTWrRf7Vg90H21EOLACvtfcHk0li5LHoeueQASw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKjtbrF&md5=a9c4420dff6764f71060b18149669767</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2008.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2008.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DHla%26aufirst%3DT.%26aulast%3DVendataraman%26aufirst%3DK.%26aulast%3DMichaud%26aufirst%3DJ.%26atitle%3DThe%2520vascular%2520S1P%2520gradient%253A%2520cellular%2520sources%2520and%2520biological%2520significance%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2008%26volume%3D1781%26spage%3D477%26epage%3D482%26doi%3D10.1016%2Fj.bbalip.2008.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schwab, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cyster, J. G.</span><span> </span><span class="NLM_article-title">Finding a way out: lymphocyte egress from lymphoid organs</span> <span class="citation_source-journal">Nat. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1295</span><span class="NLM_x">–</span> <span class="NLM_lpage">1301</span><span class="refDoi"> DOI: 10.1038/ni1545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1038%2Fni1545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=18026082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlajtr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=1295-1301&author=S.+R.+Schwabauthor=J.+G.+Cyster&title=Finding+a+way+out%3A+lymphocyte+egress+from+lymphoid+organs&doi=10.1038%2Fni1545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Finding a way out: lymphocyte egress from lymphoid organs</span></div><div class="casAuthors">Schwab, Susan R.; Cyster, Jason G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1295-1301</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The egress of lymphocytes from the thymus and secondary lymphoid organs into circulatory fluids is essential for normal immune function.  The discovery that a small-mol. inhibitor of lymphocyte exit, FTY720, is a ligand for sphingosine 1-phosphate (S1P) receptors led to studies demonstrating that S1P receptor type 1 (S1P1) is needed in T cells and B cells for their egress from lymphoid organs.  S1P exists in higher concns. in blood and lymph than in lymphoid organs, and this differential is also required for lymphocyte exit.  Transcriptional and post-translational mechanisms regulate S1P1 and thus the egress of lymphocytes.  In this review we discuss the body of evidence supporting a model in which lymphocyte egress is promoted by encounter with S1P at exit sites.  We relate this model to work examg. the effects of S1P receptor agonists on endothelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWY-Rk111SmLVg90H21EOLACvtfcHk0li5LHoeueQASw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlajtr7J&md5=ccf7ef06130d3ebd218707ac92618f36</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1038%2Fni1545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1545%26sid%3Dliteratum%253Aachs%26aulast%3DSchwab%26aufirst%3DS.%2BR.%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26atitle%3DFinding%2520a%2520way%2520out%253A%2520lymphocyte%2520egress%2520from%2520lymphoid%2520organs%26jtitle%3DNat.%2520Immunol.%26date%3D2007%26volume%3D8%26spage%3D1295%26epage%3D1301%26doi%3D10.1038%2Fni1545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetzl, E. J.</span><span> </span><span class="NLM_article-title">Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">560</span><span class="NLM_x">–</span> <span class="NLM_lpage">570</span><span class="refDoi"> DOI: 10.1038/nri1650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1038%2Fnri1650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=15999095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsl2itr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=560-570&author=H.+Rosenauthor=E.+J.+Goetzl&title=Sphingosine+1-phosphate+and+its+receptors%3A+an+autocrine+and+paracrine+network&doi=10.1038%2Fnri1650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network</span></div><div class="casAuthors">Rosen, Hugh; Goetzl, Edward J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">560-570</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P) is a biol. active lysophospholipid that transmits signals through a family of G-protein-coupled receptors to control cellular differentiation and survival, as well as the vital functions of several types of immune cell.  In this Review article, the authors discuss recent results that indicate that S1P and its receptors are required for the emigration of thymocytes from the thymus, the trafficking of lymphocytes in secondary lymphoid organs and the migration of B cells into splenic follicles.  In an autocrine manner, through interactions with different G-protein-coupled receptors, S1P also enhances optimal mast-cell migration and release of pro-inflammatory mediators in allergic reactions.  S1P-S1P-receptor regulatory systems might therefore be novel targets for the therapy of diverse immunol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6-Zo0R14YILVg90H21EOLACvtfcHk0li5LHoeueQASw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsl2itr4%253D&md5=b680f6c9e29d407579ab7f056209d853</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1038%2Fnri1650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1650%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DGoetzl%26aufirst%3DE.%2BJ.%26atitle%3DSphingosine%25201-phosphate%2520and%2520its%2520receptors%253A%2520an%2520autocrine%2520and%2520paracrine%2520network%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2005%26volume%3D5%26spage%3D560%26epage%3D570%26doi%3D10.1038%2Fnri1650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Pappu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelissen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regard, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camerer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Y.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cyster, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coughlin, S. R.</span><span> </span><span class="NLM_article-title">Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span><span class="refDoi"> DOI: 10.1126/science.1139221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1126%2Fscience.1139221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=17363629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktVeku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=295-298&author=R.+Pappuauthor=S.+R.+Schwabauthor=I.+Cornelissenauthor=J.+P.+Pereiraauthor=J.+B.+Regardauthor=Y.+Xuauthor=E.+Camererauthor=Y.-W.+Zhengauthor=Y.+Huangauthor=J.+G.+Cysterauthor=S.+R.+Coughlin&title=Promotion+of+lymphocyte+egress+into+blood+and+lymph+by+distinct+sources+of+sphingosine-1-phosphate&doi=10.1126%2Fscience.1139221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate</span></div><div class="casAuthors">Pappu, Rajita; Schwab, Susan R.; Cornelissen, Ivo; Pereira, Joao P.; Regard, Jean B.; Xu, Ying; Camerer, Eric; Zheng, Yao-Wu; Huang, Yong; Cyster, Jason G.; Coughlin, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5822</span>),
    <span class="NLM_cas:pages">295-298</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Lymphocytes require sphingosine-1-phosphate (S1P) receptor-1 to exit lymphoid organs, but the source(s) of extracellular S1P and whether S1P directly promotes egress are unknown.  By using mice in which the two kinases that generate S1P were conditionally ablated, we find that plasma S1P is mainly hematopoietic in origin, with erythrocytes a major contributor, whereas lymph S1P is from a distinct radiation-resistant source.  Lymphocyte egress from thymus and secondary lymphoid organs was markedly reduced in kinase-deficient mice.  Restoration of S1P to plasma rescued egress to blood but not lymph, and the rescue required lymphocyte expression of S1P-receptor-1.  Thus, sep. sources provide S1P to plasma and lymph to help lymphocytes exit the low-S1P environment of lymphoid organs.  Disruption of compartmentalized S1P signaling is a plausible mechanism by which S1P-receptor-1 agonists function as immunosuppressives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMH4WVYwTIX7Vg90H21EOLACvtfcHk0ljFMO0sr7CvrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktVeku70%253D&md5=6c658296c3b1d34543c193987092506b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.1139221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1139221%26sid%3Dliteratum%253Aachs%26aulast%3DPappu%26aufirst%3DR.%26aulast%3DSchwab%26aufirst%3DS.%2BR.%26aulast%3DCornelissen%26aufirst%3DI.%26aulast%3DPereira%26aufirst%3DJ.%2BP.%26aulast%3DRegard%26aufirst%3DJ.%2BB.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DCamerer%26aufirst%3DE.%26aulast%3DZheng%26aufirst%3DY.-W.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26aulast%3DCoughlin%26aufirst%3DS.%2BR.%26atitle%3DPromotion%2520of%2520lymphocyte%2520egress%2520into%2520blood%2520and%2520lymph%2520by%2520distinct%2520sources%2520of%2520sphingosine-1-phosphate%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D295%26epage%3D298%26doi%3D10.1126%2Fscience.1139221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Singer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tobias, K.</span><span> </span><span class="NLM_article-title">Oral fingolomid for the treatment of patients with relapsing forms of multiple sclerosis</span> <span class="citation_source-journal">Int. J. Clin. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">887</span><span class="NLM_x">–</span> <span class="NLM_lpage">895</span><span class="refDoi"> DOI: 10.1111/j.1742-1241.2011.02721.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1111%2Fj.1742-1241.2011.02721.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=21679286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsV2hsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2011&pages=887-895&author=B.+Singerauthor=A.+P.+Rossauthor=K.+Tobias&title=Oral+fingolomid+for+the+treatment+of+patients+with+relapsing+forms+of+multiple+sclerosis&doi=10.1111%2Fj.1742-1241.2011.02721.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis</span></div><div class="casAuthors">Singer, B.; Ross, A. P.; Tobias, K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">887-895</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1742-1241</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Fingolimod, a sphingosine 1-phosphate receptor modulator, is the first oral treatment approved by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (MS).  The aim of this review was to provide a concise, comprehensive overview of the clin. relevant mechanism of action, efficacy and safety information available for fingolimod.  Key data were derived from two international, Phase III, double-blind, randomised trials (TRANSFORMS and FREEDOMS) performed over 12 and 24 mo, resp., which evaluated fingolimod 0.5 and 1.25 mg daily in 1703 patients with relapsing forms of MS.  In TRANSFORMS, there was a 52% redn. in the annualised relapse rate (ARR) with fingolimod 0.5 mg vs. 30 μg i.m. interferon beta-1a (0.16 vs. 0.33; p < 0.001) at 1 yr.  In FREEDOMS, there was a 55% decrease in ARR at 2 years with fingolimod 0.5 mg vs. placebo (0.18 vs. 0.40; p < 0.001).  Risk of disability progression, confirmed at 3 mo, was also reduced by 30% over the 2-yr study period with fingolimod vs. placebo (p = 0.02).  Significantly fewer new or enlarged lesions on T2-weighted images were seen in both studies (TRANSFORMS, p = 0.002 vs. interferon beta-1a at 1 yr; FREEDOMS, p < 0.001 vs. placebo at 2 years).  Overall, fingolimod 0.5 mg was well tolerated by patients.  Transient, generally asymptomatic bradycardia and infrequent atrioventricular block were seen with the administration of the first dose.  Macular edema and serious infections occurred infrequently.  Reversible, asymptomatic elevations of liver enzymes could also occur.  As the first approved oral disease-modifying treatment, fingolimod offers patients a convenient alternative to regular self-injection for the treatment of relapsing forms of MS.  In addn. to high efficacy with a relatively acceptable safety profile, fingolimod provides a therapy with a new mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVKs1Biiz177Vg90H21EOLACvtfcHk0ljFMO0sr7CvrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsV2hsbY%253D&md5=8be8ad56fc253ddccb59597c041b9ff8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-1241.2011.02721.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-1241.2011.02721.x%26sid%3Dliteratum%253Aachs%26aulast%3DSinger%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DA.%2BP.%26aulast%3DTobias%26aufirst%3DK.%26atitle%3DOral%2520fingolomid%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520relapsing%2520forms%2520of%2520multiple%2520sclerosis%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2011%26volume%3D65%26spage%3D887%26epage%3D895%26doi%3D10.1111%2Fj.1742-1241.2011.02721.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Sanchez, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada-Hernandez, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paik, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, M.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venkataraman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claffey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span> </span><span class="NLM_article-title">Phosphorylation and action of the immunomodulatory FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">47281</span><span class="NLM_x">–</span> <span class="NLM_lpage">47290</span><span class="refDoi"> DOI: 10.1074/jbc.M306896200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1074%2Fjbc.M306896200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=47281-47290&author=T.+Sanchezauthor=T.+Estrada-Hernandezauthor=J.-H.+Paikauthor=M.-T.+Wuauthor=K.+Venkataramanauthor=V.+Brinkmannauthor=K.+Claffeyauthor=T.+Hla&title=Phosphorylation+and+action+of+the+immunomodulatory+FTY720+inhibits+vascular+endothelial+cell+growth+factor-induced+vascular+permeability&doi=10.1074%2Fjbc.M306896200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M306896200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M306896200%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DT.%26aulast%3DEstrada-Hernandez%26aufirst%3DT.%26aulast%3DPaik%26aufirst%3DJ.-H.%26aulast%3DWu%26aufirst%3DM.-T.%26aulast%3DVenkataraman%26aufirst%3DK.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DClaffey%26aufirst%3DK.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DPhosphorylation%2520and%2520action%2520of%2520the%2520immunomodulatory%2520FTY720%2520inhibits%2520vascular%2520endothelial%2520cell%2520growth%2520factor-induced%2520vascular%2520permeability%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D47281%26epage%3D47290%26doi%3D10.1074%2Fjbc.M306896200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Kappos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montalban, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polman, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korn, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radue, E. W.</span><span> </span><span class="NLM_article-title">Oral fingolimod (FTY720) for relapsing multiple sclerosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">1124</span><span class="NLM_x">–</span> <span class="NLM_lpage">1140</span><span class="refDoi"> DOI: 10.1056/NEJMoa052643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1056%2FNEJMoa052643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=16971719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsFKku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=1124-1140&author=L.+Kapposauthor=J.+Antelauthor=G.+Comiauthor=X.+Montalbanauthor=P.+O%E2%80%99Connorauthor=C.+H.+Polmanauthor=T.+Haasauthor=A.+A.+Kornauthor=G.+Karlssonauthor=E.+W.+Radue&title=Oral+fingolimod+%28FTY720%29+for+relapsing+multiple+sclerosis&doi=10.1056%2FNEJMoa052643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Oral fingolimod (FTY720) for relapsing multiple sclerosis</span></div><div class="casAuthors">Kappos, Ludwig; Antel, Jack; Comi, Giancarlo; Montalban, Xavier; O'Connor, Paul; Polman, Chris H.; Haas, Tomas; Korn, Alexander A.; Karlsson, Goeril; Radue, Ernst W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1124-1140</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis.  We randomly assigned 281 patients to receive oral fingolimod, at a dose of 1.25 mg or 5.0 mg, or a placebo once daily, and we followed these patients for 6 mo with magnetic resonance imaging (MRI) and clin. evaluations (core study, months 0 to 6).  The primary end point was the total no. of gadolinium-enhanced lesions recorded on T1-weighted MRI at monthly intervals for 6 mo.  In an extension study in which the investigators and patients remained unaware of the dose assignments (months 7 to 12), patients who received placebo underwent randomization again to one of the fingolimod doses.  A total of 255 patients completed the core study.  The median total no. of gadolinium-enhanced lesions on MRI was lower with 1.25 mg of fingolimod (1 lesion, P < 0.001) and 5.0 mg of fingolimod (3 lesions, P = 0.006) than with placebo (5 lesions).  The annualized relapse rate was 0.77 in the placebo group, as compared with 0.35 in the group given 1.25 mg of fingolimod (P = 0.009) and 0.36 in the group given 5.0 mg of fingolimod (P = 0.01).  For the 227 patients who completed the extension study, the no. of gadolinium-enhanced lesions and relapse rates remained low in the groups that received continuous fingolimod, and both measures decreased in patients who switched from placebo to fingolimod.  Adverse events included nasopharyngitis, dyspnea, headache, diarrhea, and nausea.  Clin. asymptomatic elevations of alanine aminotransferase levels were more frequent with fingolimod (10 to 12%, vs. 1% in the placebo group).  One case of the posterior reversible encephalopathy syndrome occurred in the 5.0-mg group.  Fingolimod was also assocd. with an initial redn. in the heart rate and a modest decrease in the forced expiratory vol. in 1 s.  In this proof-of-concept study, fingolimod reduced the no. of lesions detected on MRI and clin. disease activity in patients with multiple sclerosis.  Evaluation in larger, longer-term studies is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA4MSvDIuvV7Vg90H21EOLACvtfcHk0ljFMO0sr7CvrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsFKku78%253D&md5=2a84e8f5fb92091782406da9dcbc1453</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa052643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa052643%26sid%3Dliteratum%253Aachs%26aulast%3DKappos%26aufirst%3DL.%26aulast%3DAntel%26aufirst%3DJ.%26aulast%3DComi%26aufirst%3DG.%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DP.%26aulast%3DPolman%26aufirst%3DC.%2BH.%26aulast%3DHaas%26aufirst%3DT.%26aulast%3DKorn%26aufirst%3DA.%2BA.%26aulast%3DKarlsson%26aufirst%3DG.%26aulast%3DRadue%26aufirst%3DE.%2BW.%26atitle%3DOral%2520fingolimod%2520%2528FTY720%2529%2520for%2520relapsing%2520multiple%2520sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D1124%26epage%3D1140%26doi%3D10.1056%2FNEJMoa052643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Sanna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfonso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Sphingosine 1-phosphate (S1P) receptor subtypes S1P<sub>1</sub> and S1P<sub>3</sub>, respectively, regulate lymphocyte recirculation and heart rate</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">13839</span><span class="NLM_x">–</span> <span class="NLM_lpage">13848</span><span class="refDoi"> DOI: 10.1074/jbc.M311743200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1074%2Fjbc.M311743200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=14732717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1elsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=13839-13848&author=M.+G.+Sannaauthor=J.+Liaoauthor=E.+Joauthor=C.+Alfonsoauthor=M.-Y.+Ahnauthor=M.+S.+Petersonauthor=B.+Webbauthor=S.+Lefebvreauthor=J.+Chunauthor=N.+Grayauthor=H.+Rosen&title=Sphingosine+1-phosphate+%28S1P%29+receptor+subtypes+S1P1+and+S1P3%2C+respectively%2C+regulate+lymphocyte+recirculation+and+heart+rate&doi=10.1074%2Fjbc.M311743200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate</span></div><div class="casAuthors">Sanna, M. Germana; Liao, Jiayu; Jo, Euijung; Alfonso, Christopher; Ahn, Min-Young; Peterson, Melissa S.; Webb, Bill; Lefebvre, Sophie; Chun, Jerold; Gray, Nathanael; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">13839-13848</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) influences heart rate, coronary artery caliber, endothelial integrity, and lymphocyte recirculation through five related high affinity G-protein-coupled receptors.  Inhibition of lymphocyte recirculation by non-selective S1P receptor agonists produces clin. immunosuppression preventing transplant rejection but is assocd. with transient bradycardia.  Understanding the contribution of individual receptors has been limited by the embryonic lethality of the S1P1 knock-out and the unavailability of selective agonists or antagonists.  A potent, S1P1-receptor selective agonist structurally unrelated to S1P was found to activate multiple signals triggered by S1P, including guanosine 5'-3-O-(thio)triphosphate binding, calcium flux, Akt and ERK1/2 phosphorylation, and stimulation of migration of S1P1- but not S1P3-expressing cells in vitro.  The agonist also alters lymphocyte trafficking in vivo.  Use of selective agonism together with deletant mice lacking S1P3 receptor reveals that agonism of S1P1 receptor alone is sufficient to control lymphocyte recirculation.  Moreover, S1P1 receptor agonist plasma levels are causally assocd. with induction and maintenance of lymphopenia.  S1P3, and not S1P1, is directly implicated in sinus bradycardia.  The sustained bradycardia induced by S1P receptor non-selective immunosuppressive agonists in wild-type mice is abolished in S1P3-/- mice, whereas S1P1-selective agonist does not produce bradycardia.  Sepn. of receptor subtype usage for control of lymphocyte recirculation and heart rate may allow the identification of selective immunosuppressive S1P1 receptor agonists with an enhanced therapeutic window.  S1P1-selective agonists will be of broad utility in understanding cell functions in vitro, and vascular physiol. in vivo, and the success of the chem. approach for S1P1 suggests that selective tools for the resoln. of function across this broad lipid receptor family are now possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoztTB58pXPA7Vg90H21EOLACvtfcHk0lh2wXDVoqUtWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1elsb8%253D&md5=5b720513c7c550bfdf55e5344efc8f16</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M311743200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M311743200%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DM.%2BG.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DAlfonso%26aufirst%3DC.%26aulast%3DAhn%26aufirst%3DM.-Y.%26aulast%3DPeterson%26aufirst%3DM.%2BS.%26aulast%3DWebb%26aufirst%3DB.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DSphingosine%25201-phosphate%2520%2528S1P%2529%2520receptor%2520subtypes%2520S1P1%2520and%2520S1P3%252C%2520respectively%252C%2520regulate%2520lymphocyte%2520recirculation%2520and%2520heart%2520rate%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D13839%26epage%3D13848%26doi%3D10.1074%2Fjbc.M311743200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Forrest, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, I. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">309</span><span class="NLM_x">, </span> <span class="NLM_fpage">758</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span><span class="refDoi"> DOI: 10.1124/jpet.103.062828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1124%2Fjpet.103.062828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=14747617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1ygsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2004&pages=758-768&author=M.+Forrestauthor=S.-Y.+Sunauthor=R.+Hajduauthor=J.+Bergstromauthor=D.+Cardauthor=G.+Dohertyauthor=J.+Haleauthor=C.+Keohaneauthor=C.+Meyersauthor=J.+Milliganauthor=S.+Millsauthor=N.+Nomuraauthor=H.+Rosenauthor=M.+Rosenbachauthor=G.-J.+Sheiauthor=I.+I.+Singerauthor=M.+Tianauthor=S.+Westauthor=V.+Whiteauthor=J.+Xieauthor=R.+L.+Proiaauthor=S.+Mandala&title=Immune+cell+regulation+and+cardiovascular+effects+of+sphingosine+1-phosphate+receptor+agonists+in+rodents+are+mediated+via+distinct+receptor+subtypes&doi=10.1124%2Fjpet.103.062828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes</span></div><div class="casAuthors">Forrest, M.; Sun, S.-Y.; Hajdu, R.; Bergstrom, J.; Card, D.; Doherty, G.; Hale, J.; Keohane, C.; Meyers, C.; Milligan, J.; Mills, S.; Nomura, N.; Rosen, H.; Rosenbach, M.; Shei, G.-J.; Singer, I. I.; Tian, M.; West, S.; White, V.; Xie, J.; Proia, R. L.; Mandala, S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">758-768</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) is a bioactive lysolipid with pleiotropic functions mediated through a family of G protein-coupled receptors, S1P1,2,3,4,5.  Physiol. effects of S1P receptor agonists include regulation of cardiovascular function and immunosuppression via redistribution of lymphocytes from blood to secondary lymphoid organs.  The phosphorylated metabolite of the immunosuppressant agent FTY720 (2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol) and other phosphonate analogs with differential receptor selectivity were investigated.  No significant species differences in compd. potency or rank order of activity on receptors cloned from human, murine, and rat sources were obsd.  All synthetic analogs were high-affinity agonists on S1P1, with IC50 values for ligand binding between 0.3 and 14 nM.  The correlation between S1P1 receptor activation and the ED50 for lymphocyte redn. was highly significant (p < 0.001) and lower for the other receptors.  In contrast to S1P1-mediated effects on lymphocyte recirculation, three lines of evidence link S1P3 receptor activity with acute toxicity and cardiovascular regulation: compd. potency on S1P3 correlated with toxicity and bradycardia; the shift in potency of phosphorylated-FTY720 for inducing lymphopenia vs. bradycardia and hypertension was consistent with affinity for S1P1 relative to S1P3; and toxicity, bradycardia, and hypertension were absent in S1P3-/- mice.  Blood pressure effects of agonists in anesthetized rats were complex, whereas hypertension was the predominant effect in conscious rats and mice.  Immunolocalization of S1P3 in rodent heart revealed abundant expression on myocytes and perivascular smooth muscle cells consistent with regulation of bradycardia and hypertension, whereas S1P1 expression was restricted to the vascular endothelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKo2vpih4eoLVg90H21EOLACvtfcHk0lh2wXDVoqUtWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1ygsrg%253D&md5=27183d4991bffbc5d2b88174b1386d5a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.062828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.062828%26sid%3Dliteratum%253Aachs%26aulast%3DForrest%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DS.-Y.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DDoherty%26aufirst%3DG.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DKeohane%26aufirst%3DC.%26aulast%3DMeyers%26aufirst%3DC.%26aulast%3DMilligan%26aufirst%3DJ.%26aulast%3DMills%26aufirst%3DS.%26aulast%3DNomura%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DSinger%26aufirst%3DI.%2BI.%26aulast%3DTian%26aufirst%3DM.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DV.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DProia%26aufirst%3DR.%2BL.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DImmune%2520cell%2520regulation%2520and%2520cardiovascular%2520effects%2520of%2520sphingosine%25201-phosphate%2520receptor%2520agonists%2520in%2520rodents%2520are%2520mediated%2520via%2520distinct%2520receptor%2520subtypes%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D309%26spage%3D758%26epage%3D768%26doi%3D10.1124%2Fjpet.103.062828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hale, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrebet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parent, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quackenbush, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickham, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P<sub>1</sub>) receptor agonists with exceptional selectivity against S1P<sub>2</sub> and S1P<sub>3</sub></span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6169</span><span class="NLM_x">–</span> <span class="NLM_lpage">6173</span><span class="refDoi"> DOI: 10.1021/jm0503244</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0503244" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6169-6173&author=Z.+Liauthor=W.+Chenauthor=J.+J.+Haleauthor=C.+L.+Lynchauthor=S.+G.+Millsauthor=R.+Hajduauthor=C.+A.+Keohaneauthor=M.+J.+Rosenbachauthor=J.+A.+Milliganauthor=G.-J.+Sheiauthor=G.+Chrebetauthor=S.+A.+Parentauthor=J.+Bergstromauthor=D.+Cardauthor=M.+Forrestauthor=E.+J.+Quackenbushauthor=L.+A.+Wickhamauthor=H.+Vargasauthor=R.+M.+Evansauthor=H.+Rosenauthor=S.+Mandala&title=Discovery+of+potent+3%2C5-diphenyl-1%2C2%2C4-oxadiazole+sphingosine-1-phosphate-1+%28S1P1%29+receptor+agonists+with+exceptional+selectivity+against+S1P2+and+S1P3&doi=10.1021%2Fjm0503244"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm0503244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0503244%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%2BJ.%26aulast%3DMilligan%26aufirst%3DJ.%2BA.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DChrebet%26aufirst%3DG.%26aulast%3DParent%26aufirst%3DS.%2BA.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DForrest%26aufirst%3DM.%26aulast%3DQuackenbush%26aufirst%3DE.%2BJ.%26aulast%3DWickham%26aufirst%3DL.%2BA.%26aulast%3DVargas%26aufirst%3DH.%26aulast%3DEvans%26aufirst%3DR.%2BM.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520potent%25203%252C5-diphenyl-1%252C2%252C4-oxadiazole%2520sphingosine-1-phosphate-1%2520%2528S1P1%2529%2520receptor%2520agonists%2520with%2520exceptional%2520selectivity%2520against%2520S1P2%2520and%2520S1P3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6169%26epage%3D6173%26doi%3D10.1021%2Fjm0503244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Buzard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrader, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moody, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span> </span><span class="NLM_article-title">Design and synthesis of new trycyclic indoles as potent modulators of the S1P1 receptor</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">659</span><span class="NLM_x">–</span> <span class="NLM_lpage">663</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.11.089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1016%2Fj.bmcl.2014.11.089" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=659-663&author=D.+J.+Buzardauthor=O.+Schraderauthor=X.+Zhuauthor=J.+Lehmannauthor=B.+Johnsonauthor=M.+Kasemauthor=S.-H.+Kimauthor=A.+Kawasakiauthor=L.+Lopezauthor=J.+Moodyauthor=S.+Hanauthor=Y.+Gaoauthor=J.+Edwardsauthor=J.+Bardenauthor=J.+Thatteauthor=J.+Gatlinauthor=R.+M.+Jones&title=Design+and+synthesis+of+new+trycyclic+indoles+as+potent+modulators+of+the+S1P1+receptor&doi=10.1016%2Fj.bmcl.2014.11.089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.11.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.11.089%26sid%3Dliteratum%253Aachs%26aulast%3DBuzard%26aufirst%3DD.%2BJ.%26aulast%3DSchrader%26aufirst%3DO.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLehmann%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DB.%26aulast%3DKasem%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DKawasaki%26aufirst%3DA.%26aulast%3DLopez%26aufirst%3DL.%26aulast%3DMoody%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DEdwards%26aufirst%3DJ.%26aulast%3DBarden%26aufirst%3DJ.%26aulast%3DThatte%26aufirst%3DJ.%26aulast%3DGatlin%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DR.%2BM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520new%2520trycyclic%2520indoles%2520as%2520potent%2520modulators%2520of%2520the%2520S1P1%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D659%26epage%3D663%26doi%3D10.1016%2Fj.bmcl.2014.11.089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Buzard, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moody, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrader, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoresen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gharbaoui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sengupta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvano, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Usmani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadeque, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopher, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatte, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whelan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Shamma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaidarov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anthony, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unett, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackburn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. M.</span><span> </span><span class="NLM_article-title">(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acids as S1P1 functional agonists</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1334</span><span class="NLM_x">–</span> <span class="NLM_lpage">1339</span><span class="refDoi"> DOI: 10.1021/ml500422m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500422m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1334-1339&author=D.+J.+Buzardauthor=L.+Lopezauthor=J.+Moodyauthor=A.+Kawasakiauthor=T.+O.+Schraderauthor=M.+Kasemauthor=B.+Johnsonauthor=X.+Zhuauthor=L.+Thoresenauthor=S.+H.+Kimauthor=T.+Gharbaouiauthor=D.+Senguptaauthor=L.+Calvanoauthor=A.+Krishnanauthor=Y.+Gaoauthor=G.+Sempleauthor=J.+Edwardsauthor=J.+Bardenauthor=M.+Morganauthor=K.+Usmaniauthor=C.+Chenauthor=A.+Sadequeauthor=W.+Chenauthor=R.+J.+Christopherauthor=J.+Thatteauthor=L.+Fuauthor=M.+Solomonauthor=K.+Whelanauthor=H.+Al-Shammaauthor=J.+Gatlinauthor=I.+Gaidarovauthor=T.+Anthonyauthor=M.+Leauthor=D.+J.+Unettauthor=S.+Stirnauthor=A.+Blackburnauthor=D.+P.+Behanauthor=R.+M.+Jones&title=%287-Benzyloxy-2%2C3-dihydro-1H-pyrrolo%5B1%2C2-a%5Dindol-1-yl%29acetic+acids+as+S1P1+functional+agonists&doi=10.1021%2Fml500422m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1021%2Fml500422m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500422m%26sid%3Dliteratum%253Aachs%26aulast%3DBuzard%26aufirst%3DD.%2BJ.%26aulast%3DLopez%26aufirst%3DL.%26aulast%3DMoody%26aufirst%3DJ.%26aulast%3DKawasaki%26aufirst%3DA.%26aulast%3DSchrader%26aufirst%3DT.%2BO.%26aulast%3DKasem%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DThoresen%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DGharbaoui%26aufirst%3DT.%26aulast%3DSengupta%26aufirst%3DD.%26aulast%3DCalvano%26aufirst%3DL.%26aulast%3DKrishnan%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DSemple%26aufirst%3DG.%26aulast%3DEdwards%26aufirst%3DJ.%26aulast%3DBarden%26aufirst%3DJ.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DUsmani%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DSadeque%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DChristopher%26aufirst%3DR.%2BJ.%26aulast%3DThatte%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DSolomon%26aufirst%3DM.%26aulast%3DWhelan%26aufirst%3DK.%26aulast%3DAl-Shamma%26aufirst%3DH.%26aulast%3DGatlin%26aufirst%3DJ.%26aulast%3DGaidarov%26aufirst%3DI.%26aulast%3DAnthony%26aufirst%3DT.%26aulast%3DLe%26aufirst%3DM.%26aulast%3DUnett%26aufirst%3DD.%2BJ.%26aulast%3DStirn%26aufirst%3DS.%26aulast%3DBlackburn%26aufirst%3DA.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DJones%26aufirst%3DR.%2BM.%26atitle%3D%25287-Benzyloxy-2%252C3-dihydro-1H-pyrrolo%255B1%252C2-a%255Dindol-1-yl%2529acetic%2520acids%2520as%2520S1P1%2520functional%2520agonists%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D1334%26epage%3D1339%26doi%3D10.1021%2Fml500422m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Skidmore, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redshaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeting, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurst, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cridland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vesey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wall, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myatt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giblin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpott, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bit, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haynes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witherington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demont, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heightman, T. D.</span><span> </span><span class="NLM_article-title">Optimization of sphingosine-1-phosphate receptor agonists: effects of acidic, basic, and zwitterionic chemotypes on pharmacokinetic and pharmacodynamics profiles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">10424</span><span class="NLM_x">–</span> <span class="NLM_lpage">10442</span><span class="refDoi"> DOI: 10.1021/jm5010336</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5010336" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10424-10442&author=J.+Skidmoreauthor=J.+Heerauthor=C.+N.+Johnsonauthor=D.+Nortonauthor=S.+Redshawauthor=J.+Sweetingauthor=D.+Hurstauthor=A.+Cridlandauthor=D.+Veseyauthor=I.+Wallauthor=M.+Ahmedauthor=D.+Riversauthor=J.+Myattauthor=G.+Giblinauthor=K.+Philpottauthor=U.+Kumarauthor=A.+Stevensauthor=R.+A.+Bitauthor=A.+Haynesauthor=S.+Taylorauthor=R.+Watsonauthor=J.+Witheringtonauthor=E.+Demontauthor=T.+D.+Heightman&title=Optimization+of+sphingosine-1-phosphate+receptor+agonists%3A+effects+of+acidic%2C+basic%2C+and+zwitterionic+chemotypes+on+pharmacokinetic+and+pharmacodynamics+profiles&doi=10.1021%2Fjm5010336"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1021%2Fjm5010336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5010336%26sid%3Dliteratum%253Aachs%26aulast%3DSkidmore%26aufirst%3DJ.%26aulast%3DHeer%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DC.%2BN.%26aulast%3DNorton%26aufirst%3DD.%26aulast%3DRedshaw%26aufirst%3DS.%26aulast%3DSweeting%26aufirst%3DJ.%26aulast%3DHurst%26aufirst%3DD.%26aulast%3DCridland%26aufirst%3DA.%26aulast%3DVesey%26aufirst%3DD.%26aulast%3DWall%26aufirst%3DI.%26aulast%3DAhmed%26aufirst%3DM.%26aulast%3DRivers%26aufirst%3DD.%26aulast%3DMyatt%26aufirst%3DJ.%26aulast%3DGiblin%26aufirst%3DG.%26aulast%3DPhilpott%26aufirst%3DK.%26aulast%3DKumar%26aufirst%3DU.%26aulast%3DStevens%26aufirst%3DA.%26aulast%3DBit%26aufirst%3DR.%2BA.%26aulast%3DHaynes%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DWatson%26aufirst%3DR.%26aulast%3DWitherington%26aufirst%3DJ.%26aulast%3DDemont%26aufirst%3DE.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26atitle%3DOptimization%2520of%2520sphingosine-1-phosphate%2520receptor%2520agonists%253A%2520effects%2520of%2520acidic%252C%2520basic%252C%2520and%2520zwitterionic%2520chemotypes%2520on%2520pharmacokinetic%2520and%2520pharmacodynamics%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10424%26epage%3D10442%26doi%3D10.1021%2Fjm5010336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Bolli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abele, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kanter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimont, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lescop, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathys, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seifert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, T.</span><span> </span><span class="NLM_article-title">Novel S1P1 receptor agonists – part 3: from thiophenes to pyridines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">110</span><span class="NLM_x">–</span> <span class="NLM_lpage">130</span><span class="refDoi"> DOI: 10.1021/jm4014696</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4014696" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=110-130&author=M.+H.+Bolliauthor=S.+Abeleauthor=M.+Birkerauthor=R.+Bravoauthor=D.+Burauthor=R.+de+Kanterauthor=C.+Kohlauthor=J.+Grimontauthor=P.+Hessauthor=C.+Lescopauthor=B.+Mathysauthor=C.+Mullerauthor=O.+Naylerauthor=M.+Reyauthor=M.+Scherzauthor=G.+Schmidtauthor=J.+Seifertauthor=B.+Steinerauthor=J.+Velkerauthor=T.+Weller&title=Novel+S1P1+receptor+agonists+%E2%80%93+part+3%3A+from+thiophenes+to+pyridines&doi=10.1021%2Fjm4014696"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1021%2Fjm4014696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4014696%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DAbele%26aufirst%3DS.%26aulast%3DBirker%26aufirst%3DM.%26aulast%3DBravo%26aufirst%3DR.%26aulast%3DBur%26aufirst%3DD.%26aulast%3Dde%2BKanter%26aufirst%3DR.%26aulast%3DKohl%26aufirst%3DC.%26aulast%3DGrimont%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DLescop%26aufirst%3DC.%26aulast%3DMathys%26aufirst%3DB.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DRey%26aufirst%3DM.%26aulast%3DScherz%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DG.%26aulast%3DSeifert%26aufirst%3DJ.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DVelker%26aufirst%3DJ.%26aulast%3DWeller%26aufirst%3DT.%26atitle%3DNovel%2520S1P1%2520receptor%2520agonists%2520%25E2%2580%2593%2520part%25203%253A%2520from%2520thiophenes%2520to%2520pyridines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D110%26epage%3D130%26doi%3D10.1021%2Fjm4014696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Bolli, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathys, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Kanter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B.</span><span> </span><span class="NLM_article-title">Novel S1P1 receptor agonists – part 2: from bicylco[3.1.0]hexane-fused thiophenes to isobutyl substituted thiophenes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">97</span><span class="refDoi"> DOI: 10.1021/jm401456d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401456d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=78-97&author=M.+H.+Bolliauthor=J.+Velkerauthor=C.+Mullerauthor=B.+Mathysauthor=M.+Birkerauthor=R.+Bravoauthor=D.+Burauthor=R.+de+Kanterauthor=P.+Hessauthor=C.+Kohlauthor=D.+Lehmannauthor=S.+Meyerauthor=O.+Naylerauthor=M.+Reyauthor=M.+Scherzauthor=B.+Steiner&title=Novel+S1P1+receptor+agonists+%E2%80%93+part+2%3A+from+bicylco%5B3.1.0%5Dhexane-fused+thiophenes+to+isobutyl+substituted+thiophenes&doi=10.1021%2Fjm401456d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15e&amp;dbid=16384&amp;doi=10.1021%2Fjm401456d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401456d%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DVelker%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DC.%26aulast%3DMathys%26aufirst%3DB.%26aulast%3DBirker%26aufirst%3DM.%26aulast%3DBravo%26aufirst%3DR.%26aulast%3DBur%26aufirst%3DD.%26aulast%3Dde%2BKanter%26aufirst%3DR.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DKohl%26aufirst%3DC.%26aulast%3DLehmann%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3DRey%26aufirst%3DM.%26aulast%3DScherz%26aufirst%3DM.%26aulast%3DSteiner%26aufirst%3DB.%26atitle%3DNovel%2520S1P1%2520receptor%2520agonists%2520%25E2%2580%2593%2520part%25202%253A%2520from%2520bicylco%255B3.1.0%255Dhexane-fused%2520thiophenes%2520to%2520isobutyl%2520substituted%2520thiophenes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D78%26epage%3D97%26doi%3D10.1021%2Fjm401456d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Horan, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanyal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill-Drzewi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaude, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gueneva-Boucheva, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pack, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bannen, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mac, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modis, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemieux, R. M.</span><span> </span><span class="NLM_article-title">Piperazinyl-oxadiazoles as selective sphingosine-1-phosphate receptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4807</span><span class="NLM_x">–</span> <span class="NLM_lpage">4811</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1016%2Fj.bmcl.2014.09.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4807-4811&author=J.+C.+Horanauthor=S.+Sanyalauthor=Y.+Choiauthor=M.+Hill-Drzewiauthor=L.+Patnaudeauthor=S.+Andersonauthor=S.+Fogalauthor=C.+Maoauthor=B.+N.+Cookauthor=K.+Gueneva-Bouchevaauthor=M.+B.+Fisherauthor=E.+Hickeyauthor=E.+Packauthor=L.+C.+Bannenauthor=D.+S.+Chanauthor=M.+B.+Macauthor=S.+M.+Ngauthor=Y.+Wangauthor=W.+Xuauthor=L.+K.+Modisauthor=R.+M.+Lemieux&title=Piperazinyl-oxadiazoles+as+selective+sphingosine-1-phosphate+receptor+agonists&doi=10.1016%2Fj.bmcl.2014.09.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15f&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DHoran%26aufirst%3DJ.%2BC.%26aulast%3DSanyal%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DHill-Drzewi%26aufirst%3DM.%26aulast%3DPatnaude%26aufirst%3DL.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DFogal%26aufirst%3DS.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DB.%2BN.%26aulast%3DGueneva-Boucheva%26aufirst%3DK.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHickey%26aufirst%3DE.%26aulast%3DPack%26aufirst%3DE.%26aulast%3DBannen%26aufirst%3DL.%2BC.%26aulast%3DChan%26aufirst%3DD.%2BS.%26aulast%3DMac%26aufirst%3DM.%2BB.%26aulast%3DNg%26aufirst%3DS.%2BM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DModis%26aufirst%3DL.%2BK.%26aulast%3DLemieux%26aufirst%3DR.%2BM.%26atitle%3DPiperazinyl-oxadiazoles%2520as%2520selective%2520sphingosine-1-phosphate%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4807%26epage%3D4811%26doi%3D10.1016%2Fj.bmcl.2014.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dyckman, A.</span><span> </span><span class="NLM_article-title">Recent advances in the discovery and development of sphingosine-1-phosphate-1 receptor agonists</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span><span class="refDoi"> DOI: 10.1016/B978-0-12-396492-2.00013-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1016%2FB978-0-12-396492-2.00013-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2012&pages=195-207&author=A.+Dyckman&title=Recent+advances+in+the+discovery+and+development+of+sphingosine-1-phosphate-1+receptor+agonists&doi=10.1016%2FB978-0-12-396492-2.00013-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396492-2.00013-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396492-2.00013-8%26sid%3Dliteratum%253Aachs%26aulast%3DDyckman%26aufirst%3DA.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520and%2520development%2520of%2520sphingosine-1-phosphate-1%2520receptor%2520agonists%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2012%26volume%3D47%26spage%3D195%26epage%3D207%26doi%3D10.1016%2FB978-0-12-396492-2.00013-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">and references cited therein.</p></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Roberts, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span> </span><span class="NLM_article-title">Sphingosine 1-phosphate receptor agonists: a patent review (2010–2012)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">841</span><div class="note"><p class="first last">and references cited therein.</p></div><span class="refDoi"> DOI: 10.1517/13543776.2013.783022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1517%2F13543776.2013.783022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=23541049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslCks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=817-841&issue=7&author=E.+Robertsauthor=M.+Guerreroauthor=M.+Urbanoauthor=H.+Rosen&title=Sphingosine+1-phosphate+receptor+agonists%3A+a+patent+review+%282010%E2%80%932012%29&doi=10.1517%2F13543776.2013.783022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate receptor agonists: a patent review (2010 - 2012)</span></div><div class="casAuthors">Roberts, Edward; Guerrero, Miguel; Urbano, Mariangela; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">817-841</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The sphingosine-1-phosphate (S1P)-driven signaling regulates fundamental biol. functions, including cell proliferation, angiogenesis, endothelial cell chemotaxis, immune cell trafficking and mitogenesis.  A large body of research has been focusing on the development of immunosuppressive S1P1 receptor (S1P1-R) agonist mols.  The S1P1,3 - 5-R pan-agonist fingolimod (FTY720) has been approved by the FDA for the treatment of relapsing-remitting multiple sclerosis.  However, FTY720 is now contraindicated in patients with compromised cardiac function.  Although the main adverse effect bradycardia has been linked to the S1P3-R activation, cardiovascular liabilities persist with more selective S1P1-R agonists that have entered clin. trials.  In contrast to the S1P1-R, the therapeutic application of the S1P2 - 5-Rs remains poorly explored.  Areas covered: This review provides the patent literature from 2010 to date on S1P-R agonist mols. and their relevant biol. properties.  Expert opinion: Limited progress has been made on agonists at S1P4,5-R subtypes, with some families of S1P5-R agonists showing promising results in animal models of age-related cognitive disorders.  A discrete no. of reviewed mols. are S1P1-R agonists with a promising clin. outlook in transplantation, inflammation, cancer and autoimmune settings.  Further preclin. and clin. studies will det. whether the new developed S1P1-R agonists do indeed improve the safety profile of FTY720.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIrASpSMDS37Vg90H21EOLACvtfcHk0li8wB9bDn2Dkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslCks7o%253D&md5=405b6350b777d3040e2be21adf85d440</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.783022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.783022%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DE.%26aulast%3DGuerrero%26aufirst%3DM.%26aulast%3DUrbano%26aufirst%3DM.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DSphingosine%25201-phosphate%2520receptor%2520agonists%253A%2520a%2520patent%2520review%2520%25282010%25E2%2580%25932012%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26issue%3D7%26spage%3D817%26epage%3D841%26doi%3D10.1517%2F13543776.2013.783022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Blaho, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hla, T.</span><span> </span><span class="NLM_article-title">An update on the biology of sphingosine 1-phosphate receptors</span> <span class="citation_source-journal">J. Lipid Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1596</span><span class="NLM_x">–</span> <span class="NLM_lpage">1608</span><span class="refDoi"> DOI: 10.1194/jlr.R046300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1194%2Fjlr.R046300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=24459205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1agsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1596-1608&author=V.+A.+Blahoauthor=T.+Hla&title=An+update+on+the+biology+of+sphingosine+1-phosphate+receptors&doi=10.1194%2Fjlr.R046300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">An update on the biology of sphingosine 1-phosphate receptors</span></div><div class="casAuthors">Blaho, Victoria A.; Hla, Timothy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Lipid Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1596-1608</span>CODEN:
                <span class="NLM_cas:coden">JLPRAW</span>;
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology, Inc.</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P) is a membrane-derived lysophospholipid that acts primarily as an extracellular signaling mol.  Signals initiated by S1P are transduced by five G protein-coupled receptors, named S1P1-5.  Cellular and temporal expression of the S1P receptors (S1PRs) det. their specific roles in various organ systems, but they are particularly crit. for regulation of the cardiovascular, immune, and nervous systems, with the most well-known contributions of S1PR signaling being modulation of vascular barrier function, vascular tone, and regulation of lymphocyte trafficking.  However, our knowledge of S1PR biol. is rapidly increasing as they become attractive therapeutic targets in several diseases, such as chronic inflammatory pathologies, autoimmunity, and cancer.  Understanding how the S1PRs regulate interactions between biol. systems will allow for greater efficacy in this novel therapeutic strategy as well as characterization of complex physiol. networks.  Because of the rapidly expanding body of research, this review will focus on the most recent advances in S1PRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIZfnE0tv0rbVg90H21EOLACvtfcHk0lgunq6SY2Vm-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1agsrnP&md5=3939398b28359c3be8d38b3b49be3d4c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R046300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R046300%26sid%3Dliteratum%253Aachs%26aulast%3DBlaho%26aufirst%3DV.%2BA.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DAn%2520update%2520on%2520the%2520biology%2520of%2520sphingosine%25201-phosphate%2520receptors%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2014%26volume%3D55%26spage%3D1596%26epage%3D1608%26doi%3D10.1194%2Fjlr.R046300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Gergely, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuesslein-Hildesheim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brinkmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traebert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruns, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinterding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groenewegen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vitaliti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sing, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttringer, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumb, W. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallstrom, E.</span><span> </span><span class="NLM_article-title">The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">167</span><span class="NLM_x">, </span> <span class="NLM_fpage">1035</span><span class="NLM_x">–</span> <span class="NLM_lpage">1047</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.02061.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1111%2Fj.1476-5381.2012.02061.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=22646698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2012&pages=1035-1047&author=P.+Gergelyauthor=B.+Nuesslein-Hildesheimauthor=D.+Gueriniauthor=V.+Brinkmannauthor=M.+Traebertauthor=C.+Brunsauthor=S.+Panauthor=N.+S.+Grayauthor=K.+Hinterdingauthor=N.+G.+Cookeauthor=A.+Groenewegenauthor=A.+Vitalitiauthor=T.+Singauthor=O.+Luttringerauthor=J.+Yangauthor=A.+Gardinauthor=N.+Wangauthor=W.+J.+Crumbauthor=M.+Saltzmanauthor=M.+Rosenbergauthor=E.+Wallstrom&title=The+selective+sphingosine+1-phosphate+receptor+modulator+BAF312+redirects+lymphocyte+distribution+and+has+species-specific+effects+on+heart+rate&doi=10.1111%2Fj.1476-5381.2012.02061.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate</span></div><div class="casAuthors">Gergely, P.; Nuesslein-Hildesheim, B.; Guerini, D.; Brinkmann, V.; Traebert, M.; Bruns, C.; Pan, S.; Gray, N. S.; Hinterding, K.; Cooke, N. G.; Groenewegen, A.; Vitaliti, A.; Sing, T.; Luttringer, O.; Yang, J.; Gardin, A.; Wang, N.; Crumb, W. J., Jr.; Saltzman, M.; Rosenberg, M.; Wallstrom, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1035-1047</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose BAF312 is a next-generation sphingosine 1-phosphate (S1P) receptor modulator, selective for S1P1 and S1P5 receptors.  S1P1 receptors are essential for lymphocyte egress from lymph nodes and a drug target in immune-mediated diseases.  Here, we have characterized the immunomodulatory potential of BAF312 and the S1P receptor-mediated effects on heart rate using preclin. and human data.  Exptl. Approach BAF312 was tested in a rat exptl. autoimmune encephalomyelitis (EAE) model.  Electrophysiol. recordings of G-protein-coupled inwardly rectifying potassium (GIRK) channels were carried out in human atrial myocytes.  A Phase I multiple-dose trial studied the pharmacokinetics, pharmacodynamics and safety of BAF312 in 48 healthy subjects.  Key Results BAF312 effectively suppressed EAE in rats by internalizing S1P1 receptors, rendering them insensitive to the egress signal from lymph nodes.  In healthy volunteers, BAF312 caused preferential decreases in CD4+ T cells, Tnaive, Tcentral memory and B cells within 4-6 h.  Cell counts returned to normal ranges within a week after stopping treatment, in line with the elimination half-life of BAF312.  Despite sparing S1P3 receptors (assocd. with bradycardia in mice), BAF312 induced rapid, transient (day 1 only) bradycardia in humans.  BAF312-mediated activation of GIRK channels in human atrial myocytes can fully explain the bradycardia.  Conclusion and Implications This study illustrates species-specific differences in S1P receptor specificity for first-dose cardiac effects.  Based on its profound but rapidly reversible inhibition of lymphocyte trafficking, BAF312 may have potential as a treatment for immune-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42VfW58NMyLVg90H21EOLACvtfcHk0lgunq6SY2Vm-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7bE&md5=0034be62fb68b10abefff50f0220be2a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.02061.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.02061.x%26sid%3Dliteratum%253Aachs%26aulast%3DGergely%26aufirst%3DP.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DTraebert%26aufirst%3DM.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DCooke%26aufirst%3DN.%2BG.%26aulast%3DGroenewegen%26aufirst%3DA.%26aulast%3DVitaliti%26aufirst%3DA.%26aulast%3DSing%26aufirst%3DT.%26aulast%3DLuttringer%26aufirst%3DO.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGardin%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DCrumb%26aufirst%3DW.%2BJ.%26aulast%3DSaltzman%26aufirst%3DM.%26aulast%3DRosenberg%26aufirst%3DM.%26aulast%3DWallstrom%26aufirst%3DE.%26atitle%3DThe%2520selective%2520sphingosine%25201-phosphate%2520receptor%2520modulator%2520BAF312%2520redirects%2520lymphocyte%2520distribution%2520and%2520has%2520species-specific%2520effects%2520on%2520heart%2520rate%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D167%26spage%3D1035%26epage%3D1047%26doi%3D10.1111%2Fj.1476-5381.2012.02061.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">David, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovarik, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmouder, R. L.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetics of fingolimod</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span><span class="refDoi"> DOI: 10.2165/11596550-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.2165%2F11596550-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=22149256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1OqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=15-28&author=O.+J.+Davidauthor=J.+M.+Kovarikauthor=R.+L.+Schmouder&title=Clinical+pharmacokinetics+of+fingolimod&doi=10.2165%2F11596550-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of fingolimod</span></div><div class="casAuthors">David, Olivier J.; Kovarik, John M.; Schmouder, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-28</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review.  Fingolimod (FTY720), a sphingosine 1-phosphate receptor modulator, is the first in a new class of therapeutic compds. and is the first oral therapy approved for the treatment of relapsing forms of multiple sclerosis (MS).  Fingolimod is a structural analog of endogenous sphingosine and undergoes phosphorylation to produce fingolimod phosphate, the active moiety.  Fingolimod targets MS via effects on the immune system, and evidence from animal models indicates that it may also have actions in the central nervous system.  In phase III studies in patients with relapsing-remitting MS, fingolimod has demonstrated efficacy superior to that of an approved first-line therapy, i.m. interferon-β-1a, as well as placebo, with benefits extending across clin. and magnetic resonance imaging measures.  The pharmacokinetic profiles of fingolimod and fingolimod phosphate have been extensively investigated in studies in healthy volunteers, renal transplant recipients (the indication for which fingolimod was initially under clin. development, but the development was subsequently discontinued) and MS patients.  Results from these studies have demonstrated that fingolimod is efficiently absorbed, with an oral bioavailability of >90%, and its absorption is unaffected by dietary intake, therefore it can be taken without regard to meals.  Fingolimod and fingolimod phosphate have a half-life of 6-9 days, and steady-state pharmacokinetics are reached after 1-2 mo of daily dosing.  The long half-life of fingolimod, together with its slow absorption, means that fingolimod has a fiat concn. profile over time with once-daily dosing.  Fingolimod and fingolimod phosphate show dose-proportional exposure in single- and multiple-dose studies over a range of 0.125-5 mg; hence, there is a predictable relationship between dose and systemic exposure.  Furthermore, fingolimod and fingolimod phosphate exhibit low to moderate intersubject pharmacokinetic variability.  Fingolimod is extensively metabolized, with biotransformation occurring via three main pathways: (i) reversible phosphorylation to fingolimod phosphate; (ii) hydroxylation and oxidn. to yield a series of inactive carboxylic acid metabolites; and (iii) formation of non-polar ceramides.  Fingolimod is largely cleared through metab. by cytochrome P 450 (CYP) 4F2.  Since few drugs are metabolized by CYP4F2, fingolimod would be expected to have a relatively low potential for drug-drug interactions.  This is supported by data from in vitro studies indicating that fingolimod and fingolimod phosphate have little or no capacity to inhibit and no capacity to induce other major drug-metabolizing CYP enzymes at therapeutically relevant steady-state blood concns.  Population pharmacokinetic evaluations indicate that CYP3A inhibitors and CYP3A inducers have no effect or only a weak effect on the pharmacokinetics of fingolimod and fingolimod phosphate.  However, blood concns. of fingolimod and fingolimod phosphate are increased moderately when fingolimod is coadministered with ketoconazole, an inhibitor of CYP4F2.  The pharmacokinetics of fingolimod are unaffected by renal impairment or mild-to-moderate hepatic impairment.  However, exposure to fingolimod is increased in patients with severe hepatic impairment.  No clin. relevant effects of age, sex or ethnicity on the pharmacokinetics of fingolimod have been obsd.  Fingolimod is thus a promising new therapy for eligible patients with MS, with a predictable pharmacokinetic profile that allows effective once-daily oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoxIUshcr8m7Vg90H21EOLACvtfcHk0lhDaciJJtbglQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1OqtLg%253D&md5=a1a6d271470f6c297892ef00f0fe6ec6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2165%2F11596550-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11596550-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DDavid%26aufirst%3DO.%2BJ.%26aulast%3DKovarik%26aufirst%3DJ.%2BM.%26aulast%3DSchmouder%26aufirst%3DR.%2BL.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520fingolimod%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2012%26volume%3D51%26spage%3D15%26epage%3D28%26doi%3D10.2165%2F11596550-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hale, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neway, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajdu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbach, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shei, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parent, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chrebet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strulovici, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandala, S.</span><span> </span><span class="NLM_article-title">A rational utilization of high-throughput screening affords selective, orally bioavailable 1- benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6662</span><span class="NLM_x">–</span> <span class="NLM_lpage">6665</span><span class="refDoi"> DOI: 10.1021/jm0492507</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0492507" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6662-6665&author=J.+J.+Haleauthor=C.+L.+Lynchauthor=W.+Newayauthor=S.+G.+Millsauthor=R.+Hajduauthor=C.+A.+Keohaneauthor=M.+J.+Rosenbachauthor=J.+A.+Milliganauthor=G.+J.+Sheiauthor=S.+A.+Parentauthor=G.+Chrebetauthor=J.+Bergstromauthor=D.+Cardauthor=M.+Ferrerauthor=P.+Hodderauthor=B.+Struloviciauthor=H.+Rosenauthor=S.+Mandala&title=A+rational+utilization+of+high-throughput+screening+affords+selective%2C+orally+bioavailable+1-+benzyl-3-carboxyazetidine+sphingosine-1-phosphate-1+receptor+agonists&doi=10.1021%2Fjm0492507"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1021%2Fjm0492507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0492507%26sid%3Dliteratum%253Aachs%26aulast%3DHale%26aufirst%3DJ.%2BJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DNeway%26aufirst%3DW.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%2BJ.%26aulast%3DMilligan%26aufirst%3DJ.%2BA.%26aulast%3DShei%26aufirst%3DG.%2BJ.%26aulast%3DParent%26aufirst%3DS.%2BA.%26aulast%3DChrebet%26aufirst%3DG.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DStrulovici%26aufirst%3DB.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DMandala%26aufirst%3DS.%26atitle%3DA%2520rational%2520utilization%2520of%2520high-throughput%2520screening%2520affords%2520selective%252C%2520orally%2520bioavailable%25201-%2520benzyl-3-carboxyazetidine%2520sphingosine-1-phosphate-1%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6662%26epage%3D6665%26doi%3D10.1021%2Fjm0492507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefebvre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinterding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">End, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heining, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruns, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuesslein-Hildesheim, B.</span><span> </span><span class="NLM_article-title">Discovery of BAF312 (siponimod), a potent and selective S1P receptor modulator</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span><span class="refDoi"> DOI: 10.1021/ml300396r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300396r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVynug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=333-337&author=S.+Panauthor=N.-S.+Grayauthor=W.+Gaoauthor=Y.+Miauthor=Y.+Fanauthor=X.+Wangauthor=T.+Tuntlandauthor=J.+Cheauthor=S.+Lefebvreauthor=Y.+Chenauthor=A.+Chuauthor=K.+Hinterdingauthor=A.+Gardinauthor=P.+Endauthor=P.+Heiningauthor=C.+Brunsauthor=N.+G.+Cookeauthor=B.+Nuesslein-Hildesheim&title=Discovery+of+BAF312+%28siponimod%29%2C+a+potent+and+selective+S1P+receptor+modulator&doi=10.1021%2Fml300396r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator</span></div><div class="casAuthors">Pan, Shifeng; Gray, Nathanael S.; Gao, Wenqi; Mi, Yuan; Fan, Yi; Wang, Xing; Tuntland, Tove; Che, Jianwei; Lefebvre, Sophie; Chen, Yu; Chu, Alan; Hinterding, Klaus; Gardin, Anne; End, Peter; Heining, Peter; Bruns, Christian; Cooke, Nigel G.; Nuesslein-Hildesheim, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">333-337</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of alkoxyimino derivs. as S1P1 agonists were discovered through de novo design using FTY720 as the chem. starting point.  Extensive structure-activity relationship studies led to the discovery of (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid (I, BAF312, Siponimod), which has recently completed phase 2 clin. trials in patients with relapsing-remitting multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV0CukK1Qn3bVg90H21EOLACvtfcHk0lhDaciJJtbglQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVynug%253D%253D&md5=a410b8b34f28380a51b3ffb63ae23161</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1021%2Fml300396r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300396r%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.-S.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DMi%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DChe%26aufirst%3DJ.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DA.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DGardin%26aufirst%3DA.%26aulast%3DEnd%26aufirst%3DP.%26aulast%3DHeining%26aufirst%3DP.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DCooke%26aufirst%3DN.%2BG.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520BAF312%2520%2528siponimod%2529%252C%2520a%2520potent%2520and%2520selective%2520S1P%2520receptor%2520modulator%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D333%26epage%3D337%26doi%3D10.1021%2Fml300396r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lanman, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheruku, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marantz, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neira, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickrell, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivenzon-Segal, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schutz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharadendu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buys, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElvain, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrag, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bürli, R. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent, S1P3-sparing benzothiazole agonist of sphingosine-1-phosphate receptor 1 (S1P1)</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span><span class="refDoi"> DOI: 10.1021/ml100228m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100228m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=102-106&author=B.+A.+Lanmanauthor=V.+J.+Ceeauthor=S.+R.+Cherukuauthor=M.+Frohnauthor=J.+Goldenauthor=J.+Linauthor=M.+Loberaauthor=Y.+Marantzauthor=K.+M.+Mullerauthor=S.+C.+Neiraauthor=A.+J.+Pickrellauthor=D.+Rivenzon-Segalauthor=N.+Schutzauthor=A.+Sharadenduauthor=X.+Yuauthor=Z.+Zhangauthor=J.+Buysauthor=M.+Fiorinoauthor=A.+Goreauthor=M.+Hornerauthor=A.+Itanoauthor=M.+McElvainauthor=S.+Middletonauthor=M.+Schragauthor=H.+M.+Vargasauthor=H.+Xuauthor=Y.+Xuauthor=X.+Zhangauthor=J.+Siuauthor=R.+W.+B%C3%BCrli&title=Discovery+of+a+potent%2C+S1P3-sparing+benzothiazole+agonist+of+sphingosine-1-phosphate+receptor+1+%28S1P1%29&doi=10.1021%2Fml100228m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.1021%2Fml100228m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100228m%26sid%3Dliteratum%253Aachs%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DCheruku%26aufirst%3DS.%2BR.%26aulast%3DFrohn%26aufirst%3DM.%26aulast%3DGolden%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLobera%26aufirst%3DM.%26aulast%3DMarantz%26aufirst%3DY.%26aulast%3DMuller%26aufirst%3DK.%2BM.%26aulast%3DNeira%26aufirst%3DS.%2BC.%26aulast%3DPickrell%26aufirst%3DA.%2BJ.%26aulast%3DRivenzon-Segal%26aufirst%3DD.%26aulast%3DSchutz%26aufirst%3DN.%26aulast%3DSharadendu%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DBuys%26aufirst%3DJ.%26aulast%3DFiorino%26aufirst%3DM.%26aulast%3DGore%26aufirst%3DA.%26aulast%3DHorner%26aufirst%3DM.%26aulast%3DItano%26aufirst%3DA.%26aulast%3DMcElvain%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DS.%26aulast%3DSchrag%26aufirst%3DM.%26aulast%3DVargas%26aufirst%3DH.%2BM.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSiu%26aufirst%3DJ.%26aulast%3DB%25C3%25BCrli%26aufirst%3DR.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520S1P3-sparing%2520benzothiazole%2520agonist%2520of%2520sphingosine-1-phosphate%2520receptor%25201%2520%2528S1P1%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D102%26epage%3D106%26doi%3D10.1021%2Fml100228m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ren, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, J.-N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X.</span><span> </span><span class="NLM_article-title">Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P1)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4286</span><span class="NLM_x">–</span> <span class="NLM_lpage">4296</span><span class="refDoi"> DOI: 10.1021/jm2016107</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2016107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4286-4296&author=F.+Renauthor=G.+Dengauthor=H.+Wangauthor=L.+Luanauthor=Q.+Mengauthor=Q.+Xuauthor=H.+Xuauthor=X.+Xuauthor=H.+Zhangauthor=B.+Zhaoauthor=C.+Liauthor=T.+B.+Guoauthor=J.+Yangauthor=W.+Zhangauthor=Y.+Zhaoauthor=Q.+Jiaauthor=H.+Luauthor=J.-N.+Xiangauthor=J.+D.+Elliottauthor=X.+Lin&title=Discovery+of+novel+1%2C2%2C4-thiadiazole+derivatives+as+potent%2C+orally+active+agonists+of+sphingosine+1-phosphate+receptor+subtype+1+%28S1P1%29&doi=10.1021%2Fjm2016107"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20d&amp;dbid=16384&amp;doi=10.1021%2Fjm2016107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2016107%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DF.%26aulast%3DDeng%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLuan%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DT.%2BB.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DJia%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DXiang%26aufirst%3DJ.-N.%26aulast%3DElliott%26aufirst%3DJ.%2BD.%26aulast%3DLin%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520novel%25201%252C2%252C4-thiadiazole%2520derivatives%2520as%2520potent%252C%2520orally%2520active%2520agonists%2520of%2520sphingosine%25201-phosphate%2520receptor%2520subtype%25201%2520%2528S1P1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4286%26epage%3D4296%26doi%3D10.1021%2Fjm2016107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Cee, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanman, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neira, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickrell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnett, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buys, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElvain, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrag, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivenzon-Segal, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buerli, R. W.</span><span> </span><span class="NLM_article-title">Discovery of AMG 369, a thiazolo[5,4-b]pyridine agonist of S1P1 and S1P5</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1021/ml100306h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100306h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=107-112&author=V.+J.+Ceeauthor=M.+Frohnauthor=B.+A.+Lanmanauthor=J.+Goldenauthor=K.+Mullerauthor=S.+Neiraauthor=A.+Pickrellauthor=H.+Arnettauthor=J.+Buysauthor=A.+Goreauthor=M.+Fiorinoauthor=M.+Hornerauthor=A.+Itanoauthor=M.+R.+Leeauthor=M.+McElvainauthor=S.+Middletonauthor=M.+Schragauthor=D.+Rivenzon-Segalauthor=H.+M.+Vargasauthor=H.+Xuauthor=Y.+Xuauthor=X.+Zhangauthor=J.+Siuauthor=M.+Wongauthor=R.+W.+Buerli&title=Discovery+of+AMG+369%2C+a+thiazolo%5B5%2C4-b%5Dpyridine+agonist+of+S1P1+and+S1P5&doi=10.1021%2Fml100306h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20e&amp;dbid=16384&amp;doi=10.1021%2Fml100306h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100306h%26sid%3Dliteratum%253Aachs%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DFrohn%26aufirst%3DM.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DGolden%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DK.%26aulast%3DNeira%26aufirst%3DS.%26aulast%3DPickrell%26aufirst%3DA.%26aulast%3DArnett%26aufirst%3DH.%26aulast%3DBuys%26aufirst%3DJ.%26aulast%3DGore%26aufirst%3DA.%26aulast%3DFiorino%26aufirst%3DM.%26aulast%3DHorner%26aufirst%3DM.%26aulast%3DItano%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DMcElvain%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DS.%26aulast%3DSchrag%26aufirst%3DM.%26aulast%3DRivenzon-Segal%26aufirst%3DD.%26aulast%3DVargas%26aufirst%3DH.%2BM.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSiu%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DBuerli%26aufirst%3DR.%2BW.%26atitle%3DDiscovery%2520of%2520AMG%2520369%252C%2520a%2520thiazolo%255B5%252C4-b%255Dpyridine%2520agonist%2520of%2520S1P1%2520and%2520S1P5%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D107%26epage%3D112%26doi%3D10.1021%2Fml100306h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Watterson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spergel, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langevine, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moquin, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yarde, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cvijic, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suchard, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">RexRabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuster, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D'Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balimane, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrack, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salter-Cid, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinnon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitts, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyckman, A. J.</span><span> </span><span class="NLM_article-title">Potent and selective agonists of sphingosine-1-phosphate 1 (S1P<sub>1</sub>): the discovery and SAR of a novel isoxazole based series</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">2820</span><span class="NLM_x">–</span> <span class="NLM_lpage">2840</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00089</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00089" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2820-2840&author=S.+H.+Wattersonauthor=J.+Guoauthor=S.+H.+Spergelauthor=C.+M.+Langevineauthor=R.+V.+Moquinauthor=D.+R.+Shenauthor=M.+Yardeauthor=M.+E.+Cvijicauthor=D.+Banasauthor=R.+Liuauthor=S.+J.+Suchardauthor=K.+Gilloolyauthor=T.+Taylorauthor=S.+RexRabeauthor=D.+J.+Shusterauthor=K.+W.+McIntyreauthor=G.+Corneliusauthor=C.+D%27Arienzoauthor=A.+Marinoauthor=P.+Balimaneauthor=B.+Warrackauthor=L.+Salter-Cidauthor=M.+McKinnonauthor=J.+C.+Barrishauthor=P.+C.+Carterauthor=W.+J.+Pittsauthor=J.+Xieauthor=A.+J.+Dyckman&title=Potent+and+selective+agonists+of+sphingosine-1-phosphate+1+%28S1P1%29%3A+the+discovery+and+SAR+of+a+novel+isoxazole+based+series&doi=10.1021%2Facs.jmedchem.6b00089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00089%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DSpergel%26aufirst%3DS.%2BH.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DBanas%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DSuchard%26aufirst%3DS.%2BJ.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%26aulast%3DRexRabe%26aufirst%3DS.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DD%2527Arienzo%26aufirst%3DC.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DWarrack%26aufirst%3DB.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DMcKinnon%26aufirst%3DM.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BC.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26atitle%3DPotent%2520and%2520selective%2520agonists%2520of%2520sphingosine-1-phosphate%25201%2520%2528S1P1%2529%253A%2520the%2520discovery%2520and%2520SAR%2520of%2520a%2520novel%2520isoxazole%2520based%2520series%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2820%26epage%3D2840%26doi%3D10.1021%2Facs.jmedchem.6b00089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Watterson, S. H.; Dyckman, A. J.; Pitts, W. J.; Spergel, S. H.</span><span> </span><span class="NLM_article-title">Substituted isoxazole derivatives as S1P agonists in the treatment of autoimmune and inflammatory diseases and their preparation</span>. WO 2010085581,<span class="NLM_x"> </span><span class="NLM_year">2010</span><span class="NLM_x">, </span>(US Patent 8354398, 2013);</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+H.+Watterson&author=A.+J.+Dyckman&author=W.+J.+Pitts&author=S.+H.+Spergel&title=Substituted+isoxazole+derivatives+as+S1P+agonists+in+the+treatment+of+autoimmune+and+inflammatory+diseases+and+their+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26atitle%3DSubstituted%2520isoxazole%2520derivatives%2520as%2520S1P%2520agonists%2520in%2520the%2520treatment%2520of%2520autoimmune%2520and%2520inflammatory%2520diseases%2520and%2520their%2520preparation%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-ref21_3"><span> <span class="citation_source-journal">Chem. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">153</span><span class="NLM_x">, </span> <span class="NLM_fpage">232588</span> .</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chem.+Abstr.+2010%2C+153%2C+232588+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref21_3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Abstr.%26date%3D2010%26volume%3D153%26spage%3D232588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="note"><p class="first last">The absolute and relative stereochemistry of compound <b>14a</b> was unambiguously assigned (<i>S</i>,<i>S</i>) by X-ray crystal structure. Crystallographic data for the structures <b>14a</b> reported in this paper has been deposited with the Cambridge Crystallographic Data Centre as supplementary publication nos. CCDC 1452864. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: (+44) 1223-336-033; e-mail: <a href="/cdn-cgi/l/email-protection#ef8b8a9f809c869baf8c8c8b8cc18c8e82c18e8cc19a84"><span class="__cf_email__" data-cfemail="3753524758445e4377545453541954565a19565419425c">[email protected]</span></a>). The absolute and relative stereochemistry of <b>14b</b> was assigned (<i>S</i>,<i>R</i>) based on the crystal structure of <b>14a</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="note"><p class="first last">The stereochemical assignment of <b>15a</b> was made by preparation of the material using the procedures described in WO2009005646. The starting (2-bromoacetyl)benzonitrile was reduced with (<i>S</i>)-2-methyl-CBS-oxazaborolidine followed by BH<sub>3</sub>-SMe<sub>2</sub>, yielding a 10:1 mixture of the <i>S</i>:<i>R</i> isomer. Subsequent HPLC chiral separation removed the minor isomer and coupling with the commercially available (<i>R</i>)-ethyl 2-(piperidin-3-yl)acetate afforded <b>15a</b>, which was assigned as the (<i>R</i>,<i>S</i>) isomer.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desale, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemons, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cahalan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuerer, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">Crystal structure of a lipid G-protein coupled receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">335</span><span class="NLM_x">, </span> <span class="NLM_fpage">851</span><span class="NLM_x">–</span> <span class="NLM_lpage">855</span><span class="refDoi"> DOI: 10.1126/science.1215904</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1126%2Fscience.1215904" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=335&publication_year=2012&pages=851-855&author=M.+A.+Hansonauthor=C.+B.+Rothauthor=E.+Joauthor=M.+T.+Griffithauthor=F.+L.+Scottauthor=G.+Reinhartauthor=H.+Desaleauthor=B.+Clemonsauthor=S.+M.+Cahalanauthor=S.+C.+Schuererauthor=M.+G.+Sannaauthor=G.+W.+Hanauthor=P.+Kuhnauthor=H.+Rosenauthor=R.+C.+Stevens&title=Crystal+structure+of+a+lipid+G-protein+coupled+receptor&doi=10.1126%2Fscience.1215904"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1126%2Fscience.1215904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1215904%26sid%3Dliteratum%253Aachs%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DRoth%26aufirst%3DC.%2BB.%26aulast%3DJo%26aufirst%3DE.%26aulast%3DGriffith%26aufirst%3DM.%2BT.%26aulast%3DScott%26aufirst%3DF.%2BL.%26aulast%3DReinhart%26aufirst%3DG.%26aulast%3DDesale%26aufirst%3DH.%26aulast%3DClemons%26aufirst%3DB.%26aulast%3DCahalan%26aufirst%3DS.%2BM.%26aulast%3DSchuerer%26aufirst%3DS.%2BC.%26aulast%3DSanna%26aufirst%3DM.%2BG.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DCrystal%2520structure%2520of%2520a%2520lipid%2520G-protein%2520coupled%2520receptor%26jtitle%3DScience%26date%3D2012%26volume%3D335%26spage%3D851%26epage%3D855%26doi%3D10.1126%2Fscience.1215904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="note"><p class="first last">The des-hydroxy version of <b>11l</b> was prepared and this resulted in >380-fold loss of activity in the S1P<sub>1</sub> binding assay. Additionally, the methoxy version of <b>11b</b> resulted in a >700-fold loss of activity in the S1P<sub>1</sub> binding assay.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Bendele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McComb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAbee, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennello, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chlipala, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guy, M.</span><span> </span><span class="NLM_article-title">Animal models of arthritis: relevance to human disease</span> <span class="citation_source-journal">Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span><span class="refDoi"> DOI: 10.1177/019262339902700125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10.1177%2F019262339902700125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=10367688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;key=1%3ACAS%3A280%3ADyaK1M3psVWjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=134-142&author=A.+Bendeleauthor=J.+McCombauthor=T.+Gouldauthor=T.+McAbeeauthor=G.+Sennelloauthor=E.+Chlipalaauthor=M.+Guy&title=Animal+models+of+arthritis%3A+relevance+to+human+disease&doi=10.1177%2F019262339902700125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of arthritis: relevance to human disease</span></div><div class="casAuthors">Bendele A; McComb J; Gould T; McAbee T; Sennello G; Chlipala E; Guy M</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic pathology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">134-42</span>
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    </div><div class="casAbstract">Animal models of arthritis are used to evaluate potential antiarthritis drugs for clinical use.  Therefore capacity of the model to predict efficacy in human disease is one of the most important criteria in model selection.  Animal models of rheumatoid arthritis (RA) with a proven track record of predictability include rat adjuvant arthritis, rat type II collagen arthritis, mouse type II collagen arthritis, and antigen-induced arthritis in several species.  Agents currently in clinical use (or trials) that are active in these models include corticosteroids, methotrexate, nonsteroidal anti-inflammatory drugs, cyclosporin A, leflunomide, interleukin-1 receptor antagonist, and soluble tumor necrosis factor receptors.  For some of these agents, the models also predict that toxicities seen at higher doses for prolonged periods would preclude dosing in humans at levels that might provide disease-modifying effects.  Animal models of osteoarthritis (OA) include mouse and guinea pig spontaneous OA, meniscectomy and ligament transection in guinea pigs, meniscectomy in rabbits, and meniscectomy and cruciate transection in dogs.  None of these models have a proven track record of predictability in human disease because there are no agents that have been proven to provide anything other than symptomatic relief in human OA.  Efficacy data and features of the various models of RA and OA are discussed with emphasis on their proven relevance to human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSl_Wv0PotC6OkdrW1FkXG-fW6udTcc2eYMwOExCFceqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3psVWjug%253D%253D&md5=1b6484ca61fd10dbb07f090d376730a4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1177%2F019262339902700125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F019262339902700125%26sid%3Dliteratum%253Aachs%26aulast%3DBendele%26aufirst%3DA.%26aulast%3DMcComb%26aufirst%3DJ.%26aulast%3DGould%26aufirst%3DT.%26aulast%3DMcAbee%26aufirst%3DT.%26aulast%3DSennello%26aufirst%3DG.%26aulast%3DChlipala%26aufirst%3DE.%26aulast%3DGuy%26aufirst%3DM.%26atitle%3DAnimal%2520models%2520of%2520arthritis%253A%2520relevance%2520to%2520human%2520disease%26jtitle%3DToxicol.%2520Pathol.%26date%3D1999%26volume%3D27%26spage%3D134%26epage%3D142%26doi%3D10.1177%2F019262339902700125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Gilmore, John L.; Sheppeck, James E</span>; <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate receptor agonists</span>. WO201117578,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">, </span>(US Patent 8399451, 2013);</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=John+L.+Gilmore&author=James+E+Sheppeck&title=Sphingosine-1-phosphate+receptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGilmore%26aufirst%3DJohn%2BL.%26atitle%3DSphingosine-1-phosphate%2520receptor%2520agonists%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-ref27_2"><span> <span class="citation_source-journal">Chem. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">154</span><span class="NLM_x">, </span> <span class="NLM_fpage">259630</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chem.+Abstr.+2011%2C+154%2C+259630."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref27_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Abstr.%26date%3D2011%26volume%3D154%26spage%3D259630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V2W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3V2W','PDB','3V2W'); return false;">PDB: 3V2W</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i77"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00373">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_52565"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00373">10.1021/acs.jmedchem.6b00373</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">X-ray crystallographic structure of <b>14a</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_001.pdf">PDF</a>)</p></li><li><p class="inline">X-ray crystallographic structure of <b>14a</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Docking of <b>19a</b> into the crystal structure of S1P<sub>1</sub> in complex with ML056 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_004.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_001.pdf">jm6b00373_si_001.pdf (208.49 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_002.pdb">jm6b00373_si_002.pdb (6.63 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_003.pdb">jm6b00373_si_003.pdb (529.67 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00373/suppl_file/jm6b00373_si_004.csv">jm6b00373_si_004.csv (2.85 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-13%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00373" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00373" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a4f43ad7c3d54","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
